

Government of Pakistan Ministry of National Health Services, Regulations & Coordination Drug Regulatory Authority Of Pakistan Health & OTC Products Division (Non-Drugs) *****

Islamabad, the 04th January, 2022

"SAY NO TO CORRUPTION"

SUBMISSION OF DEFICIENT INFORMATION / DOCUMENTS **SUBJECT:**

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 111th meeting held on 30th August, 2022 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per Annexed Format at the end of this letter/document. Replies received after given time will not be entertained:-

| S.No | Brand name | Decision |
|-------|---|---|
| (1) | (2) | (3) |
| | | xport Purpose Only |
| M/s N | Nutrevo Healthcare, Khewat No. 438, Khatau | uni No.452, Khasra No. 819, 14 – Km Adyala Road, Rawalpindi |
| 1. | Lactolac Milk Powder | Deferred for clarification of formulation as per 100g provisions of |
| | E E | COAs, Undertakings and change of brand name |
| | | xport Purpose Only \5, Sector 12C, North Karachi Industrial Area, Karachi, |
| 2. | Ormig Pro Sachet | Deferred since the formulation registered as drug |
| 4. | | a Laboratories (Pvt.) Ltd., |
| | | Industrial Estate Lahore (E. No. 00730) |
| | | Deferred for clarification and provision of Pearls monograph also |
| 3. | MARHABA JAWARISH SHAHI AMBRI | provide Form-E of the consignment sent to UAE in 2022 (6867\$) |
| 4 | MADUADA UDINIOL CADQUEE | Deferred for clarification of Potassium carbonate and provision of |
| 4. | MARHABA URINOL CAPSULE | signed Form-3 |
| 5. | MARHABA URIFLOW CAPSULE | Deferred for clarification of Potassium carbonate in unani |
| 5. | MARHABA URIFLOW CAPSULE | formulation |
| 6. | MARHABA SURANJEENA CAPSULE | Deferred for clarification of Styrax benzoin in unani formulation |
| 7. | MARHABA TYPHIL SYRUP | Deferred for clarification of Zinc in unani formulation |
| 8. | MARHABA JOSHANDA (compound | Deferred for clarification of zinc compound in unani formulation |
| | Zinc) | |
| 9. | MARHABA FLUNIL DROPS | Deferred for clarification of zinc compound in unani formulation |
| 10. | MARHABA GOSHOON OIL | Deferred for clarification of copper sulphate inm unani |
| | | formulation |
| | | Life Sciences (Pvt) Ltd Highway, Phase , H. Kanachi (F. No. 01204) |
| | | Highway, Phase – II, Karachi (E. No. 01304) Deferred for clarification regarding applied formulation and dosage form and |
| 11. | NOBLOCK DROP | justification of formulation as health product |
| 10 | SELVEY Limid | Deferred for clarification regarding applied formulation and |
| 12. | SELVEX Liquid | dosage form |
| 13. | CUFBEES Nasal drops | Deferred for clarification regarding applied formulation and |
| 15. | COT DEES Masar Grops | dosage form and justification of formulation as health product |
| 14. | VIVO NASAL Drops | Deferred for clarification regarding applied formulation and dosage |
| - | â la companya de la c | form and justification of formulation as health product |
| | | istan Limited, 35-Dockyard Road, West Wharf Road, Karachi |
| agent | of M/s Pfizer Consumer Manfuacturing, Ital | ly, S.r.L, Via Nettunense 90, 04011, Aprillia, Italy (E. No. 01312) Deferred for following reasons: |
| 15. | Centrum Adult Tablet | 5 |
| 15. | Centrum Adult Tablet | Confirmation of registration status of Centrum brand from PE&R Division. |
| M/s (| | D-180, Rojhan Street, Block-5, Clifton, Karachi-75600, Pakistar |
| | | a – 00156 – VIA dei LUXARDO, 33 – VAT. 067851002, Italy (E |
| | | No. 00056) |
| 16 | | Deferred for following reasons: |
| 16. | Delphys Tablet | • Long term and accelerated Stability Studies data not provided |
| M/s Q | AS International, located at the address Opp | osite King Mall, Near WAPDA Town, G.T Road, Gujranwala i |
| | | . C-17, KM 17, 08150 Parets del Valles – Spain (E. No. 00866) |
| 17. | Impak Oral Solution (Vet) | Deferred for following reasons: |
| | | |
| | | De sunder . |
| | | Page 1 of 85 |
| | | |

| S.No | Brand name | Decision |
|-------|-------------------------------------|--|
| (1) | (2) | (3) |
| | | Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| agent | of M/s ValueMed Pharma S.r.l locate | uite No.6, First Floor, Paramount Plaza, G-15 Markaz, Islamabad, as an ed at Via 28 Luglio, 211, 47893 Borgo Maggiore, Rep. San Marino, Italy ocated at Via Del Laghetto, n110, Badia Polesine (Rovigo), Italy (E. No. 00982) |
| 18. | Natural Paus Forte Cap | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 19. | Best Berry Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 20. | Esil Natur | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 21. | Calcitrix Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 22. | Memory Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 23. | Prostaparen Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 24. | EveryDay Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 25. | Lipid Low Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 26. | Aid To Vision | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 27. | Glutamax Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 28. | NutriJoint Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 29. | Actinatur Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 30. | Cystoff Table | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 31. | Rovalac Tablet | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 32. | Extravenus Capsule | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 33. | Ferselle Sachet | Deferred for following reasons: |

Page 2 of 85 Junder.

| (1) (2) (3) (4) (2) Original and Notorized for sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide. by the firm. 34. Fersen Sachet Deferred for following reasons: 35. Entero Junior Oral AMP Deferred for following reasons: 36. Probiotics & Vitamins Oral AMP Deferred for following reasons: 37. Entero Junior Oral AMP Deferred for following reasons: 38. Probiotics & Vitamins Oral AMP Deferred for following reasons: 37. Entero Face Original and Notorized for sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 38. Centella Gel Deferred for following reasons: 39. Horse ChestNut Gel Deferred for following reasons: 40. Fxtravenus Gel Deferred for following reasons: 41. Gynepink Remedy Pessaries Deferred for following reasons: 42. BHP's Shaw Aborn Affer sale certificate issued by the regulatory body and countersigned by the Embasy of Pakistan is not provide by the firm. 43. Horse ChestNut Gel Deferred for following reasons: 44. | S.No | Brand name | Decision |
|--|-------------------|--------------------------------|---|
| body and countersigned by the timbuscy of Pakistan is not provide by the firm. 34. Fersen Sachet Deferred for following reasons: 35. Entero Junior Oral AMP Deferred for following reasons: 36. Probiotics & Vitamins Oral AMP Deferred for following reasons: 37. Entero Junior Oral AMP Deferred for following reasons: 38. Probiotics & Vitamins Oral AMP Deferred for following reasons: 37. Emories Cream Deferred for following reasons: 38. Centella Gel Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 38. Centella Gel Deferred for following reasons: 39. Horse ChestNut Gel Deferred for following reasons: 40. Extravenus Gel Deferred for following reasons: 41. Gyneprink Remedy Pessaries Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embasy of Pakistan is not provide by the firm. 42. BHP's Sing You Possaries Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embasy of Pakistan is not provide by the firm. 44. BHP's Sing You Pos Syng< | (1) | (2) | (3) |
| 34. Fersen Sachet • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 35. Entero Junior Oral AMP • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 36. Probiotics. & Vitamins Oral AMP • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 37. Emortex Cream • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 38. Centella Gel • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 39. Horse ChestNut Gel • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 40. Extravenus Gel • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 41. Gynepink Remedy Pessaries • Original and Notorized fee sale certificate issued by the regulatory boly and countersigned by the Embassy of Pakistan is not provide by the firm. 43. BHP's INSOMAX DROPS • Defered for following r | | | body and countersigned by the Embassy of Pakistan is not provided |
| 35. Entero Junior Oral AMP • Original and Notorized fee sub certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 36. Probiotics & Vitamins Oral AMP • Original and Notorized fee sub certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 37. Emortex Cream • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 38. Centella Gel • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 39. Horse ChestNut Gel • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 40. Extravenus Gel • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 41. Gynepink Remedy Pessaries • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 43. BHP's SINSOMAX DROPS Deferred for following reasons: 44. BHP's Suby Rebiotic Syrup Deferred for change of brand name 45. BHP's Stury LES Syrup Deferred for change of brand name | 34. | Fersen Sachet | • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. |
| 36. Probiotics & Vitamins Oral AMP • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 37. Emorlex Cream • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 38. Centella Gel • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 39. Horse ChestNut Gel • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 40. Extravenus Gel • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 41. Gynepink Remedy Pessaries • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 42. BHP's INSOMAX DROPS Deferred for following reasons: 44. Gynepink Remedy Pessaries • Original and Notorizef fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provide by the firm. 45. BHP's INSOMAX DROPS Deferred for change of brand name 46. BHP's Stype Determed for change of brand name Deferred for change of brand n | 35. | Entero Junior Oral AMP | • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided |
| Joreferred for following reasons: 37. Emorlex Cream Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 38. Centella Gel Deferred for following reasons: 39. Horse ChestNut Gel Deferred for following reasons: 40. Extravenus Gel Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 40. Extravenus Gel Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 41. Gynepink Remedy Pessaries Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 42. BHP's INSOMAX DROPS Deferred for following reasons: 43. BHP's SMOAX DROPS Deferred for change of brand name 44. BHP's SWOAX DROPS Deferred for change of brand name 45. BHP's SWI Lik-P Syrup Deferred for change of brand name 46. BHP's SWI Lik-Syrup Deferred for change of brand name 47. BHP's SWI Jik-Syrup Deferred for change of brand name | 36. | Probiotics & Vitamins Oral AMP | • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided |
| 38. Centella Gel Deferred for following reasons: 39. Horse ChestNut Gel Deferred for following reasons: 40. Extravenus Gel Deferred for following reasons: 40. Extravenus Gel Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 41. Gynepink Remedy Pessaries Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 42. BHP's Remedy Pessaries Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 43. BHP's INSOMAX DROPS Deferred for following reasons: 44. BHP's Gyno Po Syrup Deferred for rading of brand name 44. BHP's Baby Rebiotic Syrup Deferred for change of brand name 44. BHP's Saby Rebiotic Syrup Deferred for change of brand name 44. BHP's Sup Rebiotic Syrup Deferred for change of brand name 45. BHP's Kuf Lik-P Syrup Deferred for change of brand name 46. BHP's Kuf Lik-S F SYRUP Deferred for change of brand name 50. | 37. | Emorlex Cream | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided |
| 39. Deferred for following reasons: • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 40. Extravenus Gel • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 41. Gynepink Remedy Pessaries • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 42. BHP's INSOMAX DROPS Deferred for following reasons: 43. BHP's INSOMAX DROPS Deferred for change of brand name 44. BHP's Gyno Pro Syrup Deferred for change of brand name 45. BHP's Kuf Lik-P Syrup Deferred for change of brand name 47. BHP's Kuf Lik-S Syrup Deferred for change of brand name 48. Biosom's Colic Syrup Deferred for change of brand name 49. Hey's Kuf Lik-S Syrup Deferred for change of brand name 49. BHP's Kuf Lik-S Syrup Deferred for change of brand name 41. Biosom's Colic Syrup Deferred for change of brand name 44. BHP's Kuf Lik-S Syrup Deferred for change of brand name | 38. | Centella Gel | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided |
| 40. Extravenus Gel Deferred for following reasons: • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 41. Gynepink Remedy Pessaries • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. 42. BHP's INSOMAX DROPS Deferred for safety profile of product is required 43. BHP's Gyno Pro Syrup Deferred for change of brand name 44. BHP's Baby Rebiotic Syrup Deferred for change of brand name 45. BHP's KULIk-P Syrup Deferred for change of brand name 46. BHP's KULIk-P Syrup Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for change of brand name 51. Sepia officinalis (EHPI) Deferred for change of brand name 52. Condurango (EHPI) Deferred for change of brand name 53. Cantharis (EHPI) Deferred for sarcode testing of Condurango is required </td <td>39.</td> <td>Horse ChestNut Gel</td> <td> Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided </td> | 39. | Horse ChestNut Gel | Deferred for following reasons: Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided |
| 41. Gynepink Remedy Pessaries • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm. M/s BHP Homeoo Laboratories (Pvt) Ltd., Paragon Industrial Estate, 18-Km, Multan Road, Lahore (E. No.00624) 42. BHP's INSOMAX DROPS Deferred for safety profile of product is required 43. BHP's Gyno Pro Syrup Deferred for change of brand name 44. BHP's FEVO.LESS Syrup Deferred for change of brand name 45. BHP's KUF LiK-P Syrup Deferred for change of brand name 46. BHP's KUF LiK-SF SYRUP Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for change of brand name 51. Sepia officinalis (EHPI) Deferred for sarcode testing of sepia is required 52. Condurango (EHPI) Deferred for sarcode testing of cantharis is required 53. Cantharis (EHPI) Deferred for sarcode testing of Cantharis is required 54. Calcarea renalis (EHPI) Deferred for sarco | 40. | Extravenus Gel | • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided |
| M/s BHP Homoeo Laboratories (Pvt) Ltd., Paragon Industrial Estate, 18-Km, Multan Road, Lahore (E. No.00624) 42. BHP's INSOMAX DROPS Deferred for safety profile of product is required 43. BHP's Gyno Pro Syrup Deferred for change of brand name 44. BHP's Baby Rebiotic Syrup Deferred for change of brand name 45. BHP's FEVO. LESS Syrup Deferred for change of brand name and Rhus tox is toxic in 3x potency raise the potency to 6x or above 46. BHP's KUF LiK-SF SYRUP Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for sarcode testing of sepia is required 51. Sepia officinalis (EHPI) Deferred for sarcode testing of sepia is required 52. Condurango (EHPI) Deferred for sarcode testing of cantharis is required 53. Cantharis (EHPI) Deferred for sarcode testing of cantharis is required 54. Calcarea ren | 41. | Gynepink Remedy Pessaries | • Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided |
| 42. BHP's INSOMAX DROPS Deferred for safety profile of product is required 43. BHP's Gyno Pro Syrup Deferred for change of brand name 44. BHP's Baby Rebiotic Syrup Deferred for change of brand name 45. BHP's FEVO.LESS Syrup Deferred for change of brand name and Rhus tox is toxic in 3x potency raise the potency to 6x or above 46. BHP's Kuf Lik-P Syrup Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 47. BHP's Colic Syrup Deferred for change of brand name 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for change of brand name 51. Sepia officinalis (EHPI) Deferred for Homeopathic monograph of Condurango is required 52. Condurango (EHPI) Deferred for sarcode testing of cantharis is required 53. Cantharis (EHPI) Deferred for sarcode testing of cantharis is required 54. Calcarea renalis (EHPI) Deferred for sarcode testing of cantharis is required 55. Cantharis (EHPI) Deferred for sarcode testing of cantharis is required < | | | omoeo Laboratories (Pvt) Ltd., |
| 43. BHP's Gyno Pro Syrup Deferred for change of brand name 44. BHP's Baby Rebiotic Syrup Deferred for change of brand name 45. BHP's FEVOLESS Syrup Deferred for change of brand name 46. BHP's Kuf Lik-P Syrup Deferred for change of brand name 47. BHP's Kuf Lik-SF SYRUP Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 48. Blossom Laboratories (Ptt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181) 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for change of brand name 51. Sepia officinalis (EHPI) Deferred for Homeopathic monograph of Condurango is required 52. Condurango (EHPI) Deferred for Homeopathic monograph of Condurango is required 54. Calcarea renalis (EHPI) Deferred for sarcode testing of cantharis is required 55. Cantharis (EHPI) Deferred for sarcode testing of formica rufa is required 56. Cholesterinuum (EHPI) Deferred for sarcode testing of Sepia is required | 42 | BHP's INSOMAX DROPS | |
| 44. BHP's Baby Rebiotic Syrup Deferred for change of brand name 45. BHP's FEVOLESS Syrup Deferred for change of brand name and Rhus tox is toxic in 3x potency raise the potency to 6x or above 46. BHP's Kuf Lik-P Syrup Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for change of brand name 51. Sepia officinalis (EHPI) Deferred for sarcode testing of sepia is required 52. Condurango (EHPI) Deferred for sarcode testing of Cantharis is required 53. Cartharis (EHPI) Deferred for sarcode testing of cantharis is required 54. Calcarea renalis (EHPI) Deferred for sarcode testing of cantharis is required 55. Cantharis (EHPI) Deferred for sarcode testing of Formica rufa is required 56. Cholesterinum (EHPI) Deferred for sarcode testing of Formica rufa is required 57. Lac defloratum (EHPI) Deferred for sarcode testing of Formica rufa is required 58. Formica rufa (EHPI) Deferred for sarcode testing of Formica rufa is required | | | |
| BHP's FEVOLLESS Syrup potency raise the potency to 6x or above BHP's Kuf Lik-P Syrup Deferred for change of brand name BHP's KUF LIK-SF SYRUP Deferred for change of brand name M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181) Blossom's Colic Syrup Deferred for change of brand name Hepalex Syrup Deferred for change of brand name Hepalex Syrup Deferred for change of brand name Sepia officinalis (EHPI) Deferred for change of brand name Condurango (EHPI) Deferred for sarcode testing of sepia is required Calcarea renalis (EHPI) Deferred for Homeopathic monograph of Condurango is required Calcarea renalis (EHPI) Deferred for sarcode testing of cantharis is required Calcarea renalis (EHPI) Deferred for sarcode testing of Cantharis is required Calcarea renalis (EHPI) Deferred for sarcode testing of Cantharis is required Cholesterinum (EHPI) Deferred for sarcode testing of Lac defloratum is required Lac defloratum (EHPI) Deferred for sarcode testing of Lac defloratum is required Sepia officinalis (EHPI) Deferred for sarcode testing of Sepia is required Sepia officinalis (EHPI) Deferred for sarcode testing of Lac defloratum is required Sepia officinalis (EHPI) Deferred for sarcode testing of Sepia is required Coccus Cacti Potency (EHPI) Deferred for sarcode testing of Sepia is required Coccus Cacti Potency (EHPI) Deferred for sarcode testing of Coccus Cacti is required Cocusholax Syrup Deferred for change of brand name Hemolex Syrup Deferred for change of brand name Hemolex Syrup Deferred for change of brand name Hepagold Syrup Deferred for change of brand name Hepagold Syrup Deferred for change of brand name Hepagold Syrup De | 44. | | |
| 46. BHP's Kuf Lik-P Syrup Deferred for change of brand name 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181) 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for change of brand name 51. Sepia officinalis (EHPI) Deferred for sarcode testing of sepia is required 52. Condurango (EHPI) Deferred for sarcode testing of Cantharis is required 53. Cantharis (EHPI) Deferred for sarcode testing of Cantharis is required 54. Calcarea renalis (EHPI) Deferred for sarcode testing of Cantharis is required 55. Cantharis (EHPI) Deferred for sarcode testing of Cantharis is required 56. Cholesterinum (EHPI) Deferred for sarcode testing of Lac defloratum is required 57. Lac defloratum (EHPI) Deferred for sarcode testing of Formica rufa is required 58. Formica rufa (EHPI) Deferred for sarcode testing of Formica rufa is required 59. Sepia officinalis (EHPI) Deferred for sarcode testing of Sepia is | 45 | BHP's FEVO LESS Syrup | |
| 47. BHP's KUF LIK-SF SYRUP Deferred for change of brand name M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181) 48. Blossom's Colic Syrup Deferred for change of brand name 49. Hepalex Syrup Deferred for change of brand name 50. Nervo Plus Syrup Deferred for change of brand name 51. Sepia officinalis (EHPI) Deferred for sarcode testing of sepia is required 52. Condurango (EHPI) Deferred for sarcode testing of Condurango is required 53. Cantharis (EHPI) Deferred for Homeopathic monograph of Condurango is required 54. Calcarea renalis (EHPI) Deferred for sarcode testing of cantharis is required 55. Cantharis (EHPI) Deferred for sarcode testing of cantharis is required 56. Cholesterinum (EHPI) Deferred for sarcode testing of Lac defloratum is required 58. Formica rufa (EHPI) Deferred for sarcode testing of sepia is required 59. Sepia officinalis (EHPI) Deferred for sarcode testing of sepia is required 60. Serum anguillae (EHPI) Deferred for sarcode testing of Sepia is required 61. Coccus Cacti Potency (EHPI) Deferred for sarcode tes | | • | |
| M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181)48.Blossom's Colic SyrupDeferred for change of brand name49.Hepalex SyrupDeferred for change of brand name50.Nervo Plus SyrupDeferred for change of brand name51.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required52.Condurango (EHPI)Deferred for sarcode testing of Condurango is required53.Cantharis (EHPI)Deferred for sarcode testing of Condurango is required54.Calcarea renalis (EHPI)Deferred for sarcode testing of cantharis is required55.Cantharis (EHPI)Deferred for sarcode testing of cantharis is required56.Cholesterinum (EHPI)Deferred for sarcode testing of Lac defloratum is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Formica rufa is required58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of Sepia is required50.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Sepia is required51.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Sepia is required52.Coughsolax SyrupDeferred for sarcode testing of Coccus Cacti is required53.Cantharis (EHPI)Deferred for sarcode testing of Coccus Cact is required54.Calcarea renalis (EHPI)Deferred for sarcode testing of Coccus Cact is required55.Coughsolax Syrup <td< td=""><td></td><td></td><td></td></td<> | | | |
| 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181)48.Blossom's Colic SyrupDeferred for change of brand name49.Hepalex SyrupDeferred for change of brand name50.Nervo Plus SyrupDeferred for sarcode testing of sepia is required51.Sepia officinalis (EHPI)Deferred for sarcode testing of condurango is required52.Condurango (EHPI)Deferred for Homeopathic monograph of Condurango is required53.Cantharis (EHPI)Deferred for Homeopathic monograph of renalis calcarean is required54.Calcarea renalis (EHPI)Deferred for sarcode testing of cantharis is required55.Cantharis (EHPI)Deferred for Homeopathic monograph of Cholesterine is required56.Cholesterinum (EHPI)Deferred for Homeopathic monograph of Cholesterine is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of Sepia is required50.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required51.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cact is required52.Coughsolax SyrupDeferred for change of brand name53.Gatharis (EHPI)Deferred for sarcode testing of Eel serum is required54.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Sepia is required55.Coughsolax SyrupDeferred f | 47. | | |
| 48.Blossom's Colic SyrupDeferred for change of brand name49.Hepalex SyrupDeferred for change of brand name50.Nervo Plus SyrupDeferred for change of brand name51.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required52.Condurango (EHPI)Deferred for Homeopathic monograph of Condurango is required53.Cantharis (EHPI)Deferred for sarcode testing of Cantharis is required54.Calcarea renalis (EHPI)Deferred for Homeopathic monograph of renalis calcarean is required55.Cantharis (EHPI)Deferred for sarcode testing of cantharis is required56.Cholesterinum (EHPI)Deferred for sarcode testing of Lac defloratum is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of Sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Coccus Cacti is required61.Coccus Cacti Potency (EHPI)Deferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 50.Nervo Plus SyrupDeferred for change of brand name51.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required52.Condurango (EHPI)Deferred for Homeopathic monograph of Condurango is required53.Cantharis (EHPI)Deferred for sarcode testing of Cantharis is required54.Calcarea renalis (EHPI)Deferred for sarcode testing of cantharis is required55.Cantharis (EHPI)Deferred for sarcode testing of cantharis is required56.Cholesterinum (EHPI)Deferred for sarcode testing of Lac defloratum is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of sepia is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required61.Coccus Cacti Potency (EHPI)Deferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | 48. | , , , | |
| 51.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required52.Condurango (EHPI)Deferred for Homeopathic monograph of Condurango is required53.Cantharis (EHPI)Deferred for sarcode testing of Cantharis is required54.Calcarea renalis (EHPI)Deferred for Homeopathic monograph of renalis calcarean is required55.Cantharis (EHPI)Deferred for sarcode testing of cantharis is required56.Cholesterinum (EHPI)Deferred for Homeopathic monograph of Cholesterine is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Sepia is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required61.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cacti is required62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 52.Condurango (EHPI)Deferred for Homeopathic monograph of Condurango is required53.Cantharis (EHPI)Deferred for sarcode testing of Cantharis is required54.Calcarea renalis (EHPI)Deferred for Homeopathic monograph of renalis calcarean is required55.Cantharis (EHPI)Deferred for sarcode testing of cantharis is required56.Cholesterinum (EHPI)Deferred for sarcode testing of Lac defloratum is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Sepia is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Coccus Cacti is required61.Coccus Cacti Potency (EHPI)Deferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 53.Cantharis (EHPI)Deferred for sarcode testing of Cantharis is required54.Calcarea renalis (EHPI)Deferred for Homeopathic monograph of renalis calcarean is required55.Cantharis (EHPI)Deferred for sarcode testing of cantharis is required56.Cholesterinum (EHPI)Deferred for Homeopathic monograph of Cholesterine is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Coccus Cacti is required61.Coccus Cacti Potency (EHPI)Deferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 54.Calcarea renalis (EHPI)Deferred for Homeopathic monograph of renalis calcarean is required55.Cantharis (EHPI)Deferred for sarcode testing of cantharis is required56.Cholesterinum (EHPI)Deferred for Homeopathic monograph of Cholesterine is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Coccus Cacti is required61.Coccus Cacti Potency (EHPI)Deferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 56.Cholesterinum (EHPI)Deferred for Homeopathic monograph of Cholesterine is required57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required61.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cacti is required62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | Deferred for Homeopathic monograph of renalis calcarean is |
| 57.Lac defloratum (EHPI)Deferred for sarcode testing of Lac defloratum is required58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required61.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cacti is required62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | e i i i i i i i i i i i i i i i i i i i |
| 58.Formica rufa (EHPI)Deferred for sarcode testing of Formica rufa is required59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required61.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cacti is required62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 59.Sepia officinalis (EHPI)Deferred for sarcode testing of sepia is required60.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required61.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cacti is required62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 60.Serum anguillae (EHPI)Deferred for sarcode testing of Eel serum is required61.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cacti is required62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 61.Coccus Cacti Potency (EHPI)Deferred for sarcode testing of Coccus Cacti is required62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 62.Coughsolax SyrupDeferred for change of brand name63.Hemolex SyrupDeferred for change of brand name64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 64.Hepagold SyrupDeferred for change of brand name65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | 62. | Coughsolax Syrup | Deferred for change of brand name |
| 65.Ulcelex SyrupDeferred for change of brand name66.Super Fresh Blood SyrupDeferred for change of brand name | | | |
| 66. Super Fresh Blood Syrup Deferred for change of brand name | | | |
| | | | |
| | <u>60.</u> 67. | Hepa Max Syrup | Deferred for change of brand name |

Page 3 of 85

<u>F.No.10-10/2022-OTC (M-111)</u>

| S.No | Brand name | Decision |
|--------------------|---|--|
| (1) | (2) | (3) |
| 68. | GastoP Syrup | Deferred for change of brand name |
| <u>69.</u> | BeFit Powder | Deferred for change of brand name |
| 70. | Self Guard Tablet | Deferred for change of brand name |
| 71. 72. | Alfalfa+Ginseng Syrup BCool Tablet | Deferred for change of brand name Deferred for change of brand name |
| 73. | BVision Tablet | Deferred for change of brand name |
| 74. | Histalex Syrup | Deferred for change of brand name |
| 75. | Uro Stop Syrup | Deferred for change of brand name |
| 76. | Blood Off Tablet | Deferred for change of brand name |
| 77. | Face Care Tablet | Deferred for change of brand name |
| 78. | Matti Chor Tablet | Deferred for change of brand name |
| 79. | Smoke Stop Tablet | Deferred for change of brand name |
| 80. | Weight Plus Tablet Pilzee Tablet | Deferred for change of brand name |
| 81. 82. | Pilzee Tablet Piles One Capsule | Deferred for change of brand name Deferred for change of brand name |
| | Cigrette ChhorTablet | |
| 83. | | Deferred for change of brand name |
| 84. | Neurozion Syrup | Deferred for change of brand name |
| 85. | Ashoka Cordial Syrup | Deferred for change of brand name |
| 86. | Bed Wetting Syrup | Deferred for change of brand name |
| 87. | Coughlex Syrup | Deferred for change of brand name |
| 88. | Feverlex Syrup | Deferred for change of brand name |
| 89. | Gynolex Syrup | Deferred for change of brand name |
| 90. | Luzogen Syrup | Deferred for change of brand name |
| 91. | Mega Mass Syrup | Deferred for change of brand name |
| 92. | Thandak Syrup Ginkolex Tablet | Deferred for change of brand name |
| 93. | Glikolex Tablet | Deferred for change of brand name |
| 94. | Leco Care Tablet | Deferred for change of brand name |
| 95. | Piles Shoot Syrup | Deferred for change of brand name |
| | | D.M.A Homeo Lab, 1re Road, Lahore (E. No.01009) |
| | | Deferred for sarcode tesing(TSE,BSE,Ecoli)is required or |
| 96. | DMA'S HEIGHT COMPOUND DROPS | evidence that source is free from TSE,BSE and Ecoli |
| | | omoeopathic Pharma DZHP, |
| | | ngi Industrial Area, Karachi (E. No.00176) |
| 97. | Histaminum (Potencies) | Deferred for Homeopathic monograph of Histamine is required |
| 98. | Hydrophobinum (Potencies) | Deferred for Homeopathic monograph of Lyssin |
| 99. | Insulinum (Potencies) | is required Deferred for sarcode testing of source is required |
| <u>99.</u> 100. | Pituitary gland (Potencies) | Deferred for sarcode testing of source is required |
| 100. | Adrenalinum (Potencies) | Deferred for sarcode testing of source is required |
| 102. | Sepia Officinalis Ø (Mother tincture) | Deferred for sarcode testing of source material is required |
| 103. | Bufo Rana Ø (Mother tincture) | Deferred for sarcode testing of source material is required |
| | Behind Qadir Gas Way 1, G.T. | lamabad Pharmacy, Road Wah District, Rawalpindi (E. No.00270) |
| 104. | Islamabad Pharmacy's Phosphorus potencies | Deferred for Homeopathic monograph of Phosphorus is required |
| 105. | Islamabad Pharmacy's Plumbum met potencies | Deferred for Homeopathic monograph of Plumbum met is required |
| 106. | Islamabad Pharmacy's Robinapseu potencies | Deferred for sarcode testing of Yellow locust is required |
| 107. | Islamabad Pharmacy's Sepia potencies | Deferred for sarcode testing of Inky juice of cuttlefish is required |
| 108. | Islamabad Pharmacy's | Deferred for Homeopathic monograph of Sulphur is required |
| | Sulphur potencies | Page 4 of 85 |

| S.No | Brand name | Decision |
|----------------------|---|---|
| (1) | (2) | (3) |
| 109. | GR Pilogen Ointment | Deferred for change of brand name |
| 110. | GR Crack Care Cream | Deferred for change of brand name |
| 111. | GR Burn aid Ointment | Deferred for change of brand name |
| 112. | GR Sunscreen Cream | deferred for monograph of Chamomile is required |
| 113. | GR B-glow Cream | Deferred for change of brand name |
| 114. | GR Acne care Cream | Deferred for change of brand name |
| 115. | GR Dura max Cream | Deferred for change of brand name |
| 116. | GR Warts Cure Ointment | Deferred for change of brand name |
| | | Deferred for |
| 117. | GR SELFARE Tablets | Evidence are provided in support of the claim of availability of th proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 118. | GR HIOGEN Tablets | Deferred for Evidence are provided in support of the claim of availability of th proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 119. | GR Calcimax Syrup | Deferred for Evidence are provided in support of the claim of availability of th proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 120. | GR Flu GoSyrup | Deferred for Evidence are provided in support of the claim of availability of th proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 121. | GR IvyKuff Syrup | Deferred for change of brand name |
| 122. | GR Ginseng Syrup | Deferred for Evidence are provided in support of the claim of availability of th proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 123. | GR Moringaoleifera Syrup | Deferred for evidence of fee submission is required |
| 124. | GR Gum paint Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 125. | GR Roghan e khashkhash | Deferred for change of brand name |
| 126. | GR Krela Capsule | Deferred for change of brand name |
| 120. | GR Lesona Capsule | Deferred for change of brand name |
| | | |
| 128. | GR MensoreenCapsule | Deferred for change of brand name |
| 129. | Croup off Tablet | Deferred for change of brand name |
| 130. | Islamabad pharmacy's Antim crud potencies | Deferred for safety profile of product is required |
| 131. | Islamabad pharmacy's Cholesterinum potencies | Deferred for source of cholestterine is required |
| 132. | World Arq e HepaNill | deferred for change of brand name |
| 133. | World Arq e KabirKhas | Deferred for change of brand name |
| 133. | World Arq e Supari Pak | deferred for change of brand name |
| 134. | wonu Ange Supan Pak | |
| | <u> </u> | M/s. Kamal Laboratories |
| | Sukho | o, District Rawalpindi (E. No.0020) |
| 135. | KL-71 DROPS | Deferred for clarification regarding facility ,source ,production, and storage of x ray formation is required Homeopathic monograph of X rays is required |
| 100 | KL-77 DROPS | The applied formulation contains radioactive substance X rays Deferred for clarification regarding the formulation |
| 136. | | Deferred for clarification regarding facility ,source ,production, and |
| <u>136.</u> 137. | KL-78 DROPS | storage of Radium formation is required Homeopathic monograph of X rays is required The applied formulation contains radioactive substance radium |
| | KL-78 DROPS Acetone | |
| 137. | | Homeopathic monograph of X rays is required The applied formulation contains radioactive substance radium Deferred for Homeopathic monograph of <u>Acetone</u> is required Deferred for Homeopathic monograph of Tetracycline hydrochloride is required |
| 137. 138. | Acetone Achromycin X Ray | Homeopathic monograph of X rays is required The applied formulation contains radioactive substance radium Deferred for Homeopathic monograph of Acetone is required Deferred for Homeopathic monograph of Tetracycline hydrochloride is required Deferred for The applied formulation contains Radioactive substance X rays |
| 137. 138. 139. | Acetone Achromycin | Homeopathic monograph of X rays is required The applied formulation contains radioactive substance radium Deferred for Homeopathic monograph of Acetone is required Deferred for Homeopathic monograph of Tetracycline hydrochloride is required Deferred for Homeopathic monograph of Tetracycline hydrochloride is required Deferred for The applied formulation contains Radioactive substance X |

| S.No | Brand name | Decision |
|------|-----------------------------------|--|
| (1) | (2) | |
| 142. | Alloxin | Deferred for The applied formulation contains toxic glucose analogue, which selectively destroys insulin-producing cells in the pancreas (tha is, beta cells) when administered Homeopathic monograph of Alloxin |
| 143. | Aminophyllin | Deferred for Justification regarding stability of aminophylline in oral solution form is required Homeopathic monograph of Aminophyllin is required |
| 144. | Araldite | Deferred for Homeopathic monograph of Analdite (synthetic adhesive) is higly toxic when taken orally, Justification is required for its use as orally |
| 145. | Asbestos | Deferred for Homeopathic monograph of _Asbestos is required Asbestos is highly poisonous and cause Hung cancer , Justification is required for its use as orally Asbestos is banned item By EPA,(NIOSH) due to its air born particle hazards |
| 146. | Aureomycin | Deferred for Homeopathic monograph of <u>Aureomycin</u> is required |
| 147. | Benadryl | Deferred for The firm applied product with brand name/market name Benadryl contains Diphenhydramine and Homeopathic monograph is required |
| 148. | Busubhan | Deferred for Homeopathic monograph of <u>Busubhan</u> is required |
| 149. | Butazolidin | Deferred for Homeopathic monograph of _Homeopathic monograph of Butazolidin is required |
| 150. | Chloramine-T | Deferred for Homeopathic monograph of _Homeopathic monograph of <u>Chloramine-T</u> is required |
| 151. | Chloramphenical | Deferred for Homeopathic monograph of _Homeopathic monograph of <u>Chloramphenical</u> is required |
| 152. | Chloroform | Deferred for The applied formulation contains chloroform which is highly toxic when taken orally as due to its respiratory and cardiac arrest |
| 153. | Chlorothiazide | Deferred for Homeopathic monograph of _Homeopathic monograph of Chlorothiazide is required |
| 154. | Chlorpomazine Hydrochloride | Deferred for Homeopathic monograph of _Homeopathic monograph of Chlorpomazine-Hydrochloride is required furthermore its antipsychotic drug |
| 155. | Chlortetracycline Hydrochloride | Deferred for Homeopathic monograph of _Homeopathic monograph of Chlortetracycline Hydrochlorid is required |
| 156. | Cobal Rays | Deferred for Homeopathic monograph of _Homeopathic monograph of Cobalt rays is required The facility for source ,formation, handling ,production of cobalt rays is required |
| 157. | Cortine | Deferred for Homeopathic monograph of Homeopathic monograph of Deoxyocortone acetate is required The applied formulation contains steroidal preparation of Deoxyocortone acetate as sterile facility is required |
| 158. | Cresol | Deferred for Homeopathic monograph of _Homeopathic monograph of Cresol is required |
| 159. | Dapsone | Deferred for Homeopathic monograph of _Homeopathic monograph of Dapsone is required |
| 160. | Dichloro Diphenyl Trichloroethane | Deferred for The applied formulation contains Insecticides DDT(<u>Dichloro Diphenyl Trichloroethane)</u> which is higly poisinious when taken orally |
| 161. | Durabolin | Deferred for The applied formulation contains anabolic steroids (Nandrolone cyclohexylpropionate |
| 162. | Electricity | Deferred for Justify the role of electricity in homeopathic use along with Homeopathic monograph |
| 163. | Emetin Hydrochloride | Deferred for Homeopathic monograph of _Homeopathic monograph of Emetin Hydrochloride is required |
| 164. | Endoxan | Deferred for The applied formulation contains Cyclophosphamide which is immunosuppressant drug |

| S.No | Brand name | Decision |
|------|---------------------------------|---|
| (1) | (2) | (3) Deferred for Homeopathic monograph of _Homeopathic monograph of |
| 165. | Ergotina | Ergotina is required |
| 166. | Erythromycin | Deferred for Homeopathic monograph of _Homeopathic monograph of Erythromycin is required |
| 167. | Ether | Deferred for Homeopathic monograph of _Homeopathic monograph of Ether is required Furthermore diethyl ether is highly flammable |
| 168. | Flagyl | Deferred for The firm applied product with brand name Flagyl Homeopathic monograph of _Homeopathic monograph of Metronidazol is required |
| 169. | Formalin | Deferred for The applied formulation contains Formalin which is highly poisonous when taken orally |
| 170. | Gamma | Deferred for The applied formulation contains Gamma rays which is radioactive substance |
| 171. | Chlortetracycline Hydrochloride | Deferred for Homeopathic monograph of _Homeopathic monograph of Chlortetracycline Hydrochloride is required |
| 172. | KL-64 DROPS | Deferred for justification and clarification of formulation |
| 173. | Amygdale | Deferred for Herbal monograph along with Sarcode testing/evidence the source is free from TSE,BSE and Ecoli |
| 174. | Aorte | Deferred for Herbal monograph along with Sarcode testing/evidence that |
| | | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 175. | Artere Carotide | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 176. | Artere | source is free from TSE,BSE and Ecoli |
| 177. | Ovarinum | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 178. | Bulbinum | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 179. | Cardine | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 180. | Cartilago | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 181. | Cerebellum | Deferred for Herbal monograph along with Sarcode testing/evidence the source is free from TSE,BSE and Ecoli |
| 182. | Cerebrinum | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 183. | Соссух | Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 184. | Colon (Muqueuse du) | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 185. | Corps Jaune | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 186. | Cortex Surrenal | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 187. | Disci Cervicales | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 187. | Disci Lumbales | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 189. | Epiphyse | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 189. | Estomac | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| | | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 191. | Ganglions Lymphatiques | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 192. | Gencives | source is free from TSE, BSE and Ecoli |
| 193. | Glandes Mammaires | Deferred for Herbal monograph along with Sarcode testing/evidence the source is free from TSE,BSE and Ecoli |
| 194. | Glandes Surrenales | Deferred for Herbal monograph along with Sarcode testing/evidence the source is free from TSE,BSE and Ecoli |
| 195. | Parotidinum | Deferred for Herbal monograph along with Sarcode testing/evidence the source is free from TSF,BSE and Ecoli |

<u>F.No.10-10/2022-OTC (M-111)</u>

| S.No | Brand name | Decision |
|-----------|-----------------------|--|
| (1) | (2) | (3) Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 196. | Hypophysine LA | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 197. | Pancreine | source is free from TSE, BSE and Ecoli |
| 198. | Hypophysine | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 199. | Pancreine | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 200. | Intestine Gros | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 201. | Langue | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 202. | Larynx | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 203. | Ligaments | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 204. | Mamelline | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 205. | Medulline | Deferred for Herbal monograph along with Sarcode testing/evidence that |
| 206. | Meduloss | source is free from TSE,BSE and Ecoli Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 207. | Muqueuse Endo | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 208. | Muqueuse Gastrique | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 209. | Orchitinum | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 210. | Muqueuse Intestinale | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 211. | Muqueuse Laryngee | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 212. | Muqueuse Linguale | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 213. | Muqueuse Sinusale | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 214. | Muqueuse Stomacale | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 215. | Muqueuse Uterine | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 216. | Muscle Lisse | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 217. | Muscle Oculaires | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 218. | Nerfs Moteur | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 219. | Nerfs Occipital | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 220. | Nerfs Optique | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 221. | Nerfs Parasympathique | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 222. | Nerfs | Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli |
| 223. | FERRIN CAPSULES | Deferred for Homeopathic monograph of Folic acid, Vitamin B12 are required |
| | M | Sarcode testing/evidence that source is free from TSE,BSE and Ecoli /s Mansoora Homoeo Pharma, |
| | | lock No.16, F.B. Area, Karachi (E. No.00419) |
| 224. | C5 GASTRONIN Drops | Deferred forConfirmation/Availability of Homeopathic Drops Section.Change of brand name |
| <i>~~</i> | C. ONDIKOIVITY DIOPS | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 225. | C7 NEURALGION Drops | Deferred forConfirmation/Availability of Homeopathic Drops Section.Change of brand name |
| | Criteratoron props | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 226. | C8 SINUTON Drops | Deferred for |

| S.No | Brand name | Decision |
|------|-----------------------|--|
| (1) | (2) | (3) |
| | | Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 227. | C9 RHEUMATON Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 228. | NEFRO COMPLEX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 229. | CARDUUS COMPLEX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 230. | HAIR COMPLEX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Juglans Regis in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 231. | MHP 1 GERD Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 232. | MHP 2 RUMACARB Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Bryonia alba and Rhus tox in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 233. | MHP 3 DETRULITH Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Berberis vulgaris in Q preparation which is toxic and revise the potency with 6x or above. |
| 234. | MHP 4 HEMORECT Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 235. | MHP 5 DERMECH Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name |

Page 9 of 85 Aunded.

| | Brand name | Decision |
|------|-----------------------|---|
| (1) | (2) | (3) |
| | | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formutaion contains Rhus tox in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 236. | MHP 6 HEPAMAG Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 237. | MHP 7 LEUCOHYDE Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 238. | MHP 8 ANXINAP Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Aconite in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 239. | MHP 9 VOMEZ Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 240. | MHP 10 WORMGARD Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 241. | MHP 11 SINUX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Bryonia and aconite in 3 x preapartion which is toxic and revise the potency with 6x or above. |
| 242. | MHP 12 DYROSOL Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 243. | MHP 13 DIALOX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 244. | MHP 14 CALADEX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 245. | MHP 15 PYROX Drops | Page 10 of 85 |

| <u>S.No</u> (1) | Brand name (2) | (3) |
|-----------------|-----------------------------|---|
| (1) | (2) | (3) Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Aconite,Belladonanand rhus tox in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 246. | MHP 16 URIX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 247. | MHP 17 ACNE FACE TONE Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 248. | MHP 18 CERVINEX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 249. | MHP 19 PROSTOMALE Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sale invoices including distribution record). |
| 250. | MHP 20 DENGNAL Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 251. | MHP 21 ASTHAM Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 252. | MHP 22 GOLD DROPS Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 253. | MHP 23 MENSTRAL Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 254. | MHP 24 BRAIN TONIC Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 255. | MHP 25 SMART Drops | Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name Page 11 of 85 |

| (3) Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). < |
|---|
| the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for |
| Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Deferred for |
| Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for |
| Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for |
| |
| Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| Deferred forConfirmation/Availability of Homeopathic Drops Section.Change of brand name |
| • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| |
| |

| S.No | Brand name | Decision |
|------|-------------------------------|---|
| (1) | (2) | (3) |
| | | Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 267. | MHP 38 NERVOL Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 268. | MHP 39 HOLFIX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 269. | MHP 40 HAIR CARE Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 270. | MHP 41 TRAUMIX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 271. | MHP 42 MOUTH SORE Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 272. | MHP43 STIMULATION TONIC Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 273. | MHP 44 ALBUTOX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 274. | MHP 45 GINSENG BOOST Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 275. | MHP 46 GALTOX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 276. | MHP 47 EPILEPSOL Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 277. | MHP 48 FALIJEX Drops | Page 13 of 85 |

| S.No | Brand name | Decision |
|---------------------|-------------------------|--|
| (1) | (2) | (3) |
| | | Confirmation/Availability of Homeopathic Drops Section.Change of brand name |
| | | Evidence are provided in support of the claim of availability o |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 278. | MHP 49 TONSINIL Drops | Change of brand nameEvidence are provided in support of the claim of availability o |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 279. | MHP 50 THYROXINIL Drops | Change of brand name |
| | * | • Evidence are provided in support of the claim of availability of the current of a support of the claim of availability of the support of the claim of a support of a support of the claim of a support |
| | | the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 280. | MHP 51 VERTILEX Drops | Change of brand name |
| <i>4</i> 00. | MIII 51 VENTILEA DIOPS | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred forConfirmation/Availability of Homeopathic Drops Section. |
| • • • • | | Change of brand name |
| 281. | MHP 52 MORBINIL Drops | Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 282. | MHP 53 TUMEDIC Drops | Change of brand name Evolution of the shall be a state of the shall be shall be a state of the shall be shall b |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 283. | MHP 54 HERNIZIP Drops | Change of brand name |
| 2001 | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| a e : | | Change of brand name |
| 284. | MHP 55 SCIATILAX Drops | Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. Change of hund name |
| 285. | MHP 56 SHAPEUP Drops | Change of brand nameEvidence are provided in support of the claim of availability of |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 286. | MHP 57 PAPILLOMA Drops | Change of brand name |
| | r - | • Evidence are provided in support of the claim of availability of the gran each combination in local market for loct 10 |
| | | the proposed combination in local market for last 10 years(sales invoices including distribution record) |
| | | years(sales invoices including distribution record). Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| a e= | | Change of brand name |
| 287. | MHP 58 NICOTOX Drops | Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | Page 14 of 85 |
| | | |



<u>F.No.10-10/2022-OTC (M-111)</u>

| Brand name | Decision |
|------------------------|---|
| (2) | (3) |
| MHP 59 FUNGUS Drpos | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| MHP 60 HORMODEC Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| MHP 61 VARICELLA Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| MHP 62 URTISOL Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| MHP 63 PARKINSOL Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| HEART COMPLEX Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| ALFALFA TONIC Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| ASHOKA Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| BRYCOVIT Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| GERD Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| HAPAMAG Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | Deferred for |
| | (2) MHP 59 FUNGUS Drpos MHP 60 HORMODEC Drops MHP 61 VARICELLA Drops MHP 62 URTISOL Drops MHP 63 PARKINSOL Drops HEART COMPLEX Drops ALFALFA TONIC Syrup ASHOKA Syrup BRYCOVIT Syrup |

Page 15 of 85 Juncel.

| S.No | Brand name | Decision |
|------|---------------------------|---|
| (1) | (2) | (3) |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 300. | LAXI Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Bryonia in 3x and Nux vomica in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 301. | PANTOUX Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Bryonia 3x and Belladonna in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 302. | RENECAL Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 303. | VOMEZ Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 304. | ACIDIN – C Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 305. | GINKGO BILOBA TONIC Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 306. | JAM E RAHAT Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Aconite in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 307. | MHP FEVER SYRUP Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formutation contains Aconite in 3x and Belladonna in 3x preapartion which is toxic and revise the potency with 6x or above. |
| 308. | MHP GASTRIC SYRUP Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Aconite in 3x preapartion which is toxic and revise the potency with 6x or above. |
| | | Deferred for |

Page 16 of 85 Juncel.

<u>F.No.10-10/2022-OTC (M-111)</u>

| 1 | Brand name | Decision |
|------|------------------------------|--|
| (1) | (2) | (3) |
| | | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Broyonia and Belladonna in 3x mother tincture preapartion which is toxic and revise the potency with 6x or above. |
| 310. | MHP DIARRHEA SYRUP Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 311. | MHP TONSITRIX SYRUP Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 312. | FIBROLEC MALT Syrup | Deferred for Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 313. | INFACURE COLIC DROPS Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 314. | MULLEIN EAR DROPS Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Aconite and Belladonna in mother tincture preapartion which is toxic and revise the potency with 6x or above. |
| 315. | PEDITRON GRIPE WATER Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 316. | PLANTAGO DENTAL REMEDY Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formuation contains Aconite in 3x and Belladonna in mother tincture preapartion which is toxic and revise the potency with 6x or above. |
| 317. | SINUX NASAL SPRAY Spray | Deferred for Confirmation/Availability of Homeopathic Nasal Spray section Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 318. | SHARBAT E FAULAD Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 319. | DYROSOL Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 320. | Diaracin Drops | Page 17 of 85 |

| S.No | Brand name | Decision (2) |
|------|-------------------|--|
| (1) | (2) | (3) • Confirmation/Availability of Homeopathic Drops Section. |
| | | Change of brand name |
| | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 321. | Brenol Drops | • Change of brand name |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| | | Change of brand name |
| 322. | Venrol Drops | • Evidence are provided in support of the claim of availability of |
| 522. | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | • The applied formulation contains Psorinum which is poinious |
| | | revise /clarifcation regarding formulation is required |
| | | Deferred for Confirmation (Availability of Hamaonathia Drong Section |
| | Verminal Drops | Confirmation/Availability of Homeopathic Drops Section.Change of brand name |
| 323. | verminar Drops | Change of brand name Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 224 | Sleepnex Drops | Change of brand name |
| 324. | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| | | • Change of brand name |
| 275 | Semone Drops | • Evidence are provided in support of the claim of availability of |
| 325. | | the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | The applied formulation contains Nux vomica in 3x potency |
| | | which is toxic and revise the formulation with potency of 6x of |
| | | above |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 326. | Baby Tonic Drops | Change of brand name |
| 520. | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for Confirmation (Availability of Homeonethic Drope Section |
| | Yohimbitone Drops | Confirmation/Availability of Homeopathic Drops Section.Change of brand name |
| 327. | rommonone Drops | Change of brand name Evidence are provided in support of the claim of availability of |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 328. | Diagoline Drops | Change of brand name |
| 340. | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 329. | Eyetis Drops | • Change of brand name |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for lost 10 |
| | | the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 330. | Rheumacin Drops | Deferred for |
| | | Page 18 of 85 |
| | | |

| <u>5.No</u> | Brand name | Decision (3) |
|-------------|--|---|
| (1) | (2) | (3) • Confirmation/Availability of Homeopathic Drops Section. |
| | | Change of brand name |
| | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | Managa Drang | Confirmation/Availability of Homeopathic Drops Section. |
| 331. | Mensee Drops | Change of brand nameEvidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 332. | Lactocin Drops | Change of brand name |
| | | • Evidence are provided in support of the claim of availability of the memory and combination in local merily for loct 10 |
| | | the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 333. | Pleuragin Drops | Change of brand name |
| | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| | Easy Birth Drops | Commutation/Availability of Homeopaulie Drops Section. Change of brand name |
| 334. | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | Bassisin Drong | Confirmation/Availability of Homeopathic Drops Section. |
| 335. | Respicin Drops | Change of brand nameEvidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 336. | Episinium Drops | Change of brand name |
| | | • Evidence are provided in support of the claim of availability of the memory and combination in local membration last 10 |
| | | the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| 337. | Strumeel Drops | Change of brand name |
| 557. | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 120 | Tonsilex Drops | Change of brand name |
| 338. | ······································ | Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | PILES FAR Powder | Confirmation/Availability of Homeopathic Drops Section.Change of brand name |
| 339. | | Change of brand name Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 340. | Scialgin Drops | • Change of brand name |
| | | • Evidence are provided in support of the claim of availability of the memory and combination in local merily for loct 10 |
| | | the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Page 19 of 85 |

| S.No | Brand name | Decision |
|------|-----------------|---|
| (1) | (2) | (3) |
| 341. | Preshole Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 342. | Redcor Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 343. | Reno Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 344. | Sinuse Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 345. | Pilex Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 346. | Alfasy Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 347. | Paralysin Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 348. | Veratrum Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 349. | Vertigone Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 350. | Baresin Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 351. | Geritax Drops | Deferred forConfirmation/Availability of Homeopathic Drops Section.Change of brand name |

Page 20 of 85 Juncel.

| S.No | Brand name | Decision |
|------|------------------|---|
| (1) | (2) | (3) |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 352. | Ulcerine Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 353. | Steron Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 354. | Nervita Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 355. | Antifebrol Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 356. | Barsal Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains poisinious preparation Psorinium revise/clarification regarding the formulation is required |
| 357. | Womenlex Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 358. | Headexine Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 359. | Menstone Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 360. | Kalsolene Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 361. | BTax Lotion | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name |

Page 21 of 85 Juncel.

| S.No | Brand name | Decision |
|------|-----------------|--|
| (1) | (2) | (3) |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | • The applied formulation contains rhus tox in mother tincture potency which is toxic and revise the formulation with potency of 6x or above |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. Change of brand name |
| 362. | Rheumalex Drops | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | The applied formulation contains Berberis vulgaris in 3x potency which is toxic and revise the formulation with potency of 6x or above |
| | | Deferred for |
| | Arteria Drops | Confirmation/Availability of Homeopathic Drops Section. Change of brand name |
| 363. | Them Diops | Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | Calardia Davar | Confirmation/Availability of Homeopathic Drops Section. |
| 364. | Calculin Drops | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | | • Confirmation/Availability of Homeopathic Drops Section. |
| | | Change of brand name |
| | Uritone Drops | • Evidence are provided in support of the claim of availability of |
| 365. | Unione Drops | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | • The applied formulation contains Berberis vulgaris in 3x |
| | | potency which is toxic and revise the formulation with potency |
| | | Of 6x or above Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| | | Change of brand name |
| | Epigo Drops | Evidence are provided in support of the claim of availability of |
| 366. | Lhigo Diopo | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | • Teasting certifacte/evidence is required that source of |
| | | sarcodes(TSE,BSE free) |
| | | Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| 367. | Vomitis Drops | Change of brand name |
| 0011 | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). Deferred for |
| | | Confirmation/Availability of Homeopathic Drops Section. |
| | Mouthogin Drops | Commandi/Availability of Homeopathic Drops Section. Change of brand name |
| 368. | noutrogin Drops | Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| | | Deferred for |
| | Jenitone Drops | Confirmation/Availability of Homeopathic Drops Section. |
| 369. | | Change of brand name |
| 507. | | • Evidence are provided in support of the claim of availability of |
| | | the proposed combination in local market for last 10 |
| | | years(sales invoices including distribution record). |
| 0=0 | Heptone Drops | Deferred for |
| 370. | r · · · · · F ~ | • Confirmation/Availability of Homeopathic Drops Section. |
| | | Change of brand name |

Page 22 of 85

| S.No | Brand name | Decision |
|------|-------------------|--|
| (1) | (2) | (3) |
| | | • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 371. | Gripsin Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia alba in 2x potency which is toxic and revise the formulation with potency of 6x or above |
| 372. | Hernex Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Nux vomica in 3x potency which is toxic and revise the formulation with potency of 6x or above |
| 373. | Cardina Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 374. | Tansol Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 375. | Rheumata Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 376. | Cancerolene Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 377. | Francy Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 378. | Lekreen Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 379. | Deafol Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 380. | Enura Drops | Deferred forConfirmation/Availability of Homeopathic Drops Section. |

Page 23 of 85 Junded.

| 382. Psorineel Drops Deferred for Change of brand name Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record). 383. Kidsal Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 384. Spermatorthin Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Confirmation/Availability of Homeopathic Drops Sect Confirmation/Availability of Homeopathic Drops Sect Change of brand name 384. Spermatorthin Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 385. Gelsemium Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Jatiol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 387. Jatiol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Jatiol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Steme Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Jatiol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops | S.No | Brand name | Decision |
|---|------|---------------------|--|
| 381. But Drops Deferred for Confirmation Availability of Homeopathic Drops Sect Charge of brand name 382. Psorineel Drops Deferred for Confirmation Availability of Homeopathic Drops Sect Charge of brand name 383. Kidsal Drops Deferred for Confirmation Availability of Homeopathic Drops Sect Confirmation Availability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation Availability of Homeopathic Drops Sect Change of brand name 387. Jaitol Drops Deferred for Confirmation Availability of Homeopathic Drops Sect Change of brand name 388. Jaitol Drops Deferred for Confirmation Availability of Homeopathic Drops S | (1) | (2) | |
| 381. But Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 382. Psorineel Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 383. Fasting Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 384. Psorineel Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 385. Kidsal Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Spermatorrhin Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 387. Spermatorrhin Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Gelsemium Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirm | | | |
| 381. Blut Drops Deferred for • Confirmation/Availability of Homeopathic Drops Sect 382. Psorineel Drops • Confirmation/Availability of Homeopathic Drops Sect 383. Kidsal Drops • Confirmation/Availability of Homeopathic Drops Sect 383. Kidsal Drops • Confirmation/Availability of Homeopathic Drops Sect 383. Kidsal Drops • Confirmation/Availability of Homeopathic Drops Sect 384. Spermatorthin Drops • Confirmation/Availability of Homeopathic Drops Sect 385. Spermatorthin Drops • Confirmation/Availability of Homeopathic Drops Sect 386. Spermatorthin Drops • Confirmation/Availability of Homeopathic Drops Sect 387. Gelsemium Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Gelsemium Drops • Confirmation/Availability of Homeopathic Drops Sect 386. Juitol Drops • Confirmation/Availability of Homeopathic Drops Sect 387. Gelsemium Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Juitol Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Juitol Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Stomolene Drops • | | | |
| 381. But Drops Confirmation Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 yearstacks invoices including distribution record). 382. Psorineel Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 yearstacks invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name | | | |
| 381. Blut Drops Change of brand name 382. Psorineel Drops Evidence are provided in support of the claim of availating distribution record). 382. Psorineel Drops Evidence are provided in support of the claim of availating distribution record). 383. Kidsal Drops Evidence are provided in support of the claim of availating distribution record). 384. Spermatorthin Drops Evidence are provided in support of the claim of availating distribution record). 384. Spermatorthin Drops Evidence are provided in support of the claim of availating the proposed combination in local market for last 10 years(asles invoices including distribution record). 384. Spermatorthin Drops Deferred for 385. Gelsemium Drops Evidence are provided in support of the claim of availating the proposed combination in local market for last 10 years(asles invoices including distribution record). 386. Gelsemium Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect 387. Gelsemium Drops Evidence are provided in support of the claim of availating the proposed combination in local market for last 10 years(asles invoices including distribution record). 388. Jatiol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect < | | | |
| 381. Evidence are provided in support of the claim of availing the proposed combination in local market for has 10 years(sales invoices including distribution record). 382. Psorineel Drops Deferred for 383. Kidsal Drops Confirmation/Availability of Homeopathic Drops Sect - Change of brand name 384. Spermatorthin Drops Deferred for 385. Spermatorthin Drops Deferred for 386. Spermatorthin Drops Deferred for 386. Spermatorthin Drops Deferred for 387. Spermatorthin Drops Deferred for 388. Spermatorthin Drops Deferred for 386. Gelsemium Drops Deferred for 386. Gelsemium Drops Deferred for 387. Gelsemium Drops Deferred for 388. Spermatorthin Drops Deferred for 386. Gelsemium Drops Deferred for 387. Gelsemium Drops Deferred for 388. Spermatorthin Drops Deferred for 386. Jatiol Drops Deferred for 386. Jatiol Drops Confirmation/Availability of Homeopathic Drops Sect 387. <td>201</td> <td>Blut Drops</td> <td></td> | 201 | Blut Drops | |
| 382. Psorineel Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avail | 381. | I I | • Evidence are provided in support of the claim of availability of |
| years(ales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(ales invoices including distribution record). 383. Kidsal Drops Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided | | | |
| 382. Psorineel Drops Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availating distribution record). years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availating distribution record). Peterred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availating the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availating the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availating the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Ruus tox 4 xpotency toxic and revise the formulation ontains Ruus tox 4 xpotency toxic and revise the formulation availating distribution record). The applied formulation contains Ruus tox 4 xpotency toxic and revise including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are pr | | | |
| 382. Psorineel Drops • Change of brand name 583. Fidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 383. Kidsal Drops 384. Spermatorrhin Drops 385. Gelsemium Drops 386. Jaitol Drops 387. Intestinal Drops 386. Jaitol Drops 387. Intestinal Drops 388. Stomolene Drops 388. Stomolene Drops 389. Skinex Drops | | | Deferred for |
| 362. Psonneer Drops 383. Fidence are provided in support of the claim of availing the proposed combination in local market for last 10 years(sales invoices including distribution record). 383. Kidsal Drops 384. Spermatorrhin Drops 384. Spermatorrhin Drops 385. Gelsemium Drops 386. Gelsemium Drops 387. Intestinal Drops 388. Jaitol Drops 388. Stomolene Drops 388. Stomolene Drops 388. Stomolene Drops 388. Stomolene Drops | | | Confirmation/Availability of Homeopathic Drops Section. |
| Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 years(sales invoices including distribution record). Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox 4 potency toxic and revise the formulation outains Rhus tox 4 potency toxic and revise the formulation in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name<!--</td--><td>382.</td><td>Psorineel Drops</td><td></td> | 382. | Psorineel Drops | |
| 383. Kidsal Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Charge of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 vears(sales invoices including distribution record). 384. Spermatorrhin Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Charge of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 vears(sales invoices including distribution record). 385. Gelsemium Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Charge of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 vears(sales invoices including distribution record). The applied formulation contains Rhus tox 4 potency toxic and revise the formulation with potency of 6x an Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 vears(sales invoices including distribution record). Section a name Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 vears(sales invoices including distribution record). The applied formulation contains Ryronia in 4x potency is toxic and revise the formulation in local market fo | | ľ | |
| 383. Kidsal Drops Deferred for • Confirmation/Availability of Homeopathic Drops Sect 384. Spermatorrhin Drops • Charge of brand name • Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 384. Spermatorrhin Drops • Confirmation/Availability of Homeopathic Drops Sect • Charge of brand name 385. Gelsemium Drops • Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Charge of brand name • Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 386. Jaitol Drops • Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 387. Jaitol Drops • Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 388. Intestinal Drops • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name 388. Stomolene Drops • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name 388. Stomolene Drops • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in suppor | | | |
| 383.Kidsal Drops• Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).384.Spermatorthin DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).385.Gelsemium DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Rbus tox A potency toxic and revise the formulation with potency of 6x an Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Rbus tox A potency toxic and revise the formulation in local market for last 10 years(sales invoices including distribution record).387.Intestinal DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided | | | |
| 383. Kidsal Drops Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 384. Spermatorrhin Drops 385. Gelsemium Drops Gelsemium Drops Deferred for Gelsemium Drops Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 385. Gelsemium Drops Deferred for 386. Jaitol Drops Deferred for 386. Jaitol Drops Deferred for 387. Intestinal Drops Deferred for 388. Intestinal Drops Deferred for 388. Stomolene Drops Deferred for 388. Stomolene Drops Deferred for 388. Stomolene Drops Deferred for 389. Skinex Drops Deferred for 389. Skinex Drops Deferred for 389. Stomolene Drops Deferred for | | | |
| 385. Nidsai Drops Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox 4 spotency toxic and revise the formulation ortin in Nus tox 4 spotency toxic and revise the formulation market for last 10 years(sales invoices including distribution record). The applied formulation in local market for last 10 years(sales invoices including distribution record). The applied formulation in local market for last 10 years(sales invoices including distribution record). The applied formulation and the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox 4 spotency is toxic and revise the formulation record). The applied formulation in local market for last 1 | | | |
| 384. Spermatorrhin Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 385. Gelsemium Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 386. Gelsemium Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 387. Gelsemium Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 387. Intestinal Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for C | 383. | Kidsal Drops | |
| 384. Spermatorrhin Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record). 385. Gelsemium Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 387. Jaitol Drops Confirmation/Availability of Homeopathic Drops Sect Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Confirmation/Availability of Homeopathic Drops Sect Confirmation/Availability of Homeopathic Drops Sect Change of brand name 387. Intestinal Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 389. Stimex Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 389. <td< td=""><td></td><td></td><td>• Evidence are provided in support of the training of availability of the proposed combination in local market for last 10</td></td<> | | | • Evidence are provided in support of the training of availability of the proposed combination in local market for last 10 |
| 384. Spermatorrhin Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of avails the proposed combination in local market for last 10 years(sales invoices including distribution record). 385. Gelsemium Drops Deferred for Confirmation/A vailability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 386. Jaitol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 387. Intestinal Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Intestinal Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stomolene Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stimex Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name 388. Stimex Drops Deferred for Confirmation/Availability of H | | | |
| 384. Spermatorrhin Drops Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availative proposed combination in local market for last 10 years(sales invoices including distribution record). Befreid for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availative proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x an Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availative proposed combination in local market for last 10 years(sales invoices including distribution record). Baitol Drops Jaitol Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availative the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availative the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonis in 4x potency for 2 confirmation/Availab | | | |
| 384. Spermatorrhin Drops Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). 385. Gelsemium Drops Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x and Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The stinal Drops Intestinal Drops Stomolene Drops Stomolene Drops Stomolene Drops Skinex Drops <li< td=""><td></td><td></td><td></td></li<> | | | |
| 334. Evidence are provided in support of the claim of availating the proposed combination in local market for last 10 years(sales invoices including distribution record). 385. Gelsemium Drops Deferred for | 20.4 | Spermatorrhin Drops | |
| 385. Gelsemium Drops Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x an Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Peferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Bryonia in 4x potenci is toxic and revise the formulation out in post above Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). * Deferred for • Confirmation/Avail | 384. | 1 1 | • Evidence are provided in support of the claim of availability of |
| 385. Gelsemium Drops Deferred for • Confirmation/Availability of Homeopathic Drops Sect 385. Gelsemium Drops • Evidence are provided in support of the claim of availit the proposed combination in local market for last 10 years(sales invoices including distribution record). 386. Jaitol Drops • Confirmation/Availability of Homeopathic Drops Sect 386. Jaitol Drops • Confirmation/Availability of Homeopathic Drops Sect 387. Intestinal Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Intestinal Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Stomolene Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Stomolene Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Stomolene Drops • Confirmation/Availability of Homeopathic Drops Sect 388. Stomolene Drops • Confirmation/Availability of Homeopathic Drops Sect 389. Skinex Drops • Confirmation/Availability of Homeopathic Drops Sect 389. Skinex Drops • Confirmation/Availability of Homeopathic Drops Sect 389. Skinex Drops • Confirmation/Availability of Homeopathic Drops Sect 389. | | | |
| 385.Gelsemium Drops• Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x an Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).386.Jaitol DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).387.Intestinal DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex | | | |
| 385.Gelsemium Drops• Change of brand name Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x and Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).386.Jaitol DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).387.Intestinal DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of avail the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability | | | Deferred for |
| 385.Gelsemium Drops• Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x an Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).387.Intestinal DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Intestinal DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Dro | | | Confirmation/Availability of Homeopathic Drops Section. |
| 380. the proposed combination in local market for last 10 years(sales invoices including distribution record). 386. Jaitol Drops The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x and Deferred for 386. Jaitol Drops Deferred for 387. Intestinal Drops Deferred for 388. Intestinal Drops Deferred for 388. Stomolene Drops Deferred for 388. Stomolene Drops Deferred for 389. Skinex Drops Deferred for 389. Sk | | | |
| 386. the proposed combination in local market for last 10 years(sales invoices including distribution record). 386. Jaitol Drops 387. Jaitol Drops 388. Intestinal Drops 388. Stomolene Drops 388. Stomolene Drops 389. Skinex Drops 389. Skinex Drops | 385. | Gelsemium Drops | • Evidence are provided in support of the claim of availability of |
| The applied formulation contains Rhus tox 4x potency toxic and revise the formulation with potency of 6x and Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox 4x potency of 6x and revise the formulation via the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potent is toxic and revise the formulation with potency of 6x and bove Stomolene Drops Skinex Drops Skinex Drops | 0000 | | |
| 386. toxic and revise the formulation with potency of 6x and Deferred for 386. Jaitol Drops 386. Jaitol Drops 386. Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). 387. Intestinal Drops 388. Stomolene Drops 388. Stomolene Drops 389. Skinex Drops Skinex Drops Skinex Drops | | | |
| 386. Jaitol Drops Jaitol Drops Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potent is toxic and revise the formulation with potency of 6x above Stomolene Drops Skinex Drops Skinex Drops | | | |
| 386.Jaitol DropsConfirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).387.Intestinal DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name389.Skinex DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name389.Skinex DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name389.Skinex DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name389.Skinex DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name389.Skinex DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name389.Skinex DropsDeferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Confirmation/Availability of Homeopathic Drops Sect Change of brand name <b< td=""><td></td><td></td><td></td></b<> | | | |
| 386.Jaitol Drops• Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).387.Intestinal DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).387.Intestinal DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsSkinex DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/A vailability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for | | | |
| Stone Bernard Drops Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potent is toxic and revise the formulation with potency of 6x i above Stomolene Drops Stomolene Drops Skinex Drops Skinex Drops | | Laital Drops | |
| 387.Intestinal DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic | 386. | Jator Drops | |
| 387. Intestinal Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect 388. Intestinal Drops Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). 388. Stomolene Drops Deferred for 389. Stomolene Drops Confirmation/Availability of Homeopathic Drops Sect 389. Skinex Drops Deferred for 389. Skinex Drops Drops | | | |
| 387. Intestinal Drops 387. Intestinal Drops 387. Intestinal Drops 387. Evidence are provided in support of the claim of availate the proposed combination in local market for last 10 years(sales invoices including distribution record). 388. Stomolene Drops 388. Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availate the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availate the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in s | | | |
| 387. Intestinal Drops Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potentis toxic and revise the formulation with potency of 6x above Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Stomolene Drops Stomolene Drops Stomolene Drops Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 387. Intestinal Drops Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potentis toxic and revise the formulation with potency of 6x above Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Stomolene Drops Stomolene Drops Stomolene Drops Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | • Confirmation/Availability of Homeopathic Drops Section. |
| 387. Intestinal Drops Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potent is toxic and revise the formulation with potency of 6x above 388. Stomolene Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). 388. Stomolene Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). 389. Skinex Drops Skinex Drops of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulat | | | |
| 387. Intestinal Drops the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potentis toxic and revise the formulation with potency of 6x a above 388. Stomolene Drops Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). 389. Skinex Drops Skinex Drops | | Intestinal Drops | • Evidence are provided in support of the claim of availability of |
| 388. Stomolene Drops Before Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Before d for Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Before d for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | 387. | mesunai Drops | the proposed combination in local market for last 10 |
| 388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex Drops | | | years(sales invoices including distribution record). |
| 388.Stomolene DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name389.Skinex DropsDeferred for • Confirmation/Availability of Homeopathic Drops Sect • Change of brand name • Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record).389.Skinex Drops | | | • The applied formulation contains Bryonia in 4x potency which |
| 388. Stomolene Drops 388. Stomolene Drops Stomolene Drops Stomolene Drops Beiter definition Change of brand name Evidence are provided in support of the claim of availathe proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availathe proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availathe proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphiand 3x potency which is toxic and revise the formulation potency of 6x and above | | | is toxic and revise the formulation with potency of 6x and |
| 388. Stomolene Drops Stomolene Drops Stomolene Drops Stomolene Drops Stomolene Drops Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availathe proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availathe proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availathe proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphiand 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 388. Stomolene Drops Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Skinex Drops Skinex Drops The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 389. Skinex Drops Exidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | Stomolono Droza | |
| 389. Skinex Drops Beferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | 388. | Stomolene Drops | |
| 389. Skinex Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 389. Skinex Drops 389. Skinex Drops Deferred for Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availathe proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphiand 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 389. Skinex Drops Skinex Drops Confirmation/Availability of Homeopathic Drops Sect Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 389. Skinex Drops Change of brand name Evidence are provided in support of the claim of availa the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 389. Skinex Drops Evidence are provided in support of the claim of availat the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| 389. Skillex brops the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | 389. | Skinex Drops | |
| • The applied formulation contains Rhus tox and Graphi and 3x potency which is toxic and revise the formulation potency of 6x and above | | | |
| and 3x potency which is toxic and revise the formulation potency of 6x and above | | | • The applied formulation contains Rhus tox and Graphite in 4x |
| potency of 6x and above | | | and 3x potency which is toxic and revise the formulation with |
| | | | potency of 6x and above |
| | | | Page 24 of 85 Junce |

| S.No | Brand name | Decision |
|---------------------|----------------------------------|---|
| (1) | (2) | (3) |
| 390. | Shifanole Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 391. | Baimisal Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 392. | Colicin Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 393. | Facit Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 394. | Gastru Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 395. | Pelone Drops | Deferred for Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | M/s Meł | ktum Homoeo Pharma, Karachi |
| 396. | T#57 | Deferred for further deliberation |
| 397. | Digi Mek Syrup | Deferred for further deliberation |
| 398. | Gyno Zin Syrup | Deferred for further deliberation |
| <u>399.</u> | Gynofex Syrup | Deferred for further deliberation |
| 400. | Mek-Safi Syrup | Deferred for further deliberation pratories (Homoeo Division), |
| | St.No.28, Nisar Colony Industria | al Area, Samanabad, Faisalabad (E. No.00551) |
| 401. | Antipyrinum Q | Deferred for Homeopathic monograph of Phenazone is required |
| 402. | Apis Mellifica Q | Deferred for evidence of sarcoce testing (TSE BSE Ecoli) free is |
| 403. | Cantharis Vesicatoria Q | required Dfereed for sarcode testing of TSE,BSE is required |
| 404. | Cola Q | Deferred for Homepathic monograph of cola is required |
| 405. | Fel Tauri Q(EHPI) | Deferred for sarcode testing (TSE,BSE is required) |
| 406. | Formica Rufa Q | Deferred for sarcode testing (TSE,BSE is required) |
| <u>407.</u> 408. | Naphthalinum Q=1CH Sepia Q | Deferred for Homeopathic mnograph of Naphthalinium is required Deferred for sarcode testing(TSE,BSE) is required |
| -001 | | ak German Pharma, |
| | | Estate, Gadoon Amzai, Swabi (E. No.00723) |
| 409. | Alfalfa China Ginseng syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 410. | Carbo Vege Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | 1 | Page 25 of 85 Sunder |

| S.No | Brand name | Decision |
|------|---------------------|---|
| (1) | (2) | (3) |
| 411. | Baby Too Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 412. | Sticta Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 413. | Khoon Safi syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 414. | Stone Crasher syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 415. | Shaticoral syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 416. | Phyto Fort syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 417. | Sandrol syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 418. | Energex syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 419. | Santo Nin syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 420. | Secale Nin syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 421. | Joint Flex syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 422. | Damiana drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 423. | Carbo Vege drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 424. | Hamamelis drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 425. | Testa ovarum drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed Page 26 of 85 |

| S.No | Brand name | Decision |
|------|------------------------------------|---|
| (1) | (2) | |
| 426. | Kali Phos drops | Evidence of source that should free from sarcodes(TSE,BSE and E coli) Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 427. | Berberis drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed Raise the strength of Belladonna from 3x to 6x or above |
| 428. | Abdamee tablet | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 429. | Agnus Plus tablet | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 430. | Calcaria Plus tablet | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 431. | UP Calcium tablet | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 432. | Luteum Tin capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 433. | Leucorrhoea Folaad capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 434. | Acid Phos capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 435. | Morgan capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 436. | B.H capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 437. | Sperma capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 438. | Shifa e Naswa Drops (External use) | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 439. | Ferrum Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 440. | Gastrozyme Syrup | Deferred for Page 27 of 85 |

| <u>5.No</u> (1) | Brand name (2) | Decision (3) |
|-----------------|------------------|--|
| (1) | | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 441. | Ashoka Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 442. | Night capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 443. | Tonsil Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 444. | Nux Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 445. | Calciron Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 446. | Kasrat Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 447. | Cystonil Capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 448. | Amenor Capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record) |
| 449. | No prol Capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 450. | Arthro Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 451. | Hydrocot Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 452. | Fertile Capsule | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 453. | Ova agnus Tablet | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 454. | Symphori Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 455. | HBP Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Page 28 of 85 |

| S.No | Brand name | Decision |
|------|----------------------------|---|
| (1) | (2) | (3) |
| 456. | No abortion Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 457. | Haemoglobin Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 458. | Faulad Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 459. | Bed wetting Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 460. | Appetite Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 461. | Freckles acne Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 462. | Collins Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 463. | Male Sex Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 464. | Kidney Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| | | aul Brooks Homoeo Labs, |
| | Plot No. A-69, S.I.T.E., S | uper Highway Phase-I, Karachi (E. No.0088) EEC was apprised that division undertook a big task of company wise |
| 465. | Rulcid Syrup | arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 466. | Antifat Plus Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 467. | Ginseng 1x Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and Page 29 of 85 |

| S.No | Brand name | Decision |
|------|----------------------------|---|
| (1) | (2) | (3) |
| | | decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 468. | Itcho Cream | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 469. | Kracko Cream | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 470. | Vitigo Ointment | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 471. | Gandhakeen Cream | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 472. | V.Care Cream | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 473. | Nozema Ointment | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 474. | Markonil Cream | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 475. | Arsenicum Album 30C Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |

Page 30 of 85 Junce

| S.No | Brand name | Decision |
|------|--------------------------|--|
| (1) | (2) | (3) |
| 476. | Caricon Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 477. | Immune Elderbarry Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 478. | Kali Plex Drops | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 479. | Malca Drops | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence , there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 480. | Podina Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence , there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 481. | Vital C Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 482. | Colic Drop | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 483. | Anti Krack Cream | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 484. | Gasgon Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent Page 31 of 85 |

| S.No | Brand name | Decision |
|------|----------------------------------|---|
| (1) | (2) | (3) |
| | | preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications |
| | | were disposed of but still their names are available in the FIFO list. |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| | | computerization of record of submitted applications and subsequent |
| | | preparation of their FIFO list, the division has been evaluating and |
| 485. | Coffic Syrup | processing files. Hence ,there are chances that some product applications |
| | | were disposed of but still their names are available in the FIFO list. |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| | | computerization of record of submitted applications and subsequent |
| 486. | Fasto Gel | preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications |
| -001 | | were disposed of but still their names are available in the FIFO list. |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| | | computerization of record of submitted applications and subsequent |
| | | preparation of their FIFO list, the division has been evaluating and |
| 487. | Pileeno Ointment | processing files. Hence ,there are chances that some product application |
| | | were disposed of but still their names are available in the FIFO list. |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| | | computerization of record of submitted applications and subsequent |
| 488. | Dilaono Conquia | preparation of their FIFO list, the division has been evaluating and |
| 400. | Pileeno Capsule | processing files. Hence, there are chances that some product application |
| | | were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| | | computerization of record of submitted applications and subsequent |
| | | preparation of their FIFO list, the division has been evaluating and |
| 489. | Leuconil Capsule | processing files. Hence, there are chances that some product applications |
| | * | were disposed of but still their names are available in the FIFO list. |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| | | computerization of record of submitted applications and subsequent |
| 10.5 | | preparation of their FIFO list, the division has been evaluating and |
| 490. | Maledo Capsule | processing files. Hence, there are chances that some product application |
| | | were disposed of but still their names are available in the FIFO list. |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| | | computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and |
| 491. | Ginkgo Stress Relief Oral Liquid | processing files. Hence, there are chances that some product applications |
| 7/11 | Sinkgo Suess Kener Orai Liquiu | were disposed of but still their names are available in the FIFO list. |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company wise |
| | | arrangement of applications in various designated racks. Since |
| 402 | Snormon Con1- | computerization of record of submitted applications and subsequent |
| 492. | Spermax Capsule | preparation of their FIFO list, the division has been evaluating and |
| | | processing files. Hence , there are chances that some product applications |
| | | were disposed of but still their names are available in the FIFO list. |
| | | Page 32 of 85 Junder |
| | | |

| S.No | Brand name | Decision |
|------|---|---|
| (1) | (2) | (3) |
| | | Accordingly appreciated the services of division of health and OTC and |
| | | decided to defer decision of the instant product application to check its |
| | | status whether it has been disposed of or otherwise. |
| | | ots Pharma (Pvt) Ltd., dustrial Estate, Lahore (E. No.00553) |
| | Roots | |
| 493. | STONIL Drops | Deferred for rationality, justification and safety profile of product is required |
| 40.4 | Roots | Deferred for change |
| 494. | CoffChil Drops | of brand name |
| 405 | Roots | Deferred for rationality, justification |
| 495. | MSL VITA M SYRUP | and safety profile of product is required |
| 496. | Roots | Deferred for change |
| 490. | MSL MediPlex Syru | of brand name |
| 497. | Roots | Deferred for change |
| | AA Calbet-C Tablet Roots | of brand name |
| 498. | AA Cuf-No Plus Syrup | Deferred for change of brand name |
| 499. | Roots | Deferred for change |
| | BIO FEVER Syru | of brand name |
| 500 | Roots | Deferred for change |
| 500. | Cough Max Syrup | of brand name |
| | Roots | Deferred for rationality, justification |
| 501. | GASTRO MAX Syrup | and safety profile of product is required |
| | | |
| 502. | Roots | Deferred for change |
| | METI CHOR Syrup | of brand name |
| | | meo Research Laboratories, Sheilikahad, Talikthi Daad, Chargadda (E. No 00022) |
| | Plot No. 75-78, Sman Industrial Estate, | Sheikhabad, Takhtbhi Road, Charsadda (E. No.00932) Deferred for homeopathic monograph of Digitalis purpura along |
| 503. | Digitalis Purpurea ø | with method of preparation of Mother tincture |
| 504. | Eupatorium Perfoliatum | Deferred for specification of applied product is required |
| | Dilution | Deferred for specification of applied product is required |
| 505. | Gun Powder | clarification regarding handling source, storage and safety profile |
| 303. | Guil I Gwaei | of gun powder is required |
| | | Deferred for specification of applied product is required |
| 506. | Hekla Lava | clarification regarding handling source, storage and safety profile |
| | | of Hekla lava is required |
| 507. | Hepar Sulphure | Deferred for specification of applied product is required |
| 508. | Ignata Amara | Deferred for specification of applied product is required |
| 509. | Insulin | Deferred for sarcode testing (TSE,BSE and Ecoli) is required |
| 510. | Ipecacuanha | Deferred for specification of applied product is required |
| 511. | Iris | Deferred for specification of applied product is required |
| 512. | Kali bichromicum | Deferred for specification of applied product is required |
| 513. | Kalma Latifolia | Deferred for specification of applied product is required |
| | | Deferred for |
| 514. | Femafit | Clarification regarding dosage form of applied product, |
| | | Specification of active ingredients and 10 years sales and |
| | | distribution data of applied combination product |
| | | Deferred for Clarification regarding dosage form of applied product |
| 515. | Gout Cure | Clarification regarding dosage form of applied product, Specification of active ingredients and 10 years sales and |
| | | distribution data of applied combination product |
| | | Deferred for |
| | | Clarification regarding dosage form of applied product, |
| 516. | Fibro Cyst | Specification of active ingredients and 10 years sales and |
| | | distribution data of applied combination product |
| 517. | Justicia Adhatoda | Deferred for specification of applied product is required |
| 518. | Kreosotum | Deferred for specification of applied product is required |
| 519. | Kali Bromatum | Deferred for specification of applied product is required |
| 520. | Kali carbonicum | Deferred for specification of applied product is required |
| 521. | Kali Muriaticum | Deferred for specification of applied product is required |
| 522. | kali Arsenicosum | Deferred for specification of applied product is required |
| 523. | Lemna Minor | Deferred for specification of applied product is required |

Page 33 of 85

| S.No | Brand name | Decision |
|--------------|---------------------------------------|---|
| (1) | (2) | (3) |
| 524. | Lithium Benzoicum | Deferred for specification of applied product is required |
| 525. | Ledum Palustre | Deferred for specification of applied product is required |
| 526. | Lac Caninum | Deferred for specification of applied product is required |
| 527. | Moschus | Deferred for specification of applied product is required |
| 528. | Murex Purpurea | Deferred for specification of applied product is required |
| 529. | NAPHTHALINUM | Deferred for Homeopathic monograph of Naphthalinum is required |
| 530. | Natrum Arsenicum | Deferred for specification of applied product is required |
| 531. | Natrum Carbonicum | Deferred for specification of applied product is required |
| 532. | Natrum Phosphoricum | Deferred for specification of applied product is required |
| 533. | Natrum Salicylicum | Deferred for specification of applied product is required |
| 534. | Natrum Sulphuratum | Deferred for specification of applied product is required |
| 535. | Ocimum Canum | Deferred for specification of applied product is required |
| 536. | Onosmodium Virginianum | Deferred for specification of applied product is required |
| 537. | Pichi | Deferred for specification of applied product is required |
| 538. | Plantago Major | Deferred for specification of applied product is required |
| 539. | Plumbum Metallicum | Deferred for specification of applied product is required |
| 540. | Podophyllinum | Deferred for specification of applied product is required |
| 541. | Pothos Foetidus | Deferred for specification of applied product is required |
| 542. | Pulsatilla Nigricans | Deferred for specification of applied product is required |
| 543. | Pinus Sylvestris | Deferred for specification of applied product is required |
| 544. | Pituitaricum Pir Liquido | Deferred for sarcode testing(TSE,BSE,Ecoli) is required |
| 545. | Pix Liquida | Deferred for specification of applied product is required |
| 546. | Prostate Gland Ranunculus Bulbosus | Deferred for sarcode testing(TSE,BSE,Ecoli) is required |
| 547. 548. | Paeonia Officianlis | Deferred for specification of applied product is required Deferred for specification of applied product is required |
| 548. | Paraffinum | Deterred for specification of applied product is required |
| 549. | Diluting by 90% alcohol | Deferred for specification of applied product is required |
| 550. | Petroleum | Deferred for specification of applied product is required |
| 551. | Phosporus | Deferred for specification of applied product is required |
| 552. | Malaria Officinalis | Deferred for specification of applied product is required |
| 553. | Manganum Aceticum | Deferred for specification of applied product is required |
| 554. | Mephits Mephitica Dilution | Deferred for specification of applied product is required |
| 555. | Natrum Salicylicum Dilution | Deferred for specification of applied product is required |
| 556. | Mezereum | Deferred for specification of applied product is required |
| 557. | Happy Move 20ml | Deferred for submission of 10 years data of sales and distribution of applied combination product |
| 558. | Ginkgo-G 120ml 250 ml | Deferred for submission of 10 years data of sales and distribution of applied combination product |
| 559. | Artemet 20ml | Deferred for submission of 10 years data of sales and distribution of applied combination product |
| 560. | Pilomorm 20ml | Deferred for submission of 10 years data of sales and distribution of applied combination product |
| 561. | Ferrum Hony 120ml | Deferred for submission of 10 years data of sales and distribution of applied combination product |
| 562. | Bell-O-Nion 20ml | Deferred for submission of 10 years data of sales and distribution of applied combination product |
| 563. | Parkinsonism 20ml | Deferred for submission of 10 years data of sales and distribution of applied combination product |
| | | I/s Sadiq Pharma (Pvt) Ltd., Rawalpindi Road, Jand (E. No.00499) |
| 564. | Rani Khet Cure 1X Liquid | Deferred for change of brand name |
| 565. | Colcogest Fort 1X Liquid | Deferred for change of brand name |
| 566. | High Gest 30X Powder | Deferred for change of brand name |
| 567. | OTC 1X Liquid | Deferred for change of brand name |
| 568. | Magic OTC 3x Liquid | Deferred for change of brand name |
| 569. | Arnica Gold 30 Liquid | Deferred for change of brand name |
| | | e Graine de Vie Pharma (Pvt) Ltd., Value Addition City Khurrianwala, Faisalabad (E. No.00806) |
| 570. | PUR ESTOMAC TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record) |
| 570. | PUR ESTOMAC TABLET | |

| (1) 571. | | Decision |
|--------------|-------------------------|--|
| 571. | (2) | (3) |
| | PUR TONSIL Tab. | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 572. | PPUR VISION TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 573. | CONT.LECORR TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 574. | HAIR VITA TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 575. | CONT.HEMORR TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 576. | BEDPLASSEN TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 577. | CONT. STOM TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 578. | CONT. DEPRESSIVE TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 579. | PUR DYSMENORR Tablet | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 580. | CONT. ALLERGIN Tab. | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 581. | VOORMAN Tab. | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 582. | PROST. KEITH Tab. | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 583. | REIN STEIN Tab. | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 584. | MENOZEIT Tab. | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 585. | BIO+NO.1 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 586. | BIO+NO.2 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices |
| 587. | BIO+NO.3 | including distribution record). |
| 587. 588. | BIO+NO.3 BIO+NO.4 | |

Page 35 of 85

| S.No | Brand name | Decision |
|------|----------------------------|--|
| (1) | (2) | (3) |
| | | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record) |
| 590. | BIO+NO.6 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 591. | BIO+NO.7 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 592. | BIO+NO.8 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 593. | BIO+NO.9 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 594. | BIO+NO11 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 595. | BIO+NO.20 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 596. | BIO+NO.22 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 597. | BIO+NO.25 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 598. | BIO+NO.27 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 599. | BIO+NO.28 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 600. | HYPERT.EX TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 601. | FORT IS Tab. | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 602. | HAUTO GIN TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 603. | HEPA PRO TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 604. | PHYTOLACCA BERRY SLIM Tab. | Deferred for change of brand name |
| 605. | ALFALFA SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 606. | BRONCHCARE SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| S.No | Brand name | Decision |
|--|---|---|
| (1) | (2) | (3) |
| 607. | Grownic Syrup | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 608. | FERONISA SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 609. | Rein Stein Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 610. | CONT.HEMORR DROPS | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 611. | RHUMATISMO DROPS | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 612. | PUR ESTOMAC DROPS Each 20ml contains | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 613. | VOORMAN DROPS | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | s Sonexo Homoeo one, Turkey Road, Lahore (E. No.00758) |
| 614. | Sonexo's Robina Pseud | Deferred for sarcode testing (TSE,BSe,Ecoli) is required |
| 615. | Sonexo's Sepia | Deferred for sarcode testing (TSE,BSe,Ecoli) is required |
| | | tories, [Homeopathic Human] |
| 616. | TS CRATAEGUS POTENCY | rianwala, Faisalabad-Pakistan (E. No. 00640) Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 617. | TS CARBO VEGETABILIS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 618. | TS CIMICIFUGA RACEMOSA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 619. | TS SABINA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| (20) | | |
| 620. | TS SARSAPARILLA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial |
| 620. 621. | TS SARSAPARILLA POTENCY TS POLYGALA SENEGA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| | | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 621. | TS POLYGALA SENEGA POTENCY | Deferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied product |
| 621. 622. | TS POLYGALA SENEGA POTENCY TS SEPIA POTENCY | Deferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied product |
| 621. 622. 623. | TS POLYGALA SENEGA POTENCY TS SEPIA POTENCY TS CINA POTENCY | Deferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /Serial |
| 621.622.623.624. | TS POLYGALA SENEGA POTENCY TS SEPIA POTENCY TS CINA POTENCY TS SYZYGIUM CUMINII POTENCY | Deferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied product |
| 621. 622. 623. 624. 625. | TS POLYGALA SENEGA POTENCYTS SEPIA POTENCYTS CINA POTENCYTS SYZYGIUM CUMINII POTENCYTS STERCULIA POTENCYTS SOLIDAGO VIRGAUREA POTENCYSolidago VirgaureaPotenciesSolidago Virgaurea(EHPI) | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 621. 622. 623. 624. 625. 626. | TS POLYGALA SENEGA POTENCYTS SEPIA POTENCYTS CINA POTENCYTS SYZYGIUM CUMINII POTENCYTS STERCULIA POTENCYTS SOLIDAGO VIRGAUREA POTENCYSolidago VirgaureaPotenciesSolidago Virgaurea(EHPI)(EHPI Specifications) | Deferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied product |
| 621. 622. 623. 624. 625. 626. 627. | TS POLYGALA SENEGA POTENCYTS SEPIA POTENCYTS CINA POTENCYTS SYZYGIUM CUMINII POTENCYTS STERCULIA POTENCYTS SOLIDAGO VIRGAUREA POTENCY Solidago VirgaureaPotencies Solidago Virgaurea(EHPI) (EHPI Specifications)TS COLLINSONIA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied produ |
| 621. 622. 623. 624. 625. 626. 627. 628. | TS POLYGALA SENEGA POTENCYTS SEPIA POTENCYTS CINA POTENCYTS SYZYGIUM CUMINII POTENCYTS STERCULIA POTENCYTS SOLIDAGO VIRGAUREA POTENCY Solidago VirgaureaPotencies Solidago Virgaurea(EHPI) (EHPI Specifications)TS COLLINSONIA POTENCYTS COLOCYNTHIS POTENCY | Deferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied productDeferred for the Clarification is required regarding the potencies /SerialDilution of applied |

| S.No | Brand name | Decision |
|--------------|--|---|
| (1) | (2) | (3) |
| 632. | TS COLCHICUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 633. | TS CAMPHOR POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 634. | TS NUX VOMICA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 635. | TS ALSTONIA SCHOLARS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 636. | TS EUCALYPTUS GLOBULUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 637. | TS GENTIANA LUTEA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 638. | TS HELIANTHUS ANNUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| | TS HYDRASTIS CANADENSIS Q | |
| 639. | Each ml contains HYDRASTIS CANADENSIS(EHPI) Ø | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 640. | TS WITHANIA SOMNIFERA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 641. | TS TARAXACUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 642. | TS ORNITHOGALUM UMBELLATUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 643. | TS THUJA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 644. | TS PULSATILLA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 645. | TS ARSENICUM ALBUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 646. | TS ACIDUM BENZOICUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 647. | TS MENTHA PIPERATA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 648. | TS CHIONANTHUS VERGINICA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 649. | TS SELENIUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| 650. | TS TERMINALIA ARJUNA POTENCY | Deterred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the dosage form of |
| 651. | TS VALERIANA OFFICINALISQ | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 652. | TS ZINGIBER OFFICANALE Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 653. | TS GOSSYPIUM HERBACEUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 654. | TS ALLIUM CEPA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 655. | TS SARACA INDICA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 656. (57 | TS CHAMOMILLA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 657. | TS CHELIDONIUM MAJUS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 658. 650 | TS MORINGA OLIFERA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 659. 660 | TS PAEONIA OFFICANALIS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 660. | TS PIPER NIGRUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 661. 662. | TS RICINUS COMMUNIS Q TS AMMI VISNAGA POTENCY | applied product along with availability of section Deferred for the Clarification is required regarding the potencies /Serial |
| 663. | TS ARGENTUM NITRICUM POTENCY | Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| 664. | TS PASSIFLORA POTENCY | Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| 665. | TS ABIES NIGRA POTENCY | Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| 005. | 15 ADIES NIUKA PUTENUY | Dilution of applied product |

Page 38 of 85 Jundel.

| S.No | Brand name | Decision |
|-------------|--|--|
| (1) | (2) | (3) |
| 666. | TS RAUWOLFIA SERPENTIN POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 667. | TS CINNAMONUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 668. | TS RHUS TOXICODENDRON POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 669. | TS RUMEX CRISPUS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 670. | TS BERBERIS VULGARIS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 671. | TS BRYONIA ALBA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 672. | TS BELLADONA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| 673. | TS OPIUM POTENCY TS ROBINA PSELLDACACIA | Dilution of applied product |
| 674. | POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 675. | TS RUTA GRAVEOLENS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 676. | TS SANGUINARIA CANADENSIS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 677. | TS SPONGIA TOSTA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 678. | TS STAPHYSAGRIA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 679. | TS PHYSOSTIGMA VENENOSUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 680. | TS RAPHANUS SATIVUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 681. | TS NUPHER LUTEUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 682. | TS ORIGANUM MAJORANA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 683. | TS PAREIRA BRAVA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 684. | TS CAPSICUM ANNUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 685. | TS BAPTISIA TINCTORIA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 686. | TS BERBERIS AQUIFOLIUM Q TS CALENDULA OFFICINALIS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 687. | | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 688. | TS CARUM CARVI Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 689. | TS SENECIO AUREUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 690. | TS SLAIX NIGRA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 691. | TS RUBIA TINCTORIA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 692. | TS SCUTELLARIA LATERIFLORA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 693. | TS SABAL SERRULATA Q TS FRAXINUS AMERICANA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 694. | | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 695. | TS GINKGO BILOBA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 696. | TS FILIX MAS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 697. | TS EUPATORIUM PERFOLIATUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 698. | TS EPIGAEA REPENS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 699. | TS APIS MELLIFICA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 700. | TS BADIAGA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 701. | TS BACOPA MONNIERI Q | applied product along with availability of section |

Page 39 of 85

| S.No | Brand name | Decision |
|------|--|--|
| (1) | (2) | (3) |
| 702. | TS AZADIRACHTA INDICA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 703. | TS ASAFOETIDA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 704. | TS CASCARA SAGRADA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 705. | TS COCCULUS INDICUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 706. | TS CHELONE GLABRA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 707. | TS CEANOTHUS AMERICANUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 708. | TS CAULOPHYLLUM THALICTROIDES Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 709. | TS AGNUS CASTUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 710. | TS ALETRIS FARINOSA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 711. | TS AMBRA GRISEA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 712. | TS ANGUSTURA VERA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 713. | TS ABSINTHIUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 714. | TS GLYCYRRHIZA GLABRA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 715. | TS GINSENG Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 716. | TS GUAIACUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 717. | TS HEDERA HELIX Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 718. | TS NASTURTIUM AQUATICU Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 719. | TS SOLANUM NIGRUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 720. | TS SYMPHYTUM OFFICINALE Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 721. | TS URTICA URENS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 722. | TS YOHIMBINUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 723. | TS THLASPI BURSA PASTORIS Q TS COCCUS CACTI Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 724. | | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 725. | TS DULCAMARA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 726. | TS CROCUS SATIVUS Q TS CORIANDRUM SATIVUM Q | applied product along with availability of section |
| 727. | | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 728. | TS COFFEA CRUDA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 729. | TS THYMOL POTENCY | Deferred for Clarification is required regarding the dosage form of applied product along with arability of section |
| 730. | TS VALERIANA OFFICINALIS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 731. | TS ZINGIBER OFFICANALE POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 732. | TS GOSSYPIUM HERBACEUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 733. | TS VIBURNUM OPULUS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 734. | TS MENTHA PIPERATA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 735. | TS MORINGA OLIFERA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial |
| 735. | | |

| S.No | Brand name | Decision |
|--------------|---|--|
| (1) 736. | (2) TS PAEONIA OFFICINALIS POTENCY | (3) Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 737. | TS PIPER NIGRUM POTENCY | Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 738. | TS RICINUS COMMUNIS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 739. | TS DROSERA ROTUNDIFOLIA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 740. | TS SOLANUM DULCAMARA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 741. | TS ECHINACEA ANGUSTOFOLIA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 742. | TS EUPHRASIA OFFICINALIS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 743. | TS FUCUS VES POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 744. | TS ACIDUM BENZOICUM POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 745. | TS ALLIUM CEPA POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 746. | TS ASHOKA POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 747. | TS CHAMOMILLA POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product Deferred for the Clarification is required regarding the potencies /Seria |
| 748. | TS CHELIDONIUM MAJUS POTENCY TS CHIONANTHUS VERGINICAL | Dilution of applied product Deferred for the Clarification is required regarding the potencies /Seria |
| 749. | POTENCY | Dilution of applied product |
| 750. | TS EUCALYPTUS GLOBULUS POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 751. | TS GENTIANA LUTEA POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 752. | TS HELIANTHUS ANNUS POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 753. | TS HYDRASTIS CANADENSIS POTENCY | Deferred for the Clarification is required regarding the potencies /Seria Dilution of applied product |
| 754. | TS ROBINIA PSELLDACACIA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 755. | TS RUTA GRAVEOLENS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 756. | TS SANGUINARIA CANADENSIS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 757. | TS SPONGIA TOSTA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 758. | TS STAPHYSAGRIA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 759. | TS CINCHONA CHINA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 760. | TS CROTON TIGLIUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 761. | TS DAMIANA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 762. | TS DIGITALIS PURPUREA Q TS DIOSCOREA VILLOSA | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 763. | Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 764. | TS COLOCHICUM Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 765. | TS COLLINSONIA CANDENSIS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 766. 767. | TS COLOCYNTHIS Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 767. | TS CONVALLARIA Q TS CRATAEGUS OXYACANTYHA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 768. | TS TEUCRIUM MARUM POTENCY | applied product along with availability of section Deferred for the Clarification is required regarding the potencies /Seria |
| 769. | TS USNEA BARBATA POTENCY | Dilution of applied product Deferred for the Clarification is required regarding the potencies /Seria |
| | | Dilution of applied product Page 41 of 85 |

| S.No | Brand name | Decision |
|------|--|---|
| (1) | (2) | |
| 771. | TS VERATRUM ALBUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| 772. | TS VERATRUM VIRIDE POTENCY | Deterred for the Clarification is required regarding the potencies /Serial Dilution of applied product Deferred for the Clarification is required regarding the potencies /Serial |
| 773. | TS TRIBULUS TERRESTRIS POTENCY | Deterred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 774. | TS CHIMAPHILA UMBELLATA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 775. | TS CARDUUS MARIANUS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 776. | TS CAULOPHYLLUM THALICTROIDES POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 777. | TS ACIDUM PHOSPHORICUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 778. | TS AESCULUS HIPPOCASTANUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 779. | TS ACIDUM PHOSPHORICUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 780. | TS AESCULUS HIPPOCASTNAUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 781. | TS CARDUUS MARIANUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 782. | TS CAULOPHYLLUM THALICTROIDES Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 783. | TS CHIMAPHILA UMBELLATA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 784. | TS GELSEMIUM SEMPERVIRENS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 785. | TS GUAIAVUM OFFICINALE Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 786. | TS HAMAMELIS VIRGINICA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 787. | TS PLANTAGO MAJOR Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 788. | TS PODOPHYLLUM PELTATUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 789. | TS CINCHONA CHINA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 790. | TS CROTON TIGLUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 791. | TS DAMIANA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 792. | TS DIGITALIS PURPUREA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 793. | TS DIOSCORIA VILLOSA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 794. | TS BELLADONA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 795. | TS BERBERIS VULGARIS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 796. | TS BRYONIA ALBA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 797. | TS OPIUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 798. | TS ORNITHOGALUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 799. | TS ANACARDIUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 800. | TS ARNICA MONTANA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 801. | TS ARTEMISIA VULGARIS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 802. | TS AVENA SATIVA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 803. | TS ABIES NIGRA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 804. | TS TRIBULUS TERRESTRIS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 805. | TS TEUCRIUM MARUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |

Page 42 of 85 Junce

| S.No | Brand name | Decision |
|------|--------------------------------------|--|
| (1) | (2) | (3) Deferred for the Clarification is required regarding the dosage form of |
| 806. | TS USNEA BARBATA Q | applied product along with availability of section Deferred for the Clarification is required regarding the dosage form of |
| 807. | TS VERATRUM ALBUM Q | applied product along with availability of section |
| 808. | TS VERATRUM VIRIDE Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 809. | TS VIBURNUM OPULUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 810. | TS PASSIFLORA INCARNATA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 811. | TS PULSATILLA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 812. | TS RAWOLFIA SERPENTINA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 813. | TS RHUS TOXICODENDRON | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 814. | TS RUMEX CRISPUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 815. | TS ABROTANUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 816. | TS ACONITUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 817. | TS AETHUSA CYNAPIUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 818. | TS ALFALFA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 819. | TS ALLIUM SATIVUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 820. | TS GELSEMIUM SEMPERVIRENS POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 821. | TS GUAIACUM OFFICINALE POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 822. | TS HAMAMELIS VIRGINICA POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 823. | TS PLANTOGO MAJOR POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 824. | TS PODOPHYLLUM PELTATUM POTENCY | Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product |
| 825. | TS CAMPHOR OFFICINALIS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 826. | TS CARBO VEGETABILIS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 827. | TS CIMICIFUGA RACEMOSA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 828. | TS CINA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 829. | TS CINNAMONUM ZYLONICUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 830. | TS ARSENICUM ALBUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 831. | TS ASHWAGANDHA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 832. | TS SEPIA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 833. | TS STERCULIA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 834. | TS SELENIUM Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 835. | TS DROSERA ROTUNDIFOLIA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 836. | TS DULCAMARA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 837. | TS ECHINACEA ANGUSTIFOLIA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 838. | TS EUPHRASIA OFFICINALIS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 839. | TS FUCUS VISICULOSUS Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 840. | TS SUGER CONTROL SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |

| S.No | Brand name | Decision |
|------|----------------------------|---|
| (1) | (2) | (3) |
| 841. | TS BRAIN TONIC SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 842. | TS BABY VIT SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 843. | TS THANDAK SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 844. | TS PAIN OFF SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 845. | TS HBP SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 846. | TS COUGH DRY POWDER | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 847. | TS VITA PLUS DRY POWDER | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 848. | TS CALCIUM PLUS DRY POWDER | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 849. | TS NISA HAIR OIL | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 850. | TS GYNO REX SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 851. | TS MUSAFI KHOON SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 852. | TS BLOOD SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 853. | TS COLIREX SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 854. | TS VOMINAL SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 855. | TS DAMIANA PLUS SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Page 44 of 85 |

| S.No | Brand name | Decision |
|------|--------------------|---|
| (1) | (2) | (3) |
| 856. | TS VITA PLUS SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 857. | TS DROP 7 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 858. | TS DROP 8 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 859. | TS DROP 9 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 860. | TS DROP 10 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 861. | TS DROP 11 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 862. | TS DROP 12 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 863. | TS DROP 13 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 864. | TS DROP 14 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 865. | TS DROP 15 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 866. | TS DROP 16 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 867. | TS DROP 17 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 868. | TS DROP 18 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 869. | TS DROP 19 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section |
| 870. | TS DROP 21 | Deferred for |
| | - | l l |

Page 45 of 85 Juncel.

| S.No | Brand name | Decision |
|------|-------------------------------------|---|
| (1) | (2) | (3) Evidence are provided in support of the claim of availability of the |
| | | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 871. | TS DROP 22 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 872. | TS DROP 23 | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section) |
| 873. | TS THUJA Q | Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section |
| 874. | TS TOFEN LOTION | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 875. | TS D-TOX TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 876. | TS LICON -T TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 877. | TS P-NIL TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 878. | TS C-CEPA TABLET | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 879. | TS SACFEN LOTION | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| 880. | TS SAFOOF MAGHALAZ KHAS JWAHRDAR | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | M/s Za | am Zam Homoeo Pharma, Multan |
| 881. | ZM#1 GASTRIC Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 882. | ZM#2 URIC FLOW Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 883. | ZM#3 ALLERZ Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 884. | ZM#4 H.B.P. Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 885. | ZM#5 ACNOZ Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Page 46 of 85 |

| S.No | Brand name | Decision |
|------|------------------------------|---|
| (1) | (2) | (3) |
| 886. | ZM#6 UTRINOL Drops | Brand name needs to be changed Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 887. | ZM#7 KIDNAL Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 888. | ZM#8 CHELLICARD Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 889. | ZM#9 ZLYSIS Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 890. | ZM#10 SPERMA PHOS Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 891. | ZM#11 PILOZAM Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 892. | ZM#12 ARTHOZ Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 893. | ZM#13 SINOZ Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 894. | ZM#14 EASY FEEL Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 895. | ZM#15 SULPHUR COMPOUND Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 896. | ZM#16 MENORRHOEA Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 897. | ZM#17 BED WETTING Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 898. | ZM#18 INFECZ Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 899. | ZM#19 BARBELLA Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 900. | ZM#20 SALIX COMPOUND Drops | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Page 47 of 85 |

| S.No | Brand name | Decision |
|------|--------------------------|---|
| (1) | (2) | (3) |
| 901. | ALFA DS SYRUP | Brand name needs to be changed Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 902. | ALFA+GINSENG SYRUP S.F | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 903. | ALETRIS+ASHOKA SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 904. | APPETONE SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 905. | AVENA + SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 906. | B.COLIC SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 907. | BELLACEF SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 908. | CALZ SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 909. | CAPTAIN BABY TONIC SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 910. | CATTZ SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 911. | CHELLICARD SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 912. | DAMIANA+GINSENG S.F | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 913. | DERMOZ SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 914. | FEMOZ SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 915. | FERRO-Z SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |

| S.No | Brand name | Decision |
|--------------|-------------------------|--|
| (1) | (2) | (3) |
| | | Brand name needs to be changed Deferred for |
| 916. | FLUZ SYRUP | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Brand name needs to be changed |
| 917. | GASTO VIT SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Brand name needs to be changed |
| 918. | GASTOZ SYRUP | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| | | Deferred for |
| 919. | GENSO FORTE SYRUP: | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Brand name needs to be changed Deferred for |
| 920. | HEPAZ ELIXIR: | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| | | Deferred for |
| 921. | KIDNOZ SYRUP: | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Brand name needs to be changed Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 922. | KUFZ SYRUP: | proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| | | Deferred for |
| 923. | KURCHI COMPOUND SYRUP: | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices |
| <i>143</i> . | KORCHI COMI OUND STRUF. | including distribution record). Brand name needs to be changed |
| | | Deferred for |
| 924. | Mensocard SYRUP: | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices |
| - | | including distribution record). |
| | | Brand name needs to be changed Deferred for |
| 025 | DEDDO 7 (UDUD | Evidence are provided in support of the claim of availability of the |
| 925. | PEPPOZ SYRUP: | proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for Evidence are provided in support of the claim of availability of the |
| 926. | POWERZ SYRUP: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). Brand name needs to be changed |
| | | Deferred for |
| 027 | DIMEY CVDUD. | Evidence are provided in support of the claim of availability of the |
| 927. | RUMEX SYRUP: | proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for Evidence are provided in support of the claim of availability of the |
| 928. | SLIMZ SYRUP: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). Brand name needs to be changed |
| | | Deferred for |
| 929. | TONSI COUGH SYRUP: | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices |
| , . | | including distribution record). |
| | | Brand name needs to be changed Deferred for |
| 030 | | Evidence are provided in support of the claim of availability of the |
| 930. | VITA GLOBIN SYRUP: | proposed combination in local market for last 10 years(sales invoices |
| | | Page 49 of 85 |

<u>F.No.10-10/2022-OTC (M-111)</u>

| S.No | Brand name | Decision |
|------|--|--|
| (1) | (2) | (3) |
| | | Brand name needs to be changed |
| 931. | VITAZ SYRUP: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 932. | VOMITOZ SYRUP: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 933. | WARMOZ SYRUP: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 934. | ALOE SONIA ELIXIR: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 935. | BERBE CAN ELIXIR: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 936. | KUF RELIEF SYRUP: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 937. | COUGH GONE SYRUP: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 938. | ZAMZAM PLACEBO SYRUP: | Deferred for clarification regarding formulation |
| 939. | ZAMZAM DISKETTES/ ZAMZAM ICING SUGAR | Deferred for clarification regarding formulation |
| 940. | ZAMZAM BLANKETTES/ ZAMZAM MILK OF SUGAR | Deferred for clarification regarding formulation |
| 941. | DENTOZ LOTION: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 942. | MOUTH CURE LOTION: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 943. | OTALLEIN LOTION: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 944. | KRACKZ OINTMENT: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 945. | ZAMZAM BALM: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 946. | Pain Gone Lotion: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 947. | PainZ Lotion: | Deferred for |

Page 50 of 85 Juncel.

| . <u>No</u> (1) | Brand name (2) | (3) |
|----------------------------|-------------------------|---|
| (1) | (2) | Evidence are provided in support of the claim of availability of the |
| | | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 948. | SCABOZ Lotion: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| 949. | ZAMZAM KHARISH Lotion: | Evidence are provided in support of the claim of availability of the |
| 949. | ZAMZAWI KHARISH LOUOII: | proposed combination in local market for last 10 years(sales invoices including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 950. | B.P NORMAL DROPS: | proposed combination in local market for last 10 years(sales invoices |
| 200 | Dir Hordin in Dicord. | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 951. | CALCOZ DROPS: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 952. | COCAZ DROPS: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| 052 | INFEDTO Z DRODG | Evidence are provided in support of the claim of availability of the |
| 953. | INFERTOZ DROPS: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 954. | RAPHNUS + DROPS: | proposed combination in local market for last 10 years(sales invoices |
| <i>3</i> .3 4 . | KAI IIIVUS + DKOI S. | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 955. | RESCUE Oral Spray: | proposed combination in local market for last 10 years(sales invoices |
| | 1 5 | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 956. | SEPTI CURE DROPS: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| 057 | | Evidence are provided in support of the claim of availability of the |
| 957. | SPERMOZ DROPS: | proposed combination in local market for last 10 years(sales invoices including distribution record) |
| | | including distribution record). Brand name needs to be changed |
| | + | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 958. | KIDNEY WASH DROPS: | proposed combination in local market for last 10 years(sales invoices |
| 730. | KIDINET WASH DRUPS. | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 959. | MENOGIN TABLET: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 960. | FEMOGIN TABLET: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| | | Deferred for |
| | | Evidence are provided in support of the claim of availability of the |
| 961. | ANTIFEVER TABLET: | proposed combination in local market for last 10 years(sales invoices |
| | | including distribution record). |
| | | Brand name needs to be changed |
| 0.0 | ANTIPYREEN TABLET: | Page 51 of 85 |
| 962. | MUTH INCLUMINDELI. | |

| | Brand name | Decision |
|------|----------------------------|--|
| (1) | (2) | (3) |
| | | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed Deferred for |
| 963. | AVEGIN TABLET: | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 964. | BLEEDING CURE TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 965. | CHOLEZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 966. | DYROZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 967. | FERROZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 968. | FLUZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 969. | GASTOZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 970. | HAYOCYNTH COMPOUND TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 971. | HEPTOZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 972. | HISTAZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 973. | HYPERZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 974. | KUFZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 975. | L.B.P TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 976. | LECICALD TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 977. | LECOCIN TABLET: | Deferred for Page 52 of 85 |

| S.No | Brand name | Decision |
|---------------------|--------------------------------|--|
| (1) | (2) | (3) |
| | | Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 978. | MENSOGEN TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 979. | PILOZAM TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 980. | SALIX PLUS TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 981. | SPERMA PHOS TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 982. | SULPHOGEN TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 983. | TONSOZ TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 984. | TYPHOGEN TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 985. | ULSOOGEN TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 986. | URIC FLOW TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 987. | ZAMODOL TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| 988. | ZDRY TABLET: | Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed |
| | | armaceutical (Pvt) Ltd, Lahore |
| <u>989.</u> | Chelifer Tablet | Deferred for change of brand name |
| <u>990.</u> 991. | Rinon Tablet Calcify Tablet | Deferred for change of brand name Deferred for change of brand name |
| <u>991.</u> 992. | Sacran Sachet | Deferred for change of brand name |
| 993. | Calcif-D Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer |

Page 53 of 85 Junce

| S.No | Brand name | Decision |
|-----------------------|---------------------------------|---|
| (1) | (2) | (3) |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 994. | Lifolac Powder | Deferred for change of brand name |
| 995. | Sacran Syrup | Deferred for change of brand name |
| 996. | On Life Tablet | Deferred for change of brand name |
| 997. | Cranblex Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 998. | Gomeg Drop | Deferred for change of brand name |
| 999. | Neo Chline Tablet | Deferred for change of brand name |
| 1000. | Koffsafe Drops | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1001. | Magtin Tablet | Deferred for change of brand name |
| 002. | Rexbion Tablet | Deferred for change of brand name |
| 1003. | Trisafe Syrup | Deferred for change of brand name |
| 1003. | Maxfair Tablet | Deferred for change of brand name |
| | | |
| 1005. | Proneed Sachet | Deferred for change of brand name EEC was apprised that division undertook a big task of company |
| 1006. | Q-Lime Tablet | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1007 | Testron Tablet | · · · · · · · · · · · · · · · · · · · |
| <u>1007.</u> | Testron Tablet | Deferred for change of brand name |
| <u>1008.</u> 1009. | Ultra D Tablet Magtin Tablet | Deferred for change of brand nameEEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks.Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1010. | Activer Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks.Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.EEC was apprised that division undertook a big task of company |
| 1011. | Laze-D Tablet | Page 54 of 85 |

| S.No | Brand name | Decision |
|-------|----------------|--|
| (1) | (2) | (3) |
| | | subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1012. | Ripro Drops | Deferred for change of brand name |
| 1013. | Cal-X Syrup | Deferred for change of brand name |
| 1014. | Cof-Nix Syrup | Deferred for change of brand name Laboratories, Lahore |
| 1015. | Cosatin Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1016. | Ospro D3 Drops | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1017. | Genol Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1018. | Gynotol Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1019. | Pretize Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1020. | Nt.Kuff Drops | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are Page 55 of 85 |

| S.No | Brand name | Decision |
|---|---|---|
| (1) | (2) | (3) |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1001 | | evaluating and processing files. Hence, there are chances that some |
| 1021. | Chondroitin Plus Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som |
| 1022. | Berry Mic Sachet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1023. | E Tone Syrup | evaluating and processing files. Hence, there are chances that som |
| 1020. | L'Ione Syrup | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | All | omed Curatives, Islamabad |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1024. | Minto Guard Liquid | evaluating and processing files.Hence,there are chances that som |
| 1024. | Winto Ouard Elquid | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| 1025 | Henry Chiele Linesid | whether it has been disposed of or otherwise. |
| 1025. | Happy Chick Liquid | Deferred for change of brand name EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 10.5 - | T | evaluating and processing files. Hence, there are chances that som |
| 1026. | Immuno Fit Liquid | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | Liveron Liquid | Deferred for change of brand name |
| 1027. | Multi Vito Max Liquid | Deferred for change of brand name |
| 1028. | | Deferred for change of brand name |
| | Adek Fit Liquid | |
| 1028. 1029. | Adek Fit Liquid | omed Curatives, Islamabad |
| 1028. 1029. 1030. | Adek Fit Liquid Ale Super Temp Cure Oral Liquid | omed Curatives, Islamabad Deferred for change of brand name |
| 1028. 1029. 1030. 1031. | Adek Fit Liquid Ale Super Temp Cure Oral Liquid Meat Up Powder | Omed Curatives, Islamabad Deferred for change of brand name Deferred for change of brand name |
| 1028. 1029. 1030. 1031. 1032. | Adek Fit Liquid Ale Super Temp Cure Oral Liquid Meat Up Powder Milk Up Powder | omed Curatives, Islamabad Deferred for change of brand name Deferred for change of brand name Deferred for change of brand name |
| 1028. 1029. 1030. 1031. 1032. 1033. | Adek Fit Liquid Ale Super Temp Cure Oral Liquid Meat Up Powder Milk Up Powder Tempanil Liquid | omed Curatives, Islamabad Deferred for change of brand name |
| 1028. 1029. 1030. 1031. 1032. 1033. 1034. | Adek Fit Liquid Ale Super Temp Cure Oral Liquid Meat Up Powder Milk Up Powder Tempanil Liquid Bio Lizo Vit Powder | Omed Curatives, Islamabad Deferred for change of brand name Deferred for change of brand name |
| 1028. 1029. 1030. 1031. 1032. 1033. | Adek Fit Liquid Ale Super Temp Cure Oral Liquid Meat Up Powder Milk Up Powder Tempanil Liquid | omed Curatives, Islamabad Deferred for change of brand name |

| S.No | Brand name | Decision |
|-------|------------------------------|--|
| (1) | (2) | (3) |
| | | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1036. | Triple 5 Oral Solution | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1037. | Colic Star Liquid | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1038. | Pak Akseer Jair Nafas Powder | Deferred for change of brand name |
| 1039. | Bone Phosphate Powder | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1040. | B-Cure Minerals Powder | whether it has been disposed of or otherwise. Deferred for change of brand name |
| 1040. | | za Pharma, Lahore |
| 1041. | Garent-C Syrup | Deferred for the following reasons: Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing. |
| 1042. | Garent-C Tablet | Deferred for the following reasons: Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing. |
| 1043. | Garent-D Drop | Deferred for the following reasons: Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing. |
| 1044. | Kidsol Sachet | Deferred for change of brand name |
| 1045. | Mc New Sachet | Deferred for the following reasons: Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing. |
| 1046. | Qufo Tablet | Deferred for the following reasons: Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing. |
| 1047. | Qx-Forte Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |

Page 57 of 85

| S.No | Brand name | Decision |
|----------------|--------------------------------|---|
| (1) | (2) | (3) |
| | | evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1048. | Calmoon Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1049. | H-D Oral Drops | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1050. | Instacal-D Tablet | Deferred for change of brand name |
| 1051. | Tonisan Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1052. | Noni Grow Syrup | Deferred for change of brand name |
| 1053. | Noni Grow Drops | Deferred for change of brand name |
| | | r Pharma, Lahore |
| 1054. | Glosence Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1055. | Glsence Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1056. | Super-Cal Syrup | Deferred for change of brand name |
| 1057. | Super-Cal Tablet | Deferred for change of brand name |
| 1058. 1059. | Osteo-5 Tablet Bio-Mv Syrup | Deferred for change of brand name Deferred for change of brand name |
| 1059. | Bio-Mv Tablet | Deferred for change of brand name |
| 1061. | Mecolax Tablet | Deferred for change of brand name |
| 1062. | Ct Max Tablet | Deferred for change of brand name |

Page 58 of 85

| S.No | Brand name | Decision |
|-------|-----------------------|---|
| (1) | (2) | (3) |
| 1063. | Ct Max Syrup | Deferred for change of brand name |
| 1064. | Noor Colic Drops | Deferred for change of brand name |
| 1065. | Cuf-Go Syrup | Deferred for change of brand name |
| 1066. | Bio-Kuff Syrup | Deferred for change of brand name |
| 1067. | Scio-Cid Syrup | Deferred for change of brand name |
| 1068. | | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som |
| | Enuf Supplement | product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1069. | Glomom Supplement | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1070. | Nutri-M Supplement | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1071. | Suppli-M Supplement | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1072. | Wellpro Supplement | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1073. | Ovasital Sachet | Deferred for change of brand name |
| 1074. | Ad-Plus Drops | Deferred for change of brand name |
| 1075. | Go-Pep Drops | Deferred for change of brand name |
| 1076. | Spirglo Tablet | Deferred for change of brand name |
| 1077. | An Co-Q10 Vits Tablet | rzik Laboratories, Faisalabad EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that som product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the Page 59 of 85 |

| | Brand name | Decision |
|-------|---------------------|---|
| (1) | (2) | (3) |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that some |
| 1078. | Bone Plus-Z Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1079. | Multi-Vit Tablet | evaluating and processing files. Hence, there are chances that some |
| | | product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | Aurum Health Care, Lahore |
| 1080. | Fertimap Tablet | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that some |
| 1081. | Aritmove Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some |
| 1082. | Deon 200Iu Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1083. | Flobac Tablet | evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1084. | Calmax-D Tablet | Deferred for change of brand name |
| 1085. | Eatio Syrup | Deferred for change of brand name |
| 1086. | Pepice Suspension | Deferred for change of brand name |
| 1087. | Ed-Cure Tablet | Deferred for change of brand name |
| 1088. | Sensory Oral Liquid | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| 1089. | Natfol Tablet | subsequent preparation of their FIFO list, the division has been |
| 1007. | | evaluating and processing files. Hence, there are chances that some |
| | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | |
| | | Page 60 of 85 |

| S.No | Brand name | Decision |
|-------|----------------------|--|
| (1) | (2) | (3) |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | Bio C | lassic Pharma, Lahore |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files.Hence,there are chances that some |
| 1090. | Rb Plus Capsule | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1091. | Bioplex Capsule | evaluating and processing files. Hence, there are chances that some |
| | | product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | Bio Life Entern | rises Nutraceuticals, Rawalpindi |
| | * | Deferred for the following reasons: |
| 1092. | Talvit Tablat | • Form-3, brand name and contents undertakings are |
| 1092. | Talvit Tablet | unsigned/ unstamped. |
| | | • Fee receipt is missing. |
| | | Deferred for the following reasons: |
| 1093. | Biokin Tablet | • Form-3, brand name and contents undertakings are |
| 1075. | Blokin Tablet | unsigned/ unstamped. |
| 1001 | | • Fee receipt is missing. |
| 1094. | Imofer Tablet | Deferred for change of brand name |
| | | Deferred for the following reasons: |
| 1095. | Cali + Tablet | Form-3, brand name and contents undertakings are unsigned/ unstamped. |
| | | Fee receipt is missing. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1096. | Tribul Capsule | evaluating and processing files. Hence, there are chances that some |
| 1070. | Tribul Capsule | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. Deferred for the following reasons: |
| | | Form-3, brand name and contents undertakings are |
| 1097. | Tribestin Capsule | • Form-5, brand name and contents undertakings are unsigned/ unstamped. |
| | | Fee receipt is missing. |
| 1098. | Alneed Tablet | Deferred for change of brand name |
| 20200 | | Deferred for the following reasons: |
| 1000 | | Form-3, brand name and contents undertakings are |
| 1099. | Vitona Tablet | unsigned/ unstamped. |
| | | • Fee receipt is missing. |
| 1100. | Due A Drops | Deferred for change of brand name |
| 1101. | Due D Drops | Deferred for change of brand name |
| 1102. | Biofer Tablet | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| 1103. | Magnum-Z Gold Tablet | Since computerization of record of submitted applications and |
| 1103. | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files.Hence, there are chances that some |
| | | product applications were disposed of but still their names are |

Page 61 of 85

| S.No | Brand name | Decision |
|-------|------------------------|--|
| (1) | (2) | (3) |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files.Hence,there are chances that some |
| 1104. | Magnum-Z Silver Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | Deferred for the following reasons: |
| 1105. | Cal Dew Plus Tablet | • Form-3, brand name and contents undertakings are |
| 1100. | | unsigned/ unstamped. |
| | | • Fee receipt is missing. |
| | | Deferred for the following reasons: |
| 1106. | Cal Dew Sachet | • Form-3, brand name and contents undertakings are |
| | | unsigned/ unstamped. |
| 1107. | Primo Forte Tablet | Fee receipt is missing. |
| 1107. | Four Action Syrup | Deferred for change of brand name Deferred for change of brand name |
| 1100. | | ve Pharma, Karachi |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1109. | Chem-Cal Tablet | evaluating and processing files. Hence, there are chances that some |
| 1107. | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1110. | Pedistar Ors | evaluating and processing files.Hence,there are chances that some |
| 1110. | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | Pedicon Ors | subsequent preparation of their FIFO list, the division has been |
| 1111. | | evaluating and processing files. Hence, there are chances that some |
| 1111. | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | DIT. 1 | whether it has been disposed of or otherwise. |
| | Bless Labor | atories Pvt. Ltd., Lahore |
| | | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1114 | Mathed E Tables / | evaluating and processing files.Hence,there are chances that some |
| 1112. | Mythyl-F Tablet./l | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1113. | Iro-Fc Tablet | Deferred for change of brand name |
| | ~ | Page 62 of 85 |
| | Р | rage 0 2 of 85 |
| | | |

| S.No | Brand name | Decision |
|----------------|---|--|
| (1) | (2) | (3) |
| 1114. | Sarmaycal-D Tablet | Deferred for change of brand name |
| | | Lab, Pvt, Ltd, Lahore |
| 1115. | Sharbat E Faulad Syrup | Deferred for change of brand name |
| 1116. | Jam E Zindagi Syrup | Deferred for change of brand name |
| | | Deferred for the following reasons: |
| 1117. | Gingko Biloba Syrup | • Form-3, brand name and contents undertakings are unsigned/ |
| 111/. | Gliigko Blioba Sylup | unstamped. |
| | | Fee receipt is missing. |
| 1118. | Pain Stop Syrup | Deferred for change of brand name |
| 1119. | Damialex Plus Tablet | Deferred for change of brand name |
| 1120. | Colic Tablet | Deferred for change of brand name |
| 1121. | Tonsilex Tablet | Deferred for change of brand name |
| 1122. | Dialex Tablet | Deferred for change of brand name |
| 1123. | Asthalex Tablet | Deferred for change of brand name |
| 1124. | Calcilex Syrup | Deferred for change of brand name |
| 1125. | Gastro Ulcer Capsule | Deferred for change of brand name o Pharma Pvt Ltd, Lahore |
| 1126. | | Deferred for change of brand name |
| 1126. | Nocol Liquid Herbal Ext Stifnil Tablet | Deferred for change of brand name |
| 1127. | Carneo Plus Tablet | Deferred for change of brand name |
| 1128. 1129. | Ossocal Drops | Deferred for change of brand name |
| 1129. | Delux-D Tablet | Deferred for change of brand name |
| 1130. | Citrovit Drops | Deferred for change of brand name |
| 1132. | Maxiron Drops | Deferred for change of brand name |
| 1133. | Adtive Drops | Deferred for change of brand name |
| 1134. | Azeplex Tablet | Deferred for change of brand name |
| 1135. | Ossocal-D Sachet | Deferred for change of brand name |
| 1136. | Kofect Drops | Deferred for change of brand name |
| 1137. | Primal-Dk Drops | Deferred for change of brand name |
| | | aboratories, Peshawar |
| 1138. | Boncal-D Tablet | Deferred for change of brand name |
| 1139. | Fibo-C Sachet | Deferred for change of brand name |
| | | Deferred for the following reasons: |
| 1140. | Filbert Sharbat Podina Sharbat | • Form 7, brand name and contents undertakings are |
| | | unsigned, unstamped.Fee receipt is missing. |
| 1141. | Folit-Q Tablet | Pee receipt is missing. Deferred for change of brand name |
| 1141. | Hyomint Suspension | Deferred for change of brand name |
| 1172. | | Deferred for the following reasons: |
| | | Form 7, brand name and contents undertakings are |
| 1143. | Infa-Ad Tablet | unsigned, unstamped. |
| | | • Fee receipt is missing. |
| | | Deferred for the following reasons: |
| 1144 | Info Dron | • Form 7, brand name and contents undertakings are |
| 1144. | Infa Drop | unsigned, unstamped. |
| | | • Fee receipt is missing. |
| 1145. | Migra Fort Tablet | Deferred for change of brand name |
| 1146. | Nutracid Suspension | Deferred for change of brand name |
| 1147. | Triloba Capsule | Deferred for change of brand name |
| | Cure Inn Phy | toceuticals Pvt Ltd, Lahore |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files.Hence,there are chances that some |
| 1148. | Fevical Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| 1149. | Parofis Syrup | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files.Hence,there are chances that some |

Page 63 of 85

| S.No | Brand name | Decision |
|-------|----------------------|--|
| (1) | (2) | (3) |
| | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1150. | Fahcal Syrup | evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1151. | Iq-Mega Syrup | evaluating and processing files.Hence,there are chances that some |
| 1131, | iq-mega Syrup | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| T | Crystolite Pl | harmaceuticals, Islamabad |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1152. | Xefic 400Mcg Tablet | evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1153. | Xefic 800Mcg Tablet | evaluating and processing files.Hence,there are chances that some |
| 1155. | Actic 800Weg Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| 1 | | whether it has been disposed of or otherwise. |
| 1154. | Uribex Tablet | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1155. | Hairlet Capsule | evaluating and processing files. Hence, there are chances that some |
| | | product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | |
| | | |
| | | decision of the instant product application to check its status |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise.EEC was apprised that division undertook a big task of company |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and |
| 1 | | decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |
| 1156. | Vitovil Plus Capsule | decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some |
| 1156. | Vitovil Plus Capsule | decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |
| 1156. | Vitovil Plus Capsule | decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |
| 1156. | Vitovil Plus Capsule | decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |

Page 64 of 85

| S.No | Brand name | Decision |
|-----------------------|--|---|
| (1) | (2) | (3) |
| 1157. | Vitabit Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | Dew Nat | ural Pharma, Lahore |
| 1158. | Stasmodine Syrup | Deferred for change of brand name |
| 1159. | Dew'S Toot Siah Syrup | Deferred for change of brand name |
| 1160. | Dew-Safi Syrup | Deferred for change of brand name |
| 1161. | Orange-C Syrup | Deferred for change of brand name |
| <u>1162.</u> 1163. | Nurogin Syrup Grow Fast Baby Tonic Suspension | Deferred for change of brand name Deferred for change of brand name |
| 1163. | Dew'S Minti Syrup | Deferred for change of brand name |
| 1165. | Globiton Syrup | Deferred for change of brand name |
| 1166. | Mintdew Syrup | Deferred for change of brand name |
| 1167. | A-Plus Aletris Cordial Syrup | Deferred for change of brand name |
| 1168. | Ivy Kuf Sooth Syrup | Deferred for change of brand name |
| 1169. | Feroton-S Syrup | Deferred for change of brand name |
| 1170. | Kanavit Syrup | Deferred due to Duplication of formulation with Lumi-Vit syrup |
| <u>1171.</u> 1172. | Dew'S Mint Syrup (Sharbat Podina) Syrup | Deferred for change of brand name Deferred for change of brand name |
| 1172. | Hycid Antacid Syrup Ginko-Min Syrup | Deferred for change of brand name |
| 1173. | Honey Dew'S Cough Syrup | Deferred for change of brand name |
| 1175. | Avescon Antacid Syrup | Deferred for change of brand name |
| 1176. | Polybin Syrup | Deferred for change of brand name |
| 1177. | Hemoclean Syrup | Deferred for change of brand name |
| 1178. | Dewcid Syrup | Deferred for change of brand name |
| 1179. | Polykuf Syrup | Deferred for change of brand name |
| 1180. | Lusar Cough Syrup | Deferred for change of brand name |
| <u>1181.</u> 1182. | Luma Cough Syrup Bonofit-D Suspension | Deferred for change of brand name Deferred for change of brand name |
| 1183. | A-Plus Reton Syrup | Deferred for change of brand name |
| 1184. | Honitus Syrup | Deferred for change of brand name |
| 1185. | Stasmodine Drops | Deferred for change of brand name |
| 1186. | Diarrh Syrup | Deferred for change of brand name |
| 1187. | Ginger-Mint Syrup | Deferred for change of brand name |
| 1188. | Orange Plex Syrup | Deferred for change of brand name |
| 1 | Dolphin | Laboratories, Lahore |
| 1189. | Ora-Care Mouth Wash | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1190. | Glow Vera Face Wash | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1191. | Spectrum Sanitizer Gel | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and |
| | F | Page 65 of 85 |

<u>F.No.10-10/2022-OTC (M-111)</u>

| S.No | Brand name | Decision |
|----------------|--|--|
| (1) | (2) | (3) |
| | | subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company |
| 1192. | Aknee Face Wash | wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1193. | Gripe Water | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1104 | | harmacy, Karachi |
| 1194. 1195. | Gasnol Syrup 120Ml Syrup Arsal Natural Cough Syrup 120 Ml Syrup | Form-7 already issued Deferred for change of brand name |
| 1195. | Cough Syrup Junior 120Ml Syrup | Deferred for change of brand name |
| 1197. | Baby Balm Balm | Deferred for change of brand name |
| 1198. | Arsal Balm Balm | Deferred for change of brand name |
| 1199. | Arofen Syrup 120Ml Syrup | Deferred for change of brand name |
| 1200. | Toot Siyah Syrup 120Ml Syrup | Form-7 already issued |
| 1201. | Diarro Syrup (120Ml) Syrup | Deferred for change of brand name |
| 1202. | Gasnol Syrup 120Ml (Sugar Free) Syrup | Deferred for change of brand name |
| 1203. | Analgesic Cream Cream | Deferred for change of brand name |
| | Eson Hi E | Ierb Vision, Islamabad |
| 1204. | Biocard Plus Tablet | Deferred for change of brand name |
| 1205. | Mg-Crane Sachet | Deferred for change of brand name |
| 1206. | Levitor Tablet | Deferred for change of brand name |
| 1207. | Livitor Syrup | Deferred for change of brand name |
| 1208. | Capillus Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1209. | Neurit Tablet | Deferred for change of brand name |
| 1210. | Seflex Tablet | Deferred for change of brand name |
| 1211. | Conoff Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1212. | Livin Syrup | Deferred for change of brand name |

Page 66 of 85

| S.No | Brand name | Decision |
|-------|--|--|
| (1) | (2) | (3) |
| 1213. | Livin Tablet | Deferred for change of brand name |
| 1214. | Semilex Tablet | Deferred for change of brand name |
| 1215. | Semilex Syrup | Deferred for change of brand name |
| 1216. | Adelin Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1217. | Semibol Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1218. | Vitol Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1219. | Semiter Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1220. | High grow Tablet | Deferred for change of brand name |
| 1221. | High grow Liquid | Deferred for change of brand name |
| 1222. | Focus & Ru Satibis Oral Spray Spray | Iz Healthcare, IslamabadEEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks.Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1223. | Nabimet Capsule Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |

Page 67 of 85 Junce

| S.No | Brand name | Decision |
|-------|--------------------------------|---|
| (1) | (2) | (3) |
| 1224. | Epidiol Oral Solution Solution | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1225. | Satibis Oral Spray Spray | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1226. | Nabimet Capsule Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1227. | Epidiol Oral Solution Solution | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | Genetic | cs Healthcare, Lahore |
| 1228. | Ezegut Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1229. | Heligut Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1230. | Biolip Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |

Page 68 of 85

| S.No | Brand name | Decision |
|-----------------------|---------------------------------|--|
| (1) | (2) | (3) |
| | | available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1001 | | evaluating and processing files. Hence, there are chances that some |
| 1231. | Grab Capsule | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1232. | Sinohale Capsule | evaluating and processing files. Hence, there are chances that some |
| | - | product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1233. | Reforce Tablet | evaluating and processing files. Hence, there are chances that some |
| 1233. | Reforce Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| 1001 | | whether it has been disposed of or otherwise. |
| 1234. | Breazy Drops | Deferred for change of brand name EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1005 | Devilate 15Mr Tablet | evaluating and processing files. Hence, there are chances that som |
| 1235. | Deplate 15Mg Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1226 | | enMan Pharmaceuticals, Rawalpindi |
| <u>1236.</u> 1237. | Sizepro Tablet Lekol Capsule | Deferred for change of brand name Deferred for change of brand name |
| 1237. | Lekoi Capsule | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that som |
| 1238. | Promass Tablet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| 1239. | Suranjan Arbi Capsule | Deferred for change of brand name |
| 1240. | Barium Meal Sachet | Deferred for change of brand name |
| 1241. | Pepkon-G Capsule | Deferred for change of brand name |
| 1242. | Stoma Care Capsule | Deferred for change of brand name |
| 1243. | Ginkofyt Syrup | Deferred for change of brand name |
| 1244. | Optofyt Tablet | Deferred for change of brand name |
| | | Hinucon, Karachi EEC was apprised that division undertook a big task of company |
| | | E E E A WAS ADDUSED INAL OLVISION INDERTOOK A DIG TASK OF COMDANY |
| 1245. | Gevomin Sachet | Page 69 of 85 |

| S.No | Brand name | Decision |
|-------|----------------------------|--|
| (1) | (2) | (3) |
| | | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. |
| 1246. | Gevomin Tablet | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1247. | Hinulac Sachet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1248. | Hinulac Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1249. | Rimona-Cp 400/10Mg Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1250. | Rimona-Cp 400/20Mg Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1251. | Rimona-Cp 1000/25Mg Sachet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer |

Page 70 of 85 Junce

| S.No | Brand name | Decision |
|----------------|---|--|
| (1) | (2) | (3) |
| | | decision of the instant product application to check its status whether |
| 1252. | Rimona-Cp 1000/50Mg Sachet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1253. | Primona 275/75Mg Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1254. | Bethin Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1255. | Primona 330/100Mg Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1256. | Primona 275/75Mg Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1257. | Rimona-Cp 2000/150Mg Sachet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1059 | | ition Pvt Ltd, Lahore |
| 1258. 1259. | C-1000 Mg Effervescent Tablet C-500 Mg Effervescent Tablet | Deferred for change of brand name Deferred for change of brand name |
| 1239. 1260. | Zinc Boost Effervescent Tablet | Deferred for change of brand name |
| 1261. | Fe Boost Effervescent Tablet | Deferred for change of brand name |
| | | Page 71 of 85 |

| S.No | Brand name | Decision |
|-------|-----------------------------|---|
| (1) | (2) | (3) |
| 1262. | Bella Liquid Collagen Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1263. | C+Zn Effervescent Tablet | Deferred for change of brand name |
| 1205. | | euticals (Pvt) Limited, Karachi |
| 1264. | Lokasol Toothpaste | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1265. | Lokasol Oral Paste Liquid | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| | | ota Pharma, Taxila |
| 1266. | Wrinklex Sachet | Deferred for change of brand name |
| 1267. | Glutaglow Capsules Capsule | Deferred for change of brand name |
| 1268. | Myofert Sachet Sachet | Deferred for change of brand name |
| 1269. | Trufiber Sachet Sachet | Deferred for change of brand name |
| 1270. | Activa Capsules Capsule | Deferred for change of brand name |
| 1271. | Fiberaid Sachet | Deferred for change of brand name |
| 1272. | Mastito (Vet) Liquid | ceutical Industries, LahoreEEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks.Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1273. | Gyno-Far Tablet | Deferred for change of brand name |
| 1274. | Higlob Liquid | Deferred for change of brand name |
| 1275. | Ferofar Liquid | Deferred for change of brand name |
| | Leads In | npex Pharma, Lahore |
| 1276. | M-Fol B Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether |
| 1277. | Giga-Q Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and |
| S.No | Brand name | Decision |
|----------------|-----------------------------------|---|
| (1) | (2) | (3) |
| . , | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | cy Pharmaceuticals, Peshawar |
| 1278. | Apricare 500Mg Capsule | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1279. | Cal Poppy 500Mg Capsule | evaluating and processing files. Hence, there are chances that |
| | carr oppy booming capsure | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| 1280. | Dibcare 10Mg Tablet | Deferred for change of brand name |
| 1281. | Dibcare 25Mg Tablet | Deferred for change of brand name |
| 1282. | Ez Rest Capsule | Deferred for change of brand name |
| 1283. | Happy Mood 500Mg Capsule | Deferred for change of brand name |
| 1284. | Lesschol 375Mg Tablet | Deferred for change of brand name |
| 1285. | Lesschol 500Mg Tablet | Deferred for change of brand name |
| 1286. | Livosmin 375Mg Capsule | Deferred for change of brand name |
| 1287. | Livosmin Plus Capsule | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1288. | Marking 1000Ma Tablet | evaluating and processing files. Hence, there are chances that |
| | Magtim 1000Mg Tablet | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| 1289. | Saw Pal 800Mg Capsule | Deferred for change of brand name |
| | M. | R.G Laboratories, Karachi |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1290. | Hecho Sachet | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1291. | Celimixt Sachet | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| 1302 | Coltemple Cont. (| whether Defense of here discussed |
| 1292. 1293. | Culturela Sachet Ener-C Sachet | Deferred for change of brand name Deferred for change of brand name |
| 1293. | | ormers Neutraceutical, Lahore |
| 1294. | Neutroon Capsule | Deferred for change of brand name |
| | <u> </u> | n Research Laboratories, Lahore |
| | | EEC was apprised that division undertook a big task of company |
| 1295. | Naslus Suspension | wise arrangement of applications in various designated racks. |
| | _ | Since computerization of record of submitted applications and |
| | | Page 73 of 85 |

| (1) (2) (3) (4) subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIFO list. Accordingly.EEC appreservices of division of thein stant product application to check it whether 1296. Dravit-D Oral Drops FIFC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications for various designat some product applications are division of thein stant product application to check it whether 1296. Dravit-D Oral Drops FIFC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications is various designat some product applications is various designat some product applications is various designat whether 1297. Nthiron Symp EEC was apprised that division undertook a big task wise area product applications is various designat of division of thein transport of their FIFO list, the division various designat some product applications is various designat some product applications is various designat some product applications is various designat some product application or check it whether 1297. Nthiron Symp EEC was apprised that division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applications is various designat some product application is various designat some product application is various designat Since computerization of record of abut filt is the division various designat some product applications in various des | | Brand name | S.No |
|---|--|---------------------|-------|
| 1296. evaluating and processing files. Hence, there are changed of but still are available in the FFO list. Accordingly.EEC appropriate of division of bettilt and OTC and decided to decision of the instant product applications in various designate since computerization of their FFO list. Accordingly.EEC appropriate and processing files. Hence, there are changed and processing files. Hence, there are changen product applications and and processing files. Hence, | | (2) | (1) |
| 1296. Some product applications were disposed of but still are available in the FIPO Dist. Accordingly,EEC apprend to the instant product applications to check it weberber 1296. Dravit-D Oral Drops EEC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications of the start product applications in various designat some product applications of the start product applications in various designat some product applications of the start product application to check it whether 1296. Dravit-D Oral Drops EEC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications or other start product applications or bot still are available in the FIPO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIPO list. Accordingly, EEC appreservices of division of heatint and OTC and decided the decision of the instant product application to check it whether 1297. Nthiron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list, the division some product applications were disposed of hut still are available in the FIPO list, the division some product applications were disposed of hut still are available in the FIPO list, the division some product applications were disposed of hut still are available in the FIPO list, the division subsequent preparation of their FIPO list, the division some product applications were disposed of hut still are available in the FIPO list. Accordingly, EEC appreservices of division of heatisthat of CTC and decided the decision of their FIPO list. A | | | |
| are available in the FIFO list. Accordingly,EEC apprend of division of health and OTC and decided to decision of the instant product application to check it whether 1296. Dravit-D Oral Drops EEC was apprised that division undertook a big task wise arrangement of applications in various designat. Since computerization of their FIFO list, the division undertook a big task wise arrangement of applications were disposed of thu still in are available in the FIFO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications were disposed of thu still in are available in the FIFO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications in various designat. Since computerization of their FIFO list, the division undertook a big task wise arrangement of applications in various designat. Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are charse are char | | | |
| 1296. Services of division of health and OTC and decided to decision of the instant product applications to check it whether 1296. Dravit-D Oral Drops 1297. Dravit-D Oral Drops 1298. Dravit-D Oral Drops 1299. Dravit-D Oral Drops 1299. Dravit-D Oral Drops | | | |
| decision of the instant product applications to check it whether 1296. Dravit-D Oral Drops Parvit-D Oral Drops EEC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications were disposed of but still are available in the FIPO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate Since computerization of the irTsHO list, the division of the instant product applications in various designate Since computerization of the irTsHO list, the division of the irTsHO list, the division of the irTsHO list, the division undertook a big task wise arrangement of applications in various designate Since computerization of file irTFO list, the division some disposed of but still are available in the FIFO list. Accordingly, EFC appreservices of division of health and OTC and decided to decision of the irTsHO rad decided to decision of the irTsHO rad decided to decision of the instant product applications were disposed of but still are available in the FIFO list. Accordingly, EFC appreservices of division of health and OTC and decided to decision of the irTsHO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of health and OTC and decided to decision of the irTsHO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of health and OTC and decided to decision of the irTsHO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of health and OTC and decided to decision of the irTsHO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of health and OTC and decided to decision of health and OTC and decided to decision of health and OTC and decided to decision | | | |
| 1296. Dravit-D Oral Drops EEC was apprised that division undertook a big task: Wise arrangement of applications in various designat. Since computerization of their FIPO list, the division undertook a big task: wise arrangement of applications in various designat. Some product applications were disposed of the still are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications in various designat. Since computerization of record of submitted applications in various designat. Since computerization of their FIPO list. Accordingly, EEC appreservices of division of their HIPO list. the division undertook a big task wise arrangement of applications in various designat. Since computerization of their FIPO list. the division evaluating and processing files. Hence, there are charsome product applications in various designat. Since computerization of their HIPO list. the division of evaluating and processing files. Hence, there are charsome product applications in various designat. Since computerization of their HIPO list. the division undertook a big task wise arrangement of applications in various designat. Since computerization of their HIPO list. the division undertook a big task wise arrangement of applications in various designat. Since computerization of their HIPO list. the division some product applications in various designat. Since computerization of their HIPO list. the division undertook a big task wise arrangement of applications in various designat. Since computerization of their HIPO list. the division undertook a big task wise arrangement of applications in various designat. Since computerization of their HIPO list. the division of various designat. Since computerization of their HIPO list. the division evaluating and processing | | | |
| 1296. Dravit-D Oral Drops EEC vas apprised that division undertook a big task wise arrangement of applications in various designat subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designat the there is the subsequent preparation of their FIFO list, the division of the instant product applications in various designat Since computerization of record of submitted applications of the instant product applications in various designat Since computerization of their FIFO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of their FIFO list, the division some product applications were disposed of but still are available in the FIFO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their TIFO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their TIFO list, the division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their TIFO list, the division applications in various designat Since computerization of record of submitted applica subsequent preparation of their TIFO list, the division applications in various designat Since computerization of record of submitted applica subsequent preparation of their T | the instant product application to check its status | | |
| 1296. Dravit-D Oral Drops Since computerization of their HFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FFO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications in various designation. Since computerization of record of submitted applications in various designation of reading starbid starbids in the FFO list. Accordingly, EEC appreservices of division of applications in various designation. Since computerization of record of submitted applications in various designation. Since computerization of record of submitted applications in various designation. Since computerization of health and OTC and decided to decision of the instant product applications in various designation. Since computerization of record of submitted applications in various designation of the HFO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications in various designation of the HFO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications in various designation in various designation of the there in the HFO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product application in various designation in various designation and processing files. Hence, there are chan some product applications in various designation various designatin theffer PIC list. Accordingly, EEC appreservi | | | |
| 1296. Dravit-D Oral Drops Since computerization of the TFPO list, the division evaluating and processing files. Hence, there are chansome product applications were disposed of hut still are available in the FIPO list, Accordingly, EEC apposed of the still and OTC and decided the decision of the instant product applications in various designate Since computerization of file iTFPO list, the division undertook a big task wise arrangement of applications were disposed of but still are available in the FIPO list. Accordingly, EEC apposed of the still not health and OTC and decided the decision of the iTFPO list, the division undertook a big task wise arrangement of applications in various designate Since computerization of file iTFPO list. Accordingly, EEC apposes of division of health and OTC and decided the decision of the instant product applications were disposed of but still are available in the FIPO list. Accordingly, EEC apposes of division of health and OTC and decided the decision of the instant product applications or dravious designate Since computerization of file iTFPO list. Accordingly, EEC apposes of division of health and OTC and decided the decision of the instant product applications in various designate Since computerization of file iTFPO list. Accordingly, EEC apposes services of division of pablications in various designate Since computerization of the iTFPO list. Accordingly, EEC apposes services of division of pablications in various designate Since computerization of the iTFPO list. Accordingly, EEC apposes applications in various designate Since computerization of the iTFPO list. Accordingly, EEC apposes approach applications in various designate Since computerization of the iTFPO list. Accordingly, EEC apposes applications in various designate Since computerization of record of submitted applications in various designate Since computerization of recent of applications in various designate subsequent preparation of the iTFPO list. | | | |
| 1296. Dravit-D Oral Drops subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chansome product applications in various designation of their three of the instant product applications in various designation of their three of the instant product applications in various designation of their TFIO list, the division evaluating and processing files. Hence, there are chansome product applications in various designation of their tFIO list, the division evaluating and processing files. Hence, there are chansome product applications in various designation of their tFIO list, the division evaluating and processing files. Hence, there are chansome product applications in various designation of the division of record of submitted applications in various designation of the division division of the division undertook a big task. Wise arrangement of applications in various designation of the division of the division undertook a big task. Wise arrangement of applications in various designation of the division of the division of the division of the division undertook a big task. Wise arrangement of applications in various designation are available in the FIFO list, the division evaluating and processing files. Hence, there are chansome product applications in various designation are available in the FIFO list, the division undertook a big task. Wise arrangement of applications in various designation are available in the FIFO list, the division undertook a big task. Wise arrangement of applications in various designation are available in the FIFO list, the division undertook a big task. Wise arrangement of applications in various designation arechangementhe application in various designation are av | | | |
| 1296. Dravit-D Oral Drops evaluating and processing files. Hence, there are that are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product application to decket in whether 1297. Nthiron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designation so record of submitted applications used to submit deplications user disposed of but still are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications user disposed of but still are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided applications were disposed of but still are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications in various designation survices appresent of applications in various designation survices appresent of applications in various designation evaluating and processing files. Hence, there are chan some product application serve disposed of but still are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications were disposed of but still are available in the FIPO list. Head vision evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product applications were disposed of but still are available in the FIPO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product application to check it whether 1299. | | | |
| 1296. Dravit-D Oral Drops some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC | | | |
| 1297. Nthiron Syrup are available in the FIPO list. Accordingly,EEC apple to decision of heatth and OTC and decide to decision of heat in than oTC and the set set and the instant product application to check it whether 1297. Nthiron Syrup are available in the FIPO list. Accordingly,EEC apple subsequent preparation of their FIPO list. the division evaluating and processing files. Hence, there are chansome product applications were disposed of but still are available in the FIPO list. Accordingly,EEC apple services of division of health and OTC and decided to decision of the instant product applications in various designat Since computerization of record of submitted applications in various designat Since computerization of precedor devised applications in various designat Since computerization of their FIPO list. Accordingly,EEC apple services of division of health and OTC and decided to decision of the instant product applications in various designat Since computerization of record of submitted application evaluating and processing files. Hence, there are chansome product applications were disposed of but still are available in the FIPO list. Accordingly,EEC apple services of division of health and OTC and decided to decision of the instant product application to check it whether 1298. Marit Ors Sachet EEC was apprised that division undertook a big task wite arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list, the division evaluating and processing files. Hence, there are chansome product application serve disposed of but still are available in the FIPO list. Accordingly, EEC applications were disposed of but still are available in the FIPO list. Accordingly, EEC applications were disposed of but still are available in the FIPO list. Accordingl | | Dravit-D Oral Drops | 1296. |
| 1297. Services of division of health and OTC and decided to decision of the instant product application to check it whether 1297. Nthiron Syrup 1298. FEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still to are available in the FIPO list. Accordingly,EEC application of their FIPO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still to are available in the FIPO list. Accordingly,EEC application of their FIPO list, the division evaluating and processing files. Hence, there are char some product application of cash mether breves of division of health and OTC and decided to decision of the instant product applications undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list, the division evaluating and processing files. Hence, there are char some product applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list. Accordingly,EEC applications of health and OTC and decided to decision of the instant product applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list. Accordingly,EEC applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list. Accordingly,EEC applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list. Accordingly,EEC applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIPO list, the division evaluating and processing files. Hence, there are char some product applications in various designat Since computerization of the | | | |
| 1297. Nthiron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applications sure disposed of but still are available in the FIFO list, the division evaluating and processing files. Hence, there are character of the division undertook a big task wise arrangement of applications were disposed of but still are available in the FIFO list. Accordingly,EEC apprent with the division of health and OTC and decided to decision of the instant product application to check it whether 1298. Marit Ors Sachet 1299. Marit Ors Sachet MRG Laboratories, Karachi EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still are available in the FIFO list, the division evaluating and processing files. Hence, there are character available in the FIFO list, the division evaluating and processing files. Hence, there are character available in the FIFO list, the division evaluating and processing files. Hence, there are character available in the FIFO list, the division evaluating and processing files. Hence, there are character available in the FIFO list, the division evaluating and processing files. Hence, there are character available in the FIFO list, the division evaluating and processing files. Hence, there are character available in the FIFO list, the division undertook a big task wise arrangement of applications in various designate subsequent preparation of the instant product application to check it whether MRG Laboratories, Karachi EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still are available in the FIFO list, checordingly, EEC ap | | | |
| 1297. Whether 1297. Nthiron Syrup 1298. Merit Prit. Ltd., Lahore 1298. Merit Ors Sachet 1298. Marit Ors Sachet 1299. Howatic Sachet <td>the instant product application to check its status</td> <td></td> <td></td> | the instant product application to check its status | | |
| 1297. Nthiron Syrup wise arrangement of applications were disposed of but still are available in the FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications (the division decided to decision of the instant product applications (the division decided to decision of the instant product applications were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications in various designant Since computerization of record of submitted applica subsequent preparation of the refro list. Accordingly, EEC app Services of division undertook a big task wise arrangement of applications in various designant Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division since around decided to decision of the instant product applications in various designant Since computerization of record of submitted applica subsequent preparation of their SIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications designant Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications designant Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Henc | | | |
| 1297. Nthiron Syrup wise arrangement of applications were disposed of but still are available in the FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications (the division decided to decision of the instant product applications (the division decided to decision of the instant product applications were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications in various designant Since computerization of record of submitted applica subsequent preparation of the refro list. Accordingly, EEC app Services of division undertook a big task wise arrangement of applications in various designant Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division since around decided to decision of the instant product applications in various designant Since computerization of record of submitted applica subsequent preparation of their SIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications designant Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division were disposed of but still are available in the FIFO list. Accordingly, EEC app Services of division of health and OTC and decided to decision of the instant product applications designant Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Henc | oprised that division undertook a big task of company | | |
| 1297. Nthiron Syrup Since computerization of record of submitted applications were disposed of but still 1 are available in the FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still 1 are available in the FIFO list. Accordingly, EEC apprention of the instant product application to check it whether 1298. Marit Ors Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications were disposed of but still 1 are available in the FIFO list. Accordingly, EEC apprention of the instant product application to check it whether 1298. Marit Ors Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications in various designat some computerization of record of submitted applications in various designat some computerization of record of submitted applications evaluating and processing files. Hence, there are char some product applications in various designat some computerization of record of submitted applications evaluating and processing files. Hence, there are char some product applications in various designat some evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly, EEC apprent services of division of health and OTC and decided to decision of the instant product application to check it whether 1299. Howatic Sachet EEC was aprised that division undertook a big task wise ar | | | |
| 1297. Nthiron Syrup evaluating and processing files. Hence, there are change are variable in the FIFO list. Accordingly, EEC appreservices of division of health and OTC and decided to decision of the instant product application to check it whether Merit Ors. Sachet Marit Ors Sachet EEC was apprised that division undertook a big task. wise arrangement of applications in various designate subsequent preparation of their FIFO list. the division evaluating and processing files. Hence, there are changement of applications in various designate subsequent preparation of their FIFO list. Accordingly, EEC appreservices of division of their hard division undertook a big task. wise arrangement of applications were disposed of but still are available in the FIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of their fIFO list. Accordingly, EEC appreservices of division of the instant product applications to check it whether 1299. Howatic Sachet MIT Medical, Lahore MIT Medical, Lahore 1300. Estosan Suspension Deferred for change of brand name EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still are | | | |
| 1297. Numron Syrup some product applications were disposed of but still t are available in the FIFO list. Accordingly, EEC app services of division of health and OTC and decided t decision of the instant product applications to check it whether Merit PV. Ltd., Lahore Merit PV. Ltd., Lahore Iter VI. Ltd., Lahore Merit PV. Ltd., Lahore Merit PV. Ltd., Lahore Merit PV. Ltd., Lahore Iter VI. Ltd., Lahore Merit PV. Ltd., Lahore Merit PV. Ltd., Lahore Iter VI. I | preparation of their FIFO list, the division has been | | |
| 1300. Estosan Suspension 1301. Efron Syrup 1302. Lifolac Syrup 1302. Lifolac Syrup | | Nthiron Syrup | 1207 |
| 1298. services of division of health and OTC and decided t decision of the instant product application to check it whether 1298. Marit Ors Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product applications in various designate. 1298. Marit Ors Sachet MRG Laboratories, Karachi 1299. MRG Laboratories, Karachi EEC was apprised that division undertook a big task wise arrangement of applications in various designate. Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product applications to check it whether 1299. Howatic Sachet MTI Medical, Labore 1300. Estosan Suspension Deferred for change of brand name 1301. Efron Syrup Effor syrup Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division undertook a big task wise arrangement of applications in various designat some product applications in various designat some coduct applications in various designat some coduct application in v | | Trumon Syrup | 1491. |
| Identify the instant product application to check it whether Merit Pvt. Ltd., Lahore EEC was apprised that division undertook a big task wise arrangement of applications in various designatt Since computerization of record of submitted applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of the and OTC and decided ti decision of the instant product applications to check it whether Marit Ors Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designatt Since computerization of the application to check it whether MRG Laboratories, Karachi EEC was apprised that division undertook a big task wise arrangement of applications in various designatt Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly, EEC appr services of division of health and OTC and decided ti decision of the instant product application to check it whether 1299. Howatic Sachet EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still are available in the FIFO list. Accordingly, EEC appr services of division of health and OTC and decided ti decision of the application in various designate Since computerization of record of submitted applications were disposed of but still are available in the FIFO list. Accordingly, EEC appr services of division and netrook a big task wise arrangement of applications in various designate Since computerization of record of submitted applications were disposed of but still | | | |
| Whether Merit Pvt. Ltd, Lahore EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applications were disposed of but still t are available in the FIPO list. Accordingly,EEC apprestrices of division of their FIPO list, Accordingly,EEC apprestrices of division of their FIPO list, the division undertook a big task wise arrangement of applications were disposed of but still t are available in the FIPO list. Accordingly,EEC apprestrices of division of their FIPO list, the division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applications were disposed of but still are available in the FIPO list, Accordingly,EEC apprestrices of division of health and OTC and decided t decision of the instant product applications to check it whether 1299. Howatic Sachet EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still are available in the FIPO list, Accordingly,EEC apprestrices of division of health and OTC and decided to decision of the instant product application to check it whether 1299. Howatic Sachet MTI Medical, Lahore 1300. Estosan Suspension Deferred for change of brand name 1301. Effon Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIPO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIPO list. Accordingly,EE | division of health and OTC and decided to defer | | |
| Merit Pvt. Ltd., Lahore EEC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications in various designat some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided t decision of the instant product applications in various designat Since computerization of record of submitted applications of the instant product applications in various designat some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided t decision of the instant product applications in various designat Since computerization of record of submitted applicat subsequent preparation of their FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided t decision of the instant product applications in various designat Since computerization of their FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided t decision of the instant product application to check it whether 1299. Howatic Sachet EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided t decision of the instant product applications to check it whether 1300. Estosan Suspension Deferred for change of brand name 1301. Efron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designat Since computerization of record of submitted applications were disposeed of but still are available in the FIFO list. Acco | the instant product application to check its status | | |
| 1298. EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIFO list. Accordingly, EEC apprexervices of division of health and OTC and decided t decision of the instant product applications in various designate wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list. Accordingly, EEC apprexervices of division of nealth and OTC and decided t decision of the instant product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list. Accordingly, EEC apprexervices of division of health and OTC and decided t decision of the instant product applications to check it whether 1299. Howatic Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designate some product applications were disposed of but still 1 are available in the FIFO list. Accordingly, EEC appreservices of division of health and OTC and decided t decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name 1301. Efron Syrup Efron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate Since computerization of their FIFO list, the division eval | | | |
| 1298. Marit Ors Sachet wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product applications to check it whether 1299. MRG Laboratories, Karachi 1299. EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name 1301. Efron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate subsequent preparation of their FIFO list, the division or division of precord of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char sone product applications in various designa | | Merit | |
| 1298. Marit Ors Sachet Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided the decision of the instant product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided the decision of the instant product application to check it whether 1299. Howatic Sachet MITI Medical, Lahore 1209. Estosan Suspension Deferred for change of brand name 1300. Estosan Suspension Deferred for change of brand name 1311. Efron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications are disposed of but still are available in the FIFO list, the division evaluating and processing files. Hence, there are char some product applications are disposed of but still are available in the FIFO list. Accordingly, EEC appr services of division of health and OTC and decided the decisio | | | |
| 1298. Marit Ors Sachet subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of the instant product application to check it whether 1299. Marit Ors Sachet MRG Laboratories, Karachi 1299. EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of the instant product application to check it whether 1299. Howatic Sachet MITI Medical, Lahore 1201. Estosan Suspension Deferred for change of brand name 1301. Efron Syrup Efron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications ore disposed of but still are available in th | | | |
| 1298. Marit Ors Sachet evaluating and processing files. Hence, there are char some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designat whether 1299. Howatic Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designat some product applications of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product applications in various designat since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designat Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whether 1301. Efron Syrup | | | |
| Mart Ors Sachet some product applications were disposed of but still t are available in the FIPO list. Accordingly,EEC appr services of division of health and OTC and decided to decision of the instant product application to check it whether MRG Laboratories, Karachi 1299. Howatic Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designate Some product application of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in var | | Marit Ors Sachet | |
| are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided te decision of the instant product application to check it whether MRG Laboratories, Karachi EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided te decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applications to check it whether 1301. Estosan Suspension Deferred for change of brand name Iaron Syrup EEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still are available in the FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided te decision of the instant product applications to check it whether 1302. Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate some product applications in various designate some product applications were disposed of but still are available in the F | | | 1298. |
| Image: services of division of health and OTC and decided to decision of the instant product application to check it whether Image: services of division of health and OTC and decided to decision of the instant product application to check it whether Image: services of division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appreservices of division of the alth and OTC and decided to decision of the instant product application to check it whether Image: services of division of the services of division of the services of division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided to decision of the instant product application to check it whether 1301. Efron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of the instant product application to check it whether 1302. Lifolac Syrup EEC was apprised that division undertook a big task wise ara | | | |
| 1299. decision of the instant product application to check it whether Image: the state of the | | | |
| Whether MRG Laboratories, Karachi EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided t decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name 1301. Efron Syrup Efron Syrup Since computerization of record of submitted applica subsequent preparation of their FIFO list. Accordingly,EEC appreservices of division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided te decision of the instant product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided te decision of the instant product application to check it whether 1302. Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate Since computerization of health and OTC and decided te decision of the instant product application to check it whether 1302. Lifolac Syru | | | |
| MRG Laboratories, Karachi 1299. EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided to decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name 1301. Efron Syrup Efron Syrup Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate subsequent preparation of the instant product application to check it whether 1301. Efron Syrup Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications of be application to check it whether 1302. Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications or to check it whether 1302. Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate subsequent preparation of t | the instant product application to check its status | | |
| 1299. EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC apprent services of division of health and OTC and decided t decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name EFC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided t decision of the instant product application to check it whether 1301. Efron Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still are available in the FIFO list. Accordingly,EEC appreservices of division of the instant product applications to check it whether 1302. Lifolac Syrup < | Karachi | MRG La | |
| 1299.wise arrangement of applications in various designated Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided to decision of the instant product application to check it whether1300.Estosan SuspensionDeferred for change of brand name1301.Efron SyrupEEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of their FIFO list, the division undertook a big task wise arrangement of applications in various designated Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided to decision of the instant product application to check it whether1301.Efron SyrupEEC was apprised that division undertook a big task wise arrangement of applications were disposed of but still 1 are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided to decision of the instant product application to check it whether1302.Lifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and pr | | | |
| 1299.Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product applications in various designate Since computerization of record of submitted applica1301.Estosan SuspensionDeferred for change of brand name EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product applications to check it whether1301.Efron SyrupEfron Syrup1302.Lifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications of the instant product application to check it whether1302.Lifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing file | | | |
| 1299.Howatic Sachetsubsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whetherMTI Medical, Lahore1300.Estosan SuspensionDeferred for change of brand name1301.Efron SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whether1302.Lifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica sources of division of health and OTC and decided t decision of the instant product application to check it whether1302.Lifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications of the instant p | | | |
| 1299.Howatic Sachetevaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whetherMTI Medical, Lahore1300.Estosan SuspensionDeferred for change of brand name1301.Efron SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the divisior evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of their FIFO list, the divisior evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of their FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whether1302.Lifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still f | | Howatic Sachet | 1200 |
| isome product applications were disposed of but still in are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided to decision of the instant product application to check it whether 1300. Estosan Suspension Deferred for change of brand name EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still the decision of the instant product application to check it whether 1301. Efron Syrup Efron Syrup Efron Syrup Big and processing files. Hence, there are chan some product applications were disposed of but still the cities of division of health and OTC and decided the decision of the instant product application to check it whether 1302. Lifolac Syrup Big and processing files. Hence, there are chan some product applications in various designate some product application to the errefield by the division evaluatin | | | |
| 1301. Efron Syrup I Lifolac Syrup Lifolac Syrup Lifolac Syrup Lifolac Syrup | | | 1299. |
| Image: decision of the instant product application to check it whether Image: decision of the instant product application to check it whether Image: decision of the instant product application to check it whether Image: decision of the instant product application of the instant product applications in various designated Since computerization of the instant product applications were disposed of but still the are available in the FIFO list. Accordingly,EEC appreservices of division of the instant product application to check it whether Image: decision of the instant product applications in various designated Since computerization of the instant product application to check it whether Image: decision of the instant product applications in various designated Since computerization of record of submitted applications of the instant product application to check it whether Image: decision of the instant product application in various designated Since computerization of record of submitted application is various designated Since computerization of record of submitted application subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chart since computerization of record of submitted applications in various designated Since computerization of record of submitted applications evaluating and processing files. Hence, there are chart since computerization of record of submitted applications in various designated Since computerization of record of submitted applications in various designated Since computerization of record of submitted applications evaluating and processing files. Hence, there are chart some product applications were disposed of but still for the instant product application submitted applications evaluating and processing files. | e in the FIFO list. Accordingly, EEC appreciated the | | |
| Image: Whether Image: Whether I300. Estosan Suspension Deferred for change of brand name I300. Estosan Suspension Deferred for change of brand name Iarrangement of applications in various designated Since computerization of record of submitted applications in various designated Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still the are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided the decision of the instant product application to check it whether Iarrangement of applications in various designated Since computerization of record of submitted applications were disposed of but still the are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided the decision of the instant product application to check it whether Iarrangement of applications in various designated Since computerization of record of submitted applications in various designated Since computerization of record of submitted application subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still the subsequent preparation of their FIFO list. Accordingly, EEC appresent the subsequent preparation of their FIFO list, the division to check it whether | | | |
| MTT Medical, Lahore 1300. Estosan Suspension Deferred for change of brand name 1301. EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided to decision of the instant product application to check it whether 1302. Lifolac Syrup Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applications in various designate Since computerization of record of submitted applications in various designate Since computerization of record of submitted applications in various designate Since computerization of record of submitted applications in various designate Since computerization of record of submitted applications evaluating and processing files. Hence, there are chan subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications in various designate Since computerization of record of submitted applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are chan some product applications were disposed of but still the source product applications were disposed of but still the source product applications were disposed of but still the source product applications were disposed of but still the source product applications were disposed of but st | the instant product application to check its status | | |
| 1300.Estosan SuspensionDeferred for change of brand name1301.Efron SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whether1302.Lifolac SyrupLifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designate some product applications were disposed of but still t | | | |
| 1301. EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appr services of division of health and OTC and decided t decision of the instant product application to check it whether 1302. Lifolac SyrupLifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t | | | |
| 1301.Efron Syrupwise arrangement of applications in various designated Since computerization of record of submitted applical subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appro services of division of health and OTC and decided to decision of the instant product application to check it whether1302.Lifolac SyrupEEC was apprised that division undertook a big task since computerization of record of submitted applical subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designated Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the division some product applications were disposed of but still the division some product applications were disposed of but still the division some product applications were disposed of but still the division some product applications were disposed of but still the division | | Estosan Suspension | 1300. |
| 1301.Since computerization of record of submitted applical subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appro services of division of health and OTC and decided to decision of the instant product applications to check it whether1302.Lifolac SyrupLifolac SyrupEEC was apprised that division undertook a big task subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications in various designated Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still to evaluating and processing files. Hence, there are char some product applications were disposed of but still to subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still to | | | |
| 1301.Efron Syrupsubsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appre services of division of health and OTC and decided to decision of the instant product application to check it whether1302.Lifolac SyrupEEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t | | | |
| 1301. Efron Syrup evaluating and processing files. Hence, there are char some product applications were disposed of but still the are available in the FIFO list. Accordingly,EEC appropriate services of division of health and OTC and decided the decision of the instant product application to check it whether 1302. Lifolac Syrup Efform Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designated Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the some product appl | | | |
| 1301. Elfon Syrup some product applications were disposed of but still t are available in the FIFO list. Accordingly,EEC appreservices of division of health and OTC and decided to decision of the instant product application to check it whether 1302. Lifolac Syrup Elfon Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t | | | |
| 1302. Lifolac Syrup Some product applications were disposed of but still that division undertook a big task wise arrangement of applications in various designated Since computerization of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still that some product applications were disposed of but still that the service of th | | Efron Syrup | 1301. |
| 1302. Lifolac Syrup services of division of health and OTC and decided to decision of the instant product application to check it whether subsequent of applications in various designated subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still to some product applications. | | - 1 | - |
| 1302. Lifolac Syrup decision of the instant product application to check it whether EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applications evaluating and processing files. Hence, there are char some product applications were disposed of but still the some product applications were di | | | |
| 1302. Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applications is ubsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the some product app | | | |
| 1302. Lifolac Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various designate Since computerization of record of submitted applica subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still to the subsequent preparation of | the instant product application to check its status | | |
| 1302. Lifolac Syrup wise arrangement of applications in various designated Since computerization of record of submitted applical subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the subsequent preparation of the subsequent preparat | anniand that division and letter letter letter 1 (1) | | |
| 1302. Lifolac Syrup Since computerization of record of submitted applical subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still the some product applications. | | | |
| subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char some product applications were disposed of but still t | | | |
| evaluating and processing files. Hence, there are char some product applications were disposed of but still t | | Lifolac Syrup | 1302. |
| some product applications were disposed of but still t | | • • | |
| some product applications were disposed of but still t | | | |
| | ct applications were disposed of but still their names | | |
| Page 74 of 85 | Chundred / | | |

| S.No | Brand name | Decision |
|----------------|---|---|
| (1) | (2) | (3) |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| 1303. | Zocobin Syrup | whether Deferred for change of brand name |
| 1303. | Cistimax Syrup | Deferred for change of brand name |
| 1504. | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1305. | Sampa Syrup | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | l I | decision of the instant product application to check its status |
| | | whether |
| | | EEC was apprised that division undertook a big task of company |
| | l I | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| ſ | | subsequent preparation of their FIFO list, the division has been |
| 1306. | Complivit Syrup | evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names |
| | l I | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | l I | decision of the instant product application to check its status |
| | | whether |
| | | armaceutical, Peshawar |
| 1307. | Folic Acid Tablet | Deferred for change of brand name |
| 1308. 1309. | Feuromin Tablet Panthomine-M | Deferred for change of brand name Deferred for change of brand name |
| 1309. | Irocon Tablet | Deferred for change of brand name |
| 1310. | Cal-D Fort Tablet | Deferred for change of brand name |
| 1312. | Camzol-D Tablet | Deferred for change of brand name |
| 1313. | Calcon-D Tablet | Deferred for change of brand name |
| 1314. | Endomax Tablet | Deferred for change of brand name |
| 1315. | Cidlock Sachet | Deferred for change of brand name |
| <u>1316.</u> | Uroflux Tablet | Deferred for change of brand name |
| 1317. 1318. | Trihad Capsule Sleepwel Tablet | Deferred for change of brand name Deferred for change of brand name |
| 1319. | Sleepwel Drops | Deferred for change of brand name |
| 1320. | Ido Folic Acid Tablet | Deferred for change of brand name |
| 1321. | Aormin-D Drops | Deferred for change of brand name |
| 1322. | Lemo Cid Syrup | Deferred for change of brand name |
| 1323. | Ginsol Syrup | Deferred for change of brand name |
| 1324. 1325. | Podina Adrak Plus Calvange Syrup Megzora-D Drops | Deferred for change of brand name Deferred for change of brand name |
| 1343. | | ehban, Karachi |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1326. | Nourish & Flourish Whitening Face Wash | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| 1327. | Foot Repair Cream | subsequent preparation of their FIFO list, the division has been |
| 1541. | root repuir cream | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer |
| | | services of division of nearm and OTC and decided to defer |

Page 75 of 85 Juncel.

| S.No | Brand name | Decision |
|-----------------------|--|--|
| (1) | (2) | (3) |
| | | decision of the instant product application to check its status |
| | | whether EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1328. | Nutra Shampoo | evaluating and processing files. Hence, there are chances that |
| 10201 | Tulu Dianipoo | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1329. | Nutra Conditioner | evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |
| | Nourish & Flourish Whitening Whitening | evaluating and processing files. Hence, there are chances that |
| 1330. | Cream | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1331. | Revitalise Moisturizing Cream | evaluating and processing files. Hence, there are chances that |
| 1551. | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| 1332. | Nourish & Flourish Whitening Acne Face Wash | subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | NL-4 | whether |
| 1333. | Pre-Vomit Capsule | itional Life Sciences, Peshawar Deferred for change of brand name |
| 1334. | Foliget Tablet | Deferred for change of brand name |
| 1335. | E-Vita Tablet | Deferred for change of brand name |
| 1336. | Genmax Capsule | Deferred for change of brand name |
| 1337. | Agcal-D Tablet | Deferred for change of brand name |
| 1338. | Ginsavin Tablet | Deferred for change of brand name |
| <u>1339.</u> 1340. | Getcall-D Sachet Flexi D Tablet | Deferred for change of brand name Deferred for change of brand name |
| | | Deferred for change of brand name Deferred for change of brand name. |
| 1341. | Subtize Syrup | Defended for change of oralid name. Strength of extract of each ingredient individually is required |
| 1342. | Due Fee | Deferred for change of brand name |
| | | ratories (Pvt) Ltd, Faisalabad |
| 1343. | Apifocus Syrup | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |

| S.No | Brand name | Decision |
|----------|-----------------------------------|--|
| (1) | (2) | (3) |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that |
| 1344. | Qfend Syrup | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1345. | Nurozon Syrup | evaluating and processing files. Hence, there are chances that |
| | | some product applications were disposed of but still their names |
| | | are available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether |
| | | Oasis Pharma, Lahore |
| 1346. | Vibrox Tablet | Deferred for change of brand name |
| 1347. | Osigain Softgel Capsule | Deferred for change of brand name |
| 1348. | Ovi-Safe Sachet | Deferred for change of brand name |
| 1349. | Maxy Barry Sachet | Deferred for change of brand name |
| 1350. | Protec-1 Syrup | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | Methlox Tablet | evaluating and processing files. Hence, there are chances that som |
| 1351. | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | pal Laboratories, Karachi |
| <u> </u> | | EEC was apprised that division undertook a big task of company |
| | | |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | Cberry C Effervescent Sachet | subsequent preparation of their FIFO list, the division has been |
| 1352. | | evaluating and processing files.Hence,there are chances that some |
| | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| Ţ | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that som |
| 1353. | Cberry C Plus Effervescent Sachet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | Deferred for the following reasons: |
| 1354. | Bc-Lyse Plus Syrup | |
| 1354. | Bc-Lyse Plus Syrup | Brand name to be change. Page 77 of 85 |

| S.No Brand name Decision (1) (2) (3) (1) (2) (3) (2) (3) (3) (3) Paramount lealthcare, Islamabad (3) 1355. Maxofol Plus Tablet Deferred for change of brand name 1357. Inorih 55Mg Tablet Deferred for change of brand name 1358. Myocure-D Sachet Deferred for change of brand name 1359. Myocure-D Sachet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1350. Iv-Zone Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various design subsequent preparation of their FIFO list, the divisi subsequent preparation of their FIFO list, the divisi subsequent preparation of their BIFO list, the divisi available in the FIFO list, th | k of company ated racks. cations and on has been nces that some r names are iated the to defer |
|---|---|
| Paramount Healthcare, Islamabad 1355. Maxofol Plus Tablet Deferred for change of brand name 1356. Irocrib 120MI Syrup Deferred for change of brand name 1357. Irocrib 6SMg Tablet Deferred for change of brand name 1358. Myocure-D Sachet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1360. Iv-Zone Syrup EEC was apprised that division undertook a big task wise arrangement of applications in various design subsequent preparation of their FIFO list, the divisi evaluating and processing files.Hence, there are chane available in the FIFO list. Accordingly, EEC apprector services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. 1361. Otizer Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Def | k of company ated racks. cations and on has been nces that some r names are iated the to defer |
| Paramount Healthcare, Islamabad 1355. Maxofol Plus Tablet Deferred for change of brand name 1356. Irocrib 120MI Syrup Deferred for change of brand name 1357. Irocrib 65Mg Tablet Deferred for change of brand name 1358. Myocure-D Sachet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name Parina Pharma Pvt Ltd, Karachi EEC was apprised that division undertook a big tasl wise arrangement of applications in various design Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisi evaluating and processing files.Hence, there are change of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. 1361. Otizer Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Folrex-F Tablet Deferred for change of brand name 1366. Folrex-L Tablet Deferr | ated racks. cations and on has been nces that some r names are iated the to defer |
| 1355. Maxofol Plus Tablet Deferred for change of brand name 1356. Irocrib 120MI Syrup Deferred for change of brand name 1357. Irocrib 65Mg Tablet Deferred for change of brand name 1358. Myocure-D Sachet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1360. Iv-Zone Syrup Parina Pharma Pvt Ltd, Karachi 1360. Iv-Zone Syrup EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa brocks of duct applications were disposed of but still their available in the FIFO list, the divisi evaluating and processing files. Hence, there are chan product applications of the instant product application to check whether it has been disposed of or otherwise. 1361. Otizer Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-T Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Folrex-F Tablet Deferred for change of brand name 1366. Folrex-Tablet D | ated racks. cations and on has been nces that some r names are iated the to defer |
| 1356. Irocrib 120MI Syrup Deferred for change of brand name 1357. Irocrib 65Mg Tablet Deferred for change of brand name 1358. Myocure-D Sachet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name 1360. Iv-Zone Syrup EEC was apprised that division undertook a big tas wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FFD list, the divisi evaluating and processing files.Hence,there are cha product applications were disposed of but still their available in the FIPO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. 1361. Otizer Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1367. Eyzl Capsule Phytotia Laboratory, Peshawar 1368. Folrex-L Tablet Deferred for change of brand name 1367. Eyzl Capsule Regimen Nutraceuticas, Lahore Reguent prep | ated racks. cations and on has been nces that some r names are iated the to defer |
| 1357. Irocrib 65Mg Tablet Deferred for change of brand name 1358. Myocure-D Sachet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name Parina Pharma Pvt Ltd, Karachi EEC was apprised that division undertook a big tas wise arrangement of applications in various designe Since computerization of record of submitted appli subsequent preparation of their FIPO list, the divisi evaluating and processing files.Hence,there are cha product applications were disposed of but still their available in the FIPO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. 1361. Otizer Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-F Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1365. Folrex-F Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Folrex-F Tablet Deferred for change of brand name 1367. Eyzl Capsule EEC was apprised that division undertook a big tas wise | ated racks. cations and on has been nces that some r names are iated the to defer |
| 1358. Myocure-D Sachet Deferred for change of brand name 1359. Myocure Tablet Deferred for change of brand name Parina Pharma Pvt Lid, Karachi EEC was apprised that division undertook a big tasl wise arrangement of applications in various design Since computerization of fuer FIPO list, the divisi evaluating and processing files. Hence, there are cha product applications were disposed of but still their available in the FIFO list. Accordingly, EEC apprect services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. 1360. Iv-Zone Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-F Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1367. Eyzl Capsule Regimen Nutraccuticals, Lahore Regimen Nutraccuticals, Lahore EEC was apprised that division undertook a big tas wise arrangement of applications in various design subsequent preparation of their FIFO list, the divisi subsequent preparation of the | ated racks. cations and on has been nces that some r names are iated the to defer |
| 1359. Myocure Tablet Deferred for change of brand name Parina Pharma Pvt Lid, Karachi EEC was apprised that division undertook a big tast wise arrangement of applications in various designa Since computerization of their FIPO list, the divisi subsequent preparation of their FIPO list, the divisi subsequent preparation of their FIPO list, the divisi evaluating and processing files.Hence,there are cha product applications were disposed of but still their available in the FIPO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. 1361. Otizer Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-T Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1367. Eyzl Capsule EEC was apprised that division undertook a big tas wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisio subsequent preparation of their fIFO list, the divisio subsequent preparation of their fIFO list, the divisio subsequent preparation of their their their division undertook a big tas wise arrangement of applications in various desig | ated racks. cations and on has been nces that some r names are iated the to defer |
| Parina Pharma Pvt Ltd, Karachi EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the divisi evaluating and processing files. Hence, there are cha product applications were disposed of but still their available in the FIFO list. Accordingly,EEC apprec services of division of heath and OTC and decided decision of the instant product applications to check whether it has been disposed of or otherwise. 1360. Iv-Zone Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1367. Eyzl Capsule EEC was apprised that division undertook a big tas wise arrangement of applications in various designa subsequent preparation of their FIFO list, the divisi subsequent preparation of their theis there there are cha product applicat | ated racks. cations and on has been nces that some r names are iated the to defer |
| 1360. Iv-Zone Syrup EEC was apprised that division undertook a big tast wise arrangement of applications in various designer. Since computerization of their FIFO list, the divisi evaluating and processing files.Hence,there are cha product applications were disposed of but still their available in the FIFO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. 1361. Otizer Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-T Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Egimen Nutraccuticals, Lahore EEC was apprised that division undertook a big tas wise arrangement of applications in various design since computerization of the instant product application in various design since computerization of the instant product application in various design since computerization of the instant product application in various design since computerization of the application in various design since computerization of the instant product application in various design since computerization of the instant product application in various design since computerization of the ins | ated racks. cations and on has been nces that some r names are iated the to defer |
| iv-Zone Syrup iv-Zone | ated racks. cations and on has been nces that some r names are iated the to defer |
| 1361. Otizer Syrup Deferred for change of brand name 1362. Vitazone Syrup Deferred for change of brand name 1363. Ozocid Syrup Deferred for change of brand name 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name Regimen Nutraceuticals, Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisie evaluating and processing files.Hence, there are cha product applications were disposed of but still thei available in the FIFO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa sonce computerization of record of submitted applic subsequent preparation of their FIFO list, the divisie evaluating and processing files.Hence, there are cha product applications of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore | no status |
| 1363. Ozocid Syrup Deferred for change of brand name Phytotia Laboratory, Peshawar 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name Regimen Nutraceuticals, Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisie evaluating and processing files.Hence,there are cha product applications were disposed of but still their available in the FIFO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisio evaluating and processing files.Hence, there are char product applications in various designa as the core there are char product applications of partice application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications | |
| Phytotia Laboratory, Peshawar 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1367. Eyzl Capsule EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisio evaluating and processing files.Hence,there are chan product applications were disposed of but still their available in the FIFO list. Accordingly,EEC apprect services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa since computerization of record of submitted applic division of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisi evaluating and processing files. Hence, there are chan product applications in various designa subsequent preparation of their FIFO list, the divisi evaluating and processing files. </th <th></th> | |
| 1364. Folrex-F Tablet Deferred for change of brand name 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name Regimen Nutraceuticals, Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisie evaluating and processing files.Hence,there are cha product applications were disposed of but still their available in the FIFO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisi evaluating and processing files. Hence, there are charter are chartere are chartere are charter are charter are charter are | |
| 1365. Folrex-L Tablet Deferred for change of brand name 1366. Iroomax Tablet Deferred for change of brand name Regimen Nutraceuticals, Lahore Image: Regimen Nutraceuticals, Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal Since computerization of record of submitted applic subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan product applications were disposed of but still their available in the FIFO list. Accordingly, EEC apprect services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal specific to the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal specific to record of submitted applic subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan product applications in various designal available in the FIFO list, the division undertook a big tasl wise arrangement of applications in various designal specific the product application of record of submitted applic subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan product application of the preare division evaluating a | |
| 1366. Iroomax Tablet Deferred for change of brand name Regimen Nutraceuticals, Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal Since computerization of record of submitted applid subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan product applications were disposed of but still their available in the FIFO list. Accordingly, EEC apprect services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chan product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applicatio | |
| Regimen Nutraceuticals, Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal Since computerization of record of submitted applid subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chat product applications were disposed of but still their available in the FIFO list. Accordingly, EEC apprect services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal Since computerization of record of submitted applic subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are chat product applications in various designal since computerization of record of submitted applic devices appresed that division undertook a big tasl wise arrangement of applications in various designal since computerization of record of submitted applic subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal since computerization of record of submitted applic subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal since computerization of record of submitted applic subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal since computerization of record of submitted applic subsequent preparation of their FIFO list, the division undertook a big tasl wise arrangement of applications in various designal since computerization of record of submitted applic subsequent preparation of their FIFO list, the division undertope application to | |
| 1367. Eyzl Capsule EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal Since computerization of record of submitted applic subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are char product applications were disposed of but still their available in the FIFO list. Accordingly, EEC apprect services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. RG Pharmaceutica (Pvt.) Ltd., Lahore EEC was apprised that division undertook a big tasl wise arrangement of applications in various designal Since computerization of record of submitted applic subsequent preparation of their FIFO list, the division wise arrangement of applications in various designal Since computerization of record of submitted applic subsequent preparation of their FIFO list, the division subsequent preparation of their FIFO list, the divisio | |
| EEC was apprised that division undertook a big tasl wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the division evaluating and processing files. Hence, there are cho | ated racks. cations and on has been nces that some r names are iated the to defer |
| wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisi evaluating and processing files. Hence, there are ch | |
| some product applications were disposed of but still are available in the FIFO list. Accordingly, EEC ap services of division of health and OTC and decided decision of the instant product application to check whether it has been disposed of or otherwise. | ated racks. cations and on has been ances that I their names preciated the to defer |
| 1369. Maxocid Sachet Deferred for change of brand name | |
| 1370.Neend SyrupDeferred for change of brand name1370.EEC was apprised that division undertook a big tash wise arrangement of applications in various designa Since computerization of record of submitted applic subsequent preparation of their FIFO list, the divisie evaluating and processing files.Hence,there are chan product applications were disposed of but still their available in the FIFO list. Accordingly,EEC apprec services of division of health and OTC and decided decision of the instant product application to check whether it has hear disposed of or otherwise | ated racks. cations and on has been nces that some r names are iated the |
| whether it has been disposed of or otherwise. 1372. D-Congesta Drops Deferred for change of brand name | |
| 1372. D-Congesta Drops Deferred for change of brand name 1373. Flumca Sachet EEC was apprised that division undertook a big task wise arrangement of applications in various designal Since computerization of record of submitted applic subsequent preparation of their FIFO list, the division evaluating and processing files.Hence,there are characterization | |

Page 78 of 85

| S.No | Brand name | Decision |
|-------|-------------------------------|---|
| (1) | (2) | (3) |
| | | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1374. | Easup Drops | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some |
| 1375. | Glucoliq Sachet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1376. | Minfort Symp | evaluating and processing files.Hence,there are chances that some |
| 13/0. | Minfant Syrup | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1377. | Osteosam Tablet | Deferred for change of brand name |
| 1378. | Grobaby Drops | Deferred for change of brand name |
| 1379. | Interact Sachet | Deferred for change of brand name |
| 1380. | Colibid Drops | Deferred for change of brand name |
| 1381. | Menorag Tablet | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some |
| 1382. | Proantho Sachet | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1383. | Neend Drops | Deferred for change of brand name |
| 1384. | Stooler Drops | Deferred for change of brand name |
| 1385. | Locyst Tablet | Deferred for change of brand name |
| 1386. | Maxperm Sachet | Deferred for change of brand name |
| 1387. | Optimune Syrup | Deferred for change of brand name |
| 1388. | Diafol Tablet | Deferred for change of brand name |
| 1389. | Acd Plus Drops | Deferred for change of brand name |
| 1390. | Myfol Syrup | Deferred for change of brand name |
| 1391. | Myfol Drops | Deferred for change of brand name |
| 1392. | Myfol Tablet | Deferred for change of brand name |
| | Sa | ancura Pharma, Karachi |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1393. | Ovit-M Soft Gel Capsules | evaluating and processing files.Hence,there are chances that some |
| 1393. | Contrais Son Oer Capsules | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1394. | Suprafit Tablet | Deferred for change of brand name |
| 1395. | Epo-Soft Softgel Capsule | Deferred for change of brand name |
| 1396. | Calci Lock-D Softgel Capsules | Deferred for change of brand name |
| 1397. | Lm-Fol Tablet | Deferred for change of brand name |

Page 79 of 85

| 1399. Preco 1400. Ultra 1401. Carda 1402. Redm 1403. Crans 1404. Ivy C 1405. Cal S 1406. Folin 1407. Ris C | (2) sup-D Tablets econ Tablet ra-D Softgel Capsules rdimox Softgel Capsules rdimox Softgel Capsule dmax Tablet ansure Sachet (Cof Syrup I Soft Gel Capsule Jimax Softgel Capsules Saviou | (3) EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. Deferred for change of brand name EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and p |
|---|--|--|
| 1399. Preco 1400. Ultra 1401. Cardia 1402. Redm 1403. Crans 1404. Ivy C 1405. Cal S 1406. Folin 1407. Ris C | con Tablet ra-D Softgel Capsules rdimox Softgel Capsule dmax Tablet ansure Sachet (Cof Syrup I Soft Gel Capsule limax Softgel Capsules (Cal Syrup (Cal Syrup | wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. Deferred for change of brand name Deferred for change of brand name EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of or otherwise. Deferred for change of brand name EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications w |
| 1400. Ultra 1401. Cardi 1402. Redn 1403. Crans 1404. Ivy C 1405. Cal S 1406. Folin 1407. Ris C | ra-D Softgel Capsules rdimox Softgel Capsule dmax Tablet ansure Sachet cof Syrup l Soft Gel Capsule imax Softgel Capsules cal Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. Deferred for change of brand name Deferred for change of brand name EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. Deferred for change of brand name product applications of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. Deferred for change of brand name Deferred for change of brand name |
| 1401. Cardi 1402. Redn 1403. Crans 1404. Ivy C 1405. Cal S 1406. Folin 1407. Ris C | rdimox Softgel Capsule dmax Tablet ansure Sachet / Cof Syrup I Soft Gel Capsule limax Softgel Capsules ; Cal Syrup | Deferred for change of brand name EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. Deferred for change of brand name Deferred for change of brand name Deferred for change of brand name |
| 1402. Redn 1403. Crans 1404. Ivy C 1405. Cal S 1406. Folin 1407. Ris C | dmax Tablet ansure Sachet / Cof Syrup I Soft Gel Capsule limax Softgel Capsules ; Cal Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. Deferred for change of brand name Deferred for change of brand name Deferred for change of brand name |
| 1404. Ivy C 1405. Cal S 1406. Folin 1407. Ris C | v Cof Syrup I Soft Gel Capsule limax Softgel Capsules s Cal Syrup | Deferred for change of brand name Deferred for change of brand name Deferred for change of brand name Deferred for change of brand name |
| 1404. Ivy C 1405. Cal S 1406. Folin 1407. Ris C | v Cof Syrup I Soft Gel Capsule limax Softgel Capsules s Cal Syrup | Deferred for change of brand name Deferred for change of brand name Deferred for change of brand name |
| 1405. Cal S 1406. Folin 1407. Ris C | l Soft Gel Capsule limax Softgel Capsules s Cal Syrup | Deferred for change of brand name Deferred for change of brand name |
| 1406. Folin 1407. Ris C | limax Softgel Capsules s Cal Syrup | Deferred for change of brand name |
| 1407. Ris C | s Cal Syrup | |
| | | 2 erented for enange of orang name |
| 1408. Ss-V | | ır Pharma, Lahore |
| | Vit Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | Scotmann Ph | armaceutical, Islamabad |
| 1409. Dayv | yvit Tablet | Deferred for change of brand name |
| | man Tablet | Deferred for change of brand name |
| | com Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1412. Unpa | pause Tablet | Deferred for change of brand name |
| | | & Pharmaceuticals, Lahore |
| 1413. Calci | | Deferred for change of brand name |
| | lcinix Syrup | |
| | lcinix Syrup I-Lac Syrup | Deferred for change of brand name |
| 1416. Coral | l-Lac Syrup Isun Tablet | Deferred for change of brand name Deferred for change of brand name Deferred for change of brand name |

| S.No | Brand name | Decision | | |
|-------|--|--|--|--|
| (1) | (2) | (3) | | |
| 1417. | Iroon-F Syrup | Deferred for change of brand name | | |
| 1418. | Macovit-Advance Tablet | Deferred for change of brand name | | |
| 1419. | Mensofort Syrup | Deferred for change of brand name | | |
| 1420. | Sharbat Podina Syrup | Deferred for change of brand name | | |
| 1421. | Unicorn Syrup | Deferred for change of brand name | | |
| | | narmaceuticals, Rawalpindi | | |
| 1422. | Cran Life Syrup | Deferred for change of brand name | | |
| 1423. | Fitliv Syrup | Deferred for change of brand name | | |
| 1424. | Osofit Syrup | Deferred for change of brand name | | |
| 1425. | Liver Dtx Syrup | Deferred for change of brand name | | |
| | Sois Life Sciences, Karachi EEC was apprised that division undertook a big task of company | | | |
| 1426. | Calgi Forte Tablet | wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status | | |
| | | whether it has been disposed of or otherwise. | | |
| | Steg labo | oratories, Sheikhupura | | |
| | | EEC was apprised that division undertook a big task of company | | |
| 1427. | Retipal-A Softgel | wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. | | |
| 1428. | Elevit-E400 Softgel | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. | | |
| 1429. | Elevit-E200 Softgel | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. | | |
| 1430. | Cheervit Softgel | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. EEC was apprised that division undertook a big task of company | | |
| 1431. | Elevit-E600 Softgel | wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some | | |
| 1431. | | subsequent preparation of their FIFO list, the division has been | | |

| S.No | Brand name | Decision |
|-----------------|-----------------------------------|---|
| (1) | (2) | (3) |
| | | product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1100 0 | | en Industries Lahore |
| | ola Gin Tablet | Deferred for change of brand name |
| | ola Gin Sachet one Plus Tablet | Deferred for change of brand name |
| | one Plus Syrup | Deferred for change of brand name Deferred for change of brand name |
| | itagim Syrup | Deferred for change of brand name |
| | itagim Tablet | Deferred for change of brand name |
| | eadofer Syrup | Deferred for change of brand name |
| | olic Plus | Deferred for change of brand name |
| • | Verbana | International, Islamabad |
| | lue Min P Powder | Deferred for change of brand name |
| | -Tox | Deferred for change of brand name |
| 1442. Do | cp-Vet Powder | Deferred for change of brand name |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been |
| | | evaluating and processing files. Hence, there are chances that some |
| 1443. Al | b Entol Syrup | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | -Plcenta Off Sachet | Deferred for change of brand name |
| | nmune Plus Liquid | Deferred for change of brand name |
| | ull Max Powder espo-Vet Liquid | Deferred for change of brand name |
| 144/, K | espo-vet Liquid | Deferred for change of brand nameEEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| 1448. A | ppetonic Liquid | evaluating and processing files.Hence,there are chances that some |
| , | Appetonie Exquite | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| 1449. M | Iasti Cure Liquid | Deferred for change of brand name |
| | airy Gold Powder | Deferred for change of brand name |
| | Vida L | aboratories, Karachi |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some |
| 1451. Fa | Fair Plus Cream | product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly, EEC appreciated the |
| | | services of division of health and OTC and decided to defer |
| | | decision of the instant product application to check its status |
| | | whether it has been disposed of or otherwise. |
| | | EEC was apprised that division undertook a big task of company |
| | | wise arrangement of applications in various designated racks. |
| | | Since computerization of record of submitted applications and |
| | | subsequent preparation of their FIFO list, the division has been |
| | | |
| 1452. Fa | air Plus Cream | evaluating and processing files. Hence, there are chances that some |
| 1452. Fa | air Plus Cream | evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |
| 1452. Fa | air Plus Cream | evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the |
| 1452. Fa | air Plus Cream | evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |

Page 82 of 85 Junce

| S.No | Brand name | Decision |
|-----------------------|---|---|
| (1) | (2) | (3) |
| 1453. | Oslia (Cholecalciferol) 100000Iu Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1454. | Ornafin Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | | n Pharma, Lahore |
| 1455. | Xtramen Tablet | Deferred for change of brand name |
| 1456. | Ossetrol Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1457. | Peptol Suspension | Deferred for change of brand name |
| 1458. | Tulac Syrup | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1459. | Livsure Syrup | Deferred for change of brand name |
| 1460. | Mucare Syrup | Deferred for change of brand name |
| 1461. | Ulta Co-Q10 Tablet | Deferred for change of brand name |
| <u>1462.</u> 1463. | Urineed Sachet Vyfat Tablet | Deferred for change of brand name EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | Vital Mark Labo | pratories Pvt Ltd, Fasialabad |
| 1464. | Vita Dressing Spray | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer |

Page 83 of 85 Junce

| S.No | Brand name | Decision |
|--------|---|--|
| (1) | (2) | (3) |
| | | decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1465. | Vita Trust Extra Liquid | Deferred for change of brand name |
| 1466. | Vitox M Powder | Deferred for change of brand name |
| 1467. | Vitagest Powder | Deferred for change of brand name |
| | | poratories Pvt Ltd, Lahore |
| 1468. | Calcimax Tablet | Deferred for change of brand name |
| | Wilson's | Healthcare, Islamabad |
| 1469. | Serowil Tablet 60,000Iu Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are |
| | | available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| 1470. | Serowil Tablet 60,000Iu Tablet | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| | Xecuti | ive Pharma, Lahore |
| 1471. | Ph Pro Tablet | Deferred for change of brand name |
| 1472. | Multipro M Tablet | Deferred for change of brand name |
| 1473. | Ad-Folvitic Tablet | Deferred for change of brand name |
| 1474. | Lowcid Syrup | Deferred for change of brand name |
| 1475. | A+ Farfly Syrup | Deferred for change of brand name |
| 1476. | Spasmo Syrup | Deferred for change of brand name |
| 1477. | Respivil Syrup | Deferred for change of brand name |
| 1478. | Onefolin Tablet | Deferred for change of brand name |
| 1479. | Apiget Syrup | Deferred for change of brand name |
| 1480. | Perinef Tablet | Deferred for change of brand name |
| 1481. | Osserise Tablet | Deferred for change of brand name |
| 1482. | Diazik Tablet | Deferred for change of brand name |
| 1483. | Citiflow Tablet | Deferred for change of brand name |
| 1484. | Ardin Syrup | Deferred for change of brand name |
| | | tical Laboratories, Peshawar |
| 1485. | Deone-3 Capsule | Deferred for change of brand name |
| 1486. | Naom Capsule | Deferred for change of brand name |
| 1487. | Ked-3 Drops | Deferred for change of brand name |
| 1488. | Cren Mxx Maya Syrup | Deferred for change of brand name |
| 1489. | Amlite Capsule | EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise. |
| Manufa | cturing License No.000889 (Contract Givers) isional product enlistment on basis of contract Street No. N-1 E1, RCCI Industrial Esta | Street S-6, National Industrial Zone, RCCI, Rawat, holding Dru, has submitted the application vide letter No. Nil, dated 11-02-2027 manufacturing from M/s Damac Healthcare, located at Plot No. 5 te, Rawat, (Enlistment No. 01233) (Contract Acceptor) |
| 1490. | Dew-Max's Dew-Flex | Deferred for clarification regarding rationality of formulation along with role of ingredients |
| | Serena Laboratories, 16-17/C, Punjab Small nlistment No.01094, has submitted the applicat | I Industrial Estate, Ferozpur Road, Kasur , holding Provisional tion, vide letter No. Nil, submitted on 24-08-2022, for contract |
| | H | Page 84 of 85 |

| S.No | Brand name | Decision | | | | | |
|--|---|---|--|--|--|--|--|
| (1) | (2) | (3) | | | | | |
| | | 7-Km Off Raiwind – Manga Road, Near Haveli Bangroo Wali, | | | | | |
| Mouza Mull, Lahore (E.No.01110); | | | | | | | |
| 1491. | Lactil Drop | Deferred for confirmation of Lactase enzyme as a health product | | | | | |
| M/s My Health Pharma (Pvt) Ltd., located at the address Plot No.589, Sundar Industrial Estate, Raiwind Road, | | | | | | | |
| Lahore, holding Provisional Enlistment No.00620, has submitted the application, vide letter No. Nil, submitted on 24-08- | | | | | | | |
| 2022, for contract manufacturing from M/s Zodiac Pharma, located at 7-Km Off Raiwind – Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore (E.No.01110). | | | | | | | |
| 1492. | Lacto Lic Drop | Deferred for confirmation of Lactase enzyme as a health product | | | | | |
| | | ak No.7/11-L, Ada Dad Fatiana, Tehsil Chichawatni, Distrcit | | | | | |
| | | as submitted the application, vide letter No. Nil, submitted on 24-08- | | | | | |
| | | arma, located at 7-Km Off Raiwind – Manga Road, Near Haveli | | | | | |
| | | uza Mull, Lahore (E.No.01110). | | | | | |
| 1493. | Getlac Drop | Deferred for confirmation of Lactase enzyme as a health product | | | | | |
| | | m Sheikhupura Road, Muridke, holding Provisional Enlistment | | | | | |
| | | No. Nil, submitted on 24-08-2022, for contract manufacturing from | | | | | |
| M/s Zo | | - Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore | | | | | |
| | | (E.No.01110). | | | | | |
| 1494. | Hytase Drop | Deferred for confirmation of Lactase enzyme as a health product. | | | | | |
| | | ak No.7/11-L, Ada Dad Fatiana, Tehsil Chichawatni, District | | | | | |
| | · · · · · · · · · · · · · · · · · · · | application, vide letter No. Nil, received on 24-08-2022, for contract | | | | | |
| manu | | at Plot No. 47-A, Punjab Small Industrial Estate – II, Sundar, ore (E.No.01272) | | | | | |
| 1495. | Mentizo Capsule | Deferred for clarification regarding rationality of formulation | | | | | |
| | L L L L L L L L L L L L L L L L L L L | - Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore, | | | | | |
| | | cation, vide letter No. Nil, received on 24-08-2022, for contract | | | | | |
| | | at Plot No. 47-A, Punjab Small Industrial Estate – II, Sundar, | | | | | |
| | Lah | ore (E.No.01272). | | | | | |
| | IB-Mint Capsule | Deferred for clarification regarding rationality of formulation | | | | | |
| | | , Karachi, holding Drug Manufacturing License No.000111, has | | | | | |
| | | l on 10-08-2022, for permission of contract manufacturing from M/s | | | | | |
| Tre | nds Pharmaceuticals (Nutraceuticals & Cam | Division), located at Plot 546/ 547, Sundar Industrial Estate, | | | | | |
| | | Lahore. | | | | | |
| 4 4 6 - | | Deferred for provision of exact species of Angelica along with | | | | | |
| 1497. | IB-Mac Syrup | scientific evidences that the said ingredient does not contain | | | | | |
| N// TT | | phototoxic furanocumarins. | | | | | |
| | | I.T.E., Manghopir Road, Karachi , holding Provisional Enlistment | | | | | |
| | | No. Nil, submitted on 22-08-2022, for contract manufacturing from the address Plot No. 162 C. Sector 24 Korongi Industrial Area | | | | | |
| M/s Neu Mex Healthcare Laboratories., located at the address Plot No.162-C, Sector 24, Korangi Industrial Area, Karachi, (Enlistment No. 00728). | | | | | | | |
| 1498. | | Deferred for confirmation of Lactase enzyme as a health product | | | | | |
| | | -A8, Street I, Sector 38, Korangi Creek Industrial Park, Karachi, | | | | | |
| | | s submitted the application, vide letter No. Nil, submitted on 16-08- | | | | | |
| 2022, for contract manufacturing from M/s Neu Mex Healthcare Laboratories., located at the address Plot No.162-C, | | | | | | | |
| Sector 24, Korangi Industrial Area, Karachi, (Enlistment No. 00728). | | | | | | | |
| 1499. | Munolact Drops | Deferred for confirmation of Lactase enzyme as a health product | | | | | |
| | ł | | | | | | |

(Ayyaz Ahmad) Secretary, Enlistment Evaluation Committee

ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in USB ONLY.

| MS Excel Format | | | | | | | | | |
|-----------------|-------------|---------|--------|-------------|--------|-------------|------|------------|--|
| Sr. | Company | Product | Dosage | Composition | Common | Recommended | Pack | Date of | |
| No. | name | Name | Form | | name | use | Size | R&I | |
| | | | | | | | | submission | |
| 1. | (Company | XYZ | Tablet | Each tablet | XXX | XXX | 10's | DD.MM.Y | |
| | name, City) | | | contains: | | | 20's | YYY | |
| | Without | | | Abc | | | | | |
| | address | | | (USP)50mg | | | | | |
| 2. | | | | | | | | | |

MS Word Format

| Sr. No. | Company name | Product Name and composition | Common name | Recommended use | Pack Size |
|---------|---|---|----------------|-----------------|--------------|
| 1. | (Company name, City) Without address | XYZ Tablet Each tablet contains: Abc (USP)50mg | XXX | XXX | 10's 20's |
| 2. | | | | | |